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Tuberculosis (TB) remains difficult to control despite effective treatment and the presence of 
more sensitive diagnostic tools. Immunity against Mycobacterium tuberculosis (Mtb) infection 
can further be impacted by other concomitant infections (like human immunodeficiency virus) 
and non-communicable diseases (like Type 2 diabetes (T2D)) rendering individuals 
susceptible to TB. T2D patients are three times more likely to progress from latent to active 
TB. Therefore, it is crucial to better understand why people with T2D are at increased risk for 
TB progression. We hypothesize that distinct bio-signatures exist in whole blood of TB patients 
and close contacts (CCs) of TB patients with latent TB infection (LTBI) with T2D compared to 
those without T2D and that these bio-signatures correlate with impaired immune responses to 
Mtb in peripheral blood mononuclear cells (PBMCs) and monocytes (MNs) in CCs.  
RNA was extracted from whole blood stimulated with Mtb antigens using the Quantiferon TB 
Gold in-tube assay and NanoString analysis was performed to determine whether specific 
transcription signatures exist between CCs with LTBI with and without T2D. We characterized 
serum cytokines and endocrine signatures by luminex and enzyme-linked immunosorbent 
assay. PBMCs and MNs from the same individuals were isolated and stimulated with live 
H37Rv Mtb to determine Mtb uptake and killing. Bacterial uptake and killing was correlated 
with HbA1c to determine whether there was an association with glycaemic control. RNA from 
TB patients, TB patients with transient hyperglycaemia (TB-THG) and TB patients with T2D 
(TB-T2D) was also extracted from whole blood stimulated with Mtb antigens and analysed 
using NanoString. Interleukin-22 was also measured in serum from these patients. PBMCs 
from TB patients were further used to determine the frequency of mucosal associated invariant 
T (MAIT) cells before, during and after TB treatment.  
Fifteen gene transcripts were downregulated in TB-T2D compared to TB and TB-THG 
patients. We identified a gene signature that was able to differentiate between TB-THG and 
TB-T2D. We further identified a gene signature unique to the CCs with LTBI and T2D, which 
could be associated with an increased risk of developing active TB. Differences in cytokines, 
hormones, lipids, differential blood counts and Mtb uptake was observed when comparing 
CCs with and without T2D. Differential expression of IL-6, IL-18 and IL-22 in CCs with and 
without T2D highlights the differential regulation of the immune response during T2D. We 
showed that the frequency of MAIT cells in the periphery of TB-T2D was significantly lower 
compared to TB-THG at baseline, suggesting the MAIT cells in TB-T2D have redistributed to 
either the lung or adipose tissue. The increase of MAIT cells in the periphery at month 2 
compared to baseline could mean that MAIT cells population was restored in the blood due to 




Our gene expression results suggests that downregulated gene transcripts may be involved 
in pathways that favour immunopathology in TB-T2D. In addition, gene signatures 
differentiating THG from T2D could be useful in preventing the unnecessary diagnosis of 
patients with THG as having T2D. Differential gene expression in CCs with LTBI with and 
without T2D shows potential to be involved in the mechanisms leading to susceptibility to 
active TB. Cytokine and hormone data confirms that during T2D, the immune response is 
differentially regulated which may influence the response to infections. Lastly, MAIT cell 

























Tuberkulose (TB) bly moeilik om te beheer ten spyte van effektiewe behandeling en die 
teenwoordigheid van meer sensitiewe diagnostiese toetse. Immuniteit teen Mycobacterium 
tuberkulose (Mtb) kan verder beïnvloed word deur ander gepaardgaande infeksies (soos 
menslike immuniteitsgebrekvirus) en nie-oordraagbare siektes (soos tipe 2 diabetes (T2D)) 
wat individue vatbaar maak vir TB. Pasiënte met T2D het ŉ groter kans om van latent na 
aktiewe TB te vorder en is dit noodsaaklik om te verstaan waarom mense met T2D ‘n groter 
risiko vir TB-progressie het. Ons veronderstel dat daar afsonderlike bio-handtekeninge in heel 
bloed van TB pasiënte asook nabye kontakte (CCs) van TB pasiënte met latente TB-infeksie 
(LTBI) en T2D in vergelyking met dié sonder T2D bestaan en dat hierdie bio-handtekeninge 
met verswakte immuunresponse teenoor Mtb in mononukleêr selle in perifere bloed (PBMCs) 
en monosiete (MNs) van CCs korreleer. 
RNS is uit volbloed wat met Mtb-antigene (Quantiferon TB Gold toets) gestimuleer is onttrek. 
Nanostring-analise is uitgevoer om vas te stel of spesifieke transkripsie-patrone tussen CCs 
met LTBI en met of sonder T2D bestaan. Ons het serum sitokiene en endokriene 
handtekeninge identifiseer deur luminex en ensien-gekoppelde Immunosorbent-toetse. 
PBMCs en MNs van dieselfde individue is geïsoleer en met lewendige H37Rv Mtb gestimuleer 
om Mtb opname en beheer te bepaal. Bakteriese opname en dood was met HbA1c 
gekorreleer om vas te stel of daar 'n verband met bloedsuiker was. RNS van TB-pasiënte, TB-
pasiënte met oorgang hiperglukemie (TB-THG) en TB-pasiënte met T2D (TB-T2D) was ook 
uit heelbloed  wat met Mtb-antigene gestimuleers was onttrek en met behulp van die 
Nanostring tegnologie geanaliseer. IL-22 was ook in the serum van hierdie pasiënte gemeet. 
PBMCs van TB pasiënte is verder gebruik om die frekwensie van ‘mucosal associated 
invariant’ T (MAIT) selle voor, tydens en na TB behandeling te bepaal. 
Vyftien geen-transkripsies is in TB-T2D afwaarts gereguleer in vergelyking met TB- en TB-
THG pasiënte. Ons het 'n geen-handtekening geïdentifiseer wat in staat was om tussen TB-
THG en TB-T2D te onderskei. Ons het verder 'n handtekening van gene geïdentifiseer wat 
uniek is aan die CCs met LTBI en T2D wat met 'n verhoogde risiko om aktiewe TB te 
ontwikkeling geassosieer kan word. Verskille in sitokiene, hormone, lipiede, differensiële 
bloedtellings en Mtb opname is waargeneem tydens die vergelyking van CC's met en sonder 
T2D. Differensiële uitdrukking van IL-6, IL-18 en IL-22 in CCs met LTBI met en sonder T2D 
beklemtoon die differensiële regulering van die immuunrespons tydens T2D. Ons het getoon 
dat die frekwensie van MAIT selle in die sirkulasie van TB-T2D laer was as TB-THG by 
basislyn, wat daarop dui dat die MAIT-selle in TB-T2D na die long- of vetweefsel migreer. Die 
toename van MAIT selle in die bloed by maand 2 in vergelyking met basislyn kan beteken dat 




Ons geen-uitdrukking resultate dui daarop dat af-gereguleerde geen-transkripsies betrokke 
kan wees in immuunpaaie wat patologie in TB-T2D bevoordeel. Daarbenewens kan geen-
handtekeninge wat THG van T2D onderskei, nuttig wees om ŉ misdiagnose van THG as T2D 
te vermy. Differensiële geen-uitdrukking by individue met LTBI met en sonder T2D toon 
potensiaal om betrokke te wees by die meganismes wat lei tot vatbaarheid vir aktiewe TB. 
Sitokien- en hormoon data bevestig dat tydens T2D, die immuunrespons differensieel 
gereguleer word, wat die respons op infeksies kan beïnvloed. Laastens, MAIT-sel frekwensies 
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Literature review and introduction 
1. Diabetes 
1.1 Diabetes prevalence 
Diabetes mellitus (DM) is a chronic disease that occurs either because there are defects in 
beta cell function in the pancreatic islets, which then cannot produce adequate levels of insulin, 
like in type 1 diabetes (T1D), or the produced insulin cannot be utilized by insulin responsive 
tissues such as muscles, liver and adipocytes, like in type 2 diabetes (T2D). T2D manifests 
due to insulin resistance and/or pancreatic β-cell failure (decreased/no insulin secretion). In 
both cases, hyperglycemia occur, meaning individuals with T2D may still be secreting insulin, 
but do not respond to the insulin due to the increased insulin resistance. Chronic 
hyperglycaemia subsequently decreases beta cell function and insulin secretion as a result of 
the glucotoxicity, lipotoxicity, and enhanced oxidative stress (Guillausseau et al. 2008; 
Upadhyay et al. 2017).  T1D is the least prevalent form of diabetes and was, for many years, 
classified as the inherited form of the disease until it became evident that genetic factors and 
auto-immune reactions play a role in the development of T1D (Florez et al. 2003).  
In 2017, it was estimated that about 425 million people of the age group 20-79 years have 
T2D and this number is expected to reach 629 million by 2045 (Cho et al. 2018). Approximately 
five million people died due to T2D, globally in 2017 ( Cho et al. 2018). Asia contributes to 
about 60% of the global T2D prevalence with India having about 62 million people living with 
T2D and more than 77 million with pre-diabetes (Kaveeshwar and Cornwall, 2014). Of the 
latter, 70% will continue to develop T2D (Tabák et al. 2012). Pre-diabetes refers to impaired 
glucose tolerance, impaired fasting glucose (IFG) or intermediate hyperglycaemia (Echouffo-
Tcheugui and Dagogo-Jack, 2012). It is associated with micro-and macro-vascular 
complications, as well as an increased risk to progress to T2D (Brannick et al. 2016).  It is 
therefore important to closely monitor patients with pre-diabetes in an attempt to prevent them 
from developing T2D. In Sub-Saharan Africa (SSA), there is an estimated 15.5 million people 
with T2D between the ages of 20 and 79, and 1.8 million of those reside in South Africa 
(International Diabetes Federation, 2017). An estimated 69.2% of people living with T2D in 
SSA are undiagnosed and therefore at higher risk of developing harmful and costly 
complications (International Diabetes Federation,2017). In South Africa, the prevalence of 
self-reported T2D is 9.2% and increases with age: from 7.1% amongst 50–59-year olds to 
10.6% amongst 60–69-year olds and 12.4% amongst those 70 years and older (Werfalli et al. 
2018). In the Western Cape Province of South Africa, the highest prevalence of T2D has been 
reported in the Coloured population (Erasmus et al. 2012), who also has an undiagnosed T2D 




people with T2D because there are patients with T2D who remain undiagnosed and who are 
unaware of the damage caused by the disease (International Diabetes Federation, 2015). As 
a result, controlling this disease will be more difficult. As urbanisation increases and 
populations age, T2D will pose an ever-growing threat in these communities (International 
Diabetes Federation, 2017). 
1.2 Diagnosis of diabetes 
Measurements of plasma glucose and glycated haemoglobin A1c (HbA1c) are used as 
diagnostic tools for T2D (Florkowski, 2013). The World Health Organization (WHO) together 
with the National Diabetes Data Group in the US recommend the use of the oral glucose 
tolerance test (OGTT) measuring both fasting and two hours plasma glucose concentrations 
(National Diabetes Data Group, 1979). According to the American Diabetes Association (ADA) 
a fasting blood glucose level (FBG) of ≥ 7.0 mmol/L or a blood glucose level of ≥ 11 mmol/L 
after ingesting 75 g of glucose indicates that a person has DM (ADA, 2011). Impaired glucose 
tolerance (IGT) is characterised by a blood glucose level between 7.8 and 11 mmol/L, after 
ingesting glucose, and impaired fasting glucose (IFG) as a FBG between 6.1 and 6.9 mmol/L 
(ADA, 2011). The WHO recommends a FBG cut off of 7 mmol/L for diagnosis of DM (ADA, 
2011). Both the ADA and WHO recommended HbA1c, with a cut off of ≥ 6.5%, as an additional 
test to diagnose DM (International expert committee, 2009; WHO, 2011), however, OGTT 
remains the gold standard.. Unlike real time glucose measurements, HbA1c gives an 
indication of average blood glucose concentrations over two to three months period (Reynolds 
et al. 2006). The advantage of HbA1c measurements is that individuals are not required to be 
fasted, it requires less time to perform compared to an OGTT and the pre-analytical stability 
of HbA1c is high. Despite the advantage of HbA1c, the levels are known to vary in racial 
groups, with Black Africans having higher HbA1c compared to caucasians (Herman et al. 
2007; Kirk et al. 2013). In African Americans, changing from using glucose to HbA1c, resulted 
in about 650 000 missed T2D cases (Paterson, 2017). Furthermore, the glucose-6-phosphate 
dehydrogenase (G6PD) variant rs1050828 is common in people of African and African 
American decent and impacts HbA1c outcome, which if not recognised, can result in 
undiagnosed T2D when using HbA1c (Paterson, 2017). People with hemizygous T, 
heterozygous and homozygous T allele were found to have low HbA1c compared to those 
without T and also had lower red blood cell counts, hemotocrit and haemoglobin. It was 
suggested that the effect of rs1050828 variant on HbA1c is likely through reducing red blood 
cell lifespan (Paterson, 2017). As G6PD deficiency can be clinically ‘silent’ until illness 
strikes,some researchers suggest looking into the possible benefits of screening the G6PD 
genotype in parallel to testing HbA1c to diagnose T2D, especially in populations with African 




delayed diagnosis of the disease (Wheeler et al. 2017). Although the OGTT is the gold 
standard for T2D diagnosis, it is more challenging to perform as it requires overnight fasting 
(Florkowski, 2013). Other pre-test preparations are recommended such as ensuring that an 
appropriate diet was followed for three days prior to the test (Florkowski, 2013). The test itself 
is time-consuming, taking at least two hours. In addition, when measuring plasma glucose 
concentrations, blood should be processed within several minutes after collection, because 
red blood cells continue to consume glucose which could lead to false negative results (Bruns 
and Knowler, 2009). Missed T2D cases could be due to the lack of standardized testing for 
T2D (Matsha et al. 2016) and more studies should focus on diagnostic tools to improve 
certainty of the estimates of T2D prevalence. Earlier detection of T2D also has a benefit on 
the management of disease outcomes such as glycaemic control, which in turn will reduce the 
risk of developing T2D complications. 
1.3 Diabetes treatment 
Traditionally, diet modifications have been the basis for DM management. There are several 
classes of medications for the treatment of DM, which are used as an adjunct to diet and 
exercise. These include biguanides, sulfonylureas, meglitinide derivatives, alpha-glucosidase 
inhibitors, thiazolidinediones (TZDs), glucagon like peptide–1 (GLP-1) agonists, dipeptidyl 
peptidase IV (DPP-4) inhibitors, selective sodium-glucose transporter-2 (SGLT-2) inhibitors, 
and insulin (National diabetes service scheme, 2016). It is important that T2D medications be 
reviewed by patients’ general practitioner every year as part of the T2D annual cycle of care 
(National diabetes service scheme, 2016). 
Biguanides are the first line treatment for T2D, an example is metformin (Inzucchi et al. 2015). 
Metformin mediates its effects through two mechanisms to improve blood glucose 
concentration, it inhibits gluconeogenesis and enhances peripheral insulin sensitivity 
(Goodarzi and Bryer-ash, 2005). A dose of 500 mg metformin is initially prescribed to patients, 
once or twice a day with breakfast or/and dinner and may be increased after a week to 850 to 
1000 mg, twice a day, depending on how the patient responds to the treatment and whether 
the patient experiences any side effects (Upapdyay et al. 2017). Metformin can be used alone 
or in combination with sulfonylureas, TZDs or insulin (Khardori, 2018). On its own, it reduces 
HbA1c by an average of 1.5% (Knowles et al. 2002) and reduces the progression of pre-
diabetes to T2D by 31%. Thus, it is thought to be a good prophylaxis for T2D in individuals 
with pre-diabetes (Inzucchi et al. 2015). Metformin also reduces body weight and in 
combination with insulin therapy, reduces complications associated with DM such as 
macrovascular disease, heart failure, stroke and other peripheral artery diseases (Kooy et al. 
2009). Sulfonylureas are the second most prescribed drugs for T2D. They stimulate the 




a reduction of HbA1c by 1-2% and blood glucose levels of about 20% (Bolen et al. 2006). 
They are used both as monotherapy and in combination with insulin and other oral drugs for 
treating hyperglycaemia. An example is Glimepiride which is the only sulfonylurea approved 
by the food and drug administration (FDA) for combination therapy. Other examples include 
Glyburide and Glipizide. Meglitinide functions similarly to sulfonylurea by inducing the 
production of insulin by the pancreatic beta cells and examples include Repaglinide and 
Nateglinide (Melander, 2004). These drugs are FDA approved for monotherapy use and in 
combination with Metformin or TZDs (Khardori, 2018). TZDs include Pioglitazone and 
Rosiglitazone. These drugs improves the target cell responses to insulin by stimulating 
glucose uptake through the nuclear receptor called peroxisome proliferator-activated receptor-
γ (PPARγ) in skeletal muscles and adipose tissue and as a result, lower glucose plasma levels 
(Ahmadian et al. 2013). TZDs can be used as monotherapy and in combination with 
sulfonylureas and/or metformin and insulin (Khardori, 2018). Alpha-Glucosidase inhibitors 
promote the body to break down starchy foods and sugar, examples include Acarbose and 
Miglitol (Mendez et al. 2014). These drugs lower the blood glucose levels. They can be used 
as monotherapy or in combination with sulfonylurea (Khardori, 2018). Incretin based therapies 
consists of GLP-1 receptor agonists and DPP-4 inhibitors (Inzucchi et al. 2012). GLP-1 
receptor agonists are injectable drugs mimicking the endogenous GLP-1 which stimulates 
glucose-dependent insulin release to normalize hyperglycaemia (Meier, 2012). Exenatide, 
Albiglutide and Liraglutide are some of the examples of GLP-1 analogues and function by 
improving glycaemic control. Exenatide is administered twice daily while Albiglutide and 
Liraglutide are administered once daily (Khardori, 2018). DPP-4 is an endogenous metabolic 
enzyme that is involved in the regulation of glucose homeostasis if inhibited (Meier 2012). 
DPP-4 assists the body to continue releasing insulin by increasing the plasma levels of GLP-
1 through the inhibition of its proteolytic degradation (Meier, 2012). DPP-4 include drugs such 
as Sitagliptin, Saxagliptin, Linagliptin and Alogliptin. DPP-4 inhibitors can be used in 
combination with metformin, TZDs and sulfonylurea (Khardori, 2018). SGLT-2 inhibitors are 
agents that lower the glucose concentrations in the kidneys by increasing urinary glucose 
release (Ferrannini and Solini, 2012). Examples include Canagliflozin, Dapagliflozin and 
Empagliflozin (Khardori, 2018). 
In T2D, the use of insulin is only prescribed when beta cells are exhausted (Li et al. 2015). 
Insulin treatment is divided into three categories according to their mechanism of action, which 
are basal (long-acting), prandial (rapid-acting) or pre-mixed (mix of long- and rapid-acting). 
Basal insulin treatment uses a human preparation called protamine Hagedorn (NPH) as well 
as other insulin analogues. The analogues include detemir and glargine. The insulin 




Their HbA1c reducing abilities are however comparable. The analogues regulate early 
postprandial hyperglycaemia and late postprandial hypoglycaemia (Hirsch, 2005). The use of 
pre-mixed insulin, which is a combination of basal and prandial insulin, is convenient as it 
reduces the number of daily insulin injections and simplify insulin treatment. Studies 
comparing the three insulin types show that the HbA1c lowering capabilities are comparable 
while basal insulin reduces the risk of hypoglycaemia and weight gain (Holman et al. 2009). 
2. Tuberculosis 
2.1. Tuberculosis prevalence 
Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis (Mtb). The bacteria 
primarily affect the lungs of the infected individual. Despite being a curable disease, TB 
remains one of the top 10 causes of death globally (WHO, 2018). In 2017, there were 10 
million incident cases of TB in the world and 1.3 million people died because of TB (Figure 
1.1) (WHO, 2018). About 82% of TB deaths occurred in the African Region and the South-
East Asia Region in 2017 (WHO, 2018). South Africa has the third highest incidence of TB 
following China and India and in 2017 the WHO estimated the incident of TB to be 500 000 in 
South Africa (Figure 1.1) (WHO, 2018). It is estimated that 80% of the South African population 
is latently infected with Mtb (Kanabus, 2017). 
 
Figure 1.1: TB incidence of the highest TB endemic areas in the world reported in 2017 (WHO, 2018). 
 
Approximately 25% of people worldwide are infected with Mtb (Houben and Dodd, 2016). In 
most individuals Mtb remains in a latent, asymptomatic state called latent TB (LTBI) and 
approximately 5-10% progress to the active, symptomatic form of TB within the first two years 




increased risk of developing active TB when their immune systems becomes compromised 
due to infection with human immunodeficiency virus (HIV) (Wood et al. 2011) or have T2D 
(Jeon and Murray, 2008).  
In addition, there are about 157 505 people in South Africa who do not know that they have 
TB (WHO, 2018) and who unknowingly continue to spread the disease. Approximately 54 
million lives were saved through TB diagnosis and treatment between 2000 and 2017 (WHO, 
2018), which shows the importance of identifying and treating patients as a means to control 
the TB epidemic. Furthermore, to prevent and control TB disease, Mycobacterium bovis 
Bacillus Calmette-Guerin (BCG) is widely used as vaccine to prevent TB meningitis associated 
deaths in infants and young children (Trunz et al. 2006), however, it does not prevent the 
development of pulmonary TB in adults (Pai et al. 2016). Emphasis has therefore been placed 
on the development of more efficacious vaccines to prevent TB disease in adults. 
2.2 Diagnostic tools for TB infection and disease 
The successful management of TB depends on the ability to detect patients with the disease 
and initiating TB treatment. Currently, there are no diagnostic tools that can accurately 
differentiate between LTBI and TB disease (Tebruegge et al. 2010). Methods widely used to 
diagnose TB include microbiological, molecular as well as immunological tests and X-ray.  
2.2.1 Immunological tests determine whether a patient’s T cells have been sensitized to Mtb 
specific antigens (Andersen et al. 2000). The Tuberculin skin test (TST) using purified protein 
derivatives (PPD) is used to test for Mtb infection. The procedure involves injecting tuberculin 
PPD under the skin of the inner forearm. If the individual was exposed or infected with Mtb 
and has a memory T cell response, an induration ≥ 5 mm in children and HIV positive 
individuals and ≥ 10 mm in other high risk groups will form after 48–72 hours (CDC, 2016). It 
is however less specific as it can result in false positive readouts due to repeated TST testing, 
antigenic cross reactivity with BCG after vaccination or infection with non-tuberculous 
mycobacterium (NTM) (Tebruegge et al. 2010).  
Interferon-gamma (IFN-y) release assays (IGRA) such as the Quantiferon (QFT) TB Gold in-
tube, QFT TB Gold Plus and T-SPOT TB test are also used for the diagnosis of Mtb infection. 
These assays measure cell mediated immune responses in individuals suspected of being 
infected with Mtb. The QFT TB Gold in-tube test consists of three tubes coated with the 
following; a nil tube, containing no additives and serves as negative control to adjust for 
background IFN-y production, a TB-antigen tube, coated with an antigen cocktail containing 
region of difference-1 (RD-1) encoded Mtb antigens (early secretory antigen-6 (ESAT-6), 
culture filtrate protein-10 (CFP-10) and TB 7.7) and a mitogen tube, coated with 




overnight in the three tubes during which CD4+ T cells are stimulated to release IFN-y (Pai et 
al. 2008), which is measured by ELISA (Yi et al. 2016). The QFT TB Gold Plus assay utilizes 
two antigen tubes. The TB-1 antigen tube contains larger CFP-10 and ESAT-6 peptides that 
stimulates CD4+ T cells and the TB-2 antigen tube contains shorter peptides to stimulate CD8+ 
T cells, resulting in an increase in the sensitivity of the test (Yi et al. 2016; Losi et al. 2016). 
CD8+ sensitization is important because the IFN-ү is not only produced by CD4+ cells, also 
CD8+ cells (Petruccioli et al. 2016). CD8+ T cell activation is useful in immunocompromised 
individuals where there are poor CD4+ responses (Petruccioli et al. 2016).  
Similarly to the QFT, the T-SPOT TB assay measures IFN-y produced by activated T cells 
after Mtb antigen stimulation and by doing so indicates whether a person has developed a 
memory T cell response against Mtb (Hill et al. 2005). PBMCs are isolated and incubated with 
ESAT-6 and CFP-10 in plates coated with anti-IFN-y antibodies (Wang et al. 2007). The IFN-
y secreted by sensitized T cells is captured by specific antibodies on the plate and presented 
as spots (Oxford Immunote Ltd, Edinburgh, UK; Zhu et al. 2014). Depending on whether a 
patient presents with symptoms associated with TB or show lesions suggesting TB on chest 
X-ray or computerised tomography (CT) scan result, they will be diagnosed as either being 
LTBI or having TB when their T-SPOT result is positive (CDC, 2000).  
2.2.2 Microbiological tests include staining for acid-fast bacilli in sputum smear as well as 
culturing of sputum samples. These techniques are not specific to Mtb and are time consuming 
(Murray and Thompson, 1980). Direct sputum smear microscopy utilizes the Ziehl Nielsen 
acid-fast staining to visualize Mycobacterial species including Mtb, M. ulcerans, M. leprae and 
NTMs using a microscope. A minimum of 5000 bacilli/mL are required for the test to be positive 
(Murray and Thompson, 1980). Therefore, a negative smear does not necessarily rule out TB 
and a positive smear does not confirm Mtb infection but rather the presence of Mycobacterial 
species. 
The mycobacteria growth indicator tube (MGIT) automated mycobacterial detection system 
(BD BACTEC MGIT 960 system, BD) is the gold standard for TB diagnosis and requires at 
least 10 bacilli/mL for a positive diagnosis (Siddiqi and Rusch-Gerdes, 2006). The 
decontaminated sputum sample is inoculated in the tube and then incubated at 36°C and 
monitored continuously by a BACTEC 960 instrument for 42 days before the test can be 
deemed negative. The MGIT system allows the detection of mycobacterial growth using a 
fluorescent indicator embedded in silicone at the bottom of the tube. The fluorescent indicator 
is quenched by oxygen present in the broth. Once the growing mycobacteria replicate and 
utilise the available oxygen, the unmasked fluorescence is detected by the system and flagged 




2.2.3 Molecular test 
The GeneXpert MTB/RIF assay (GeneXpert MTB/RIF; Cepheid, Sunnyvale, CA) is a 
molecular test based on the Polymerase Chain Reaction (PCR) principle. The GeneXpert 
MTB/RIF assay was developed in 2009 to simultaneously diagnose Mtb and rifampicin (RIF) 
drug resistance within two hours (Blakemore et al. 2010). This test is recommended for use 
as an initial diagnostic tool when MDR-TB is suspected and during HIV-TB co-infection (WHO, 
2010), but is not yet a replacement for culture. In March 2017, the GeneXpert Ultra (GeneXpert 
MTB/RIF Ultra, Cepheid) was launched which has an increased sensitivity that is comparable 
to that of the MGIT (WHO, 2018). The WHO recommendations for the use of Xpert MTB/RIF 
also apply to the use of Ultra as the initial diagnostic test for all adults and children with signs 
and symptoms of TB (WHO, 2018). 
2.3. Treatment of TB 
LTBI treatment is not common in South Africa, because individuals with LTBI are likely to 
become re-infected with Mtb in such a high TB burden setting, and therefore prophylactic 
treatment is not only not effective (Churchyard et al. 2012), but may also fuel drug resistance. 
Prophylactic treatment is only given to children below the age of five years who are close 
contacts (CCs) of TB patients (WHO, 2018), individuals with LTBI who are HIV positive, 
women who are pregnant and individuals with other immunosuppressive conditions 
(Leutkemeyer, 2013). In low TB incident countries, on the other hand, preventative treatment 
is given to individuals with LTBI to prevent the development of TB (Lönnroth et al. 2015). The 
preventative therapy options includes a weekly dose of Rifapentine and INH for three to four 
months, a daily dose of RIF plus INH for three months or a daily dose of RIF for three to four 
months (WHO, 2018). 
2.3.1 The standard TB treatment reduces the number of actively growing bacteria, prevents 
transmission of the bacilli and prevents death (Nahid et al. 2016). The standard first line 
treatment regimen for new and previously treated TB patients includes Ethambutol (EMB), 
INH, RIF and Pyrazinamide (PZA). Standard TB treatment consists of two phases; an initial 
two months intensive phase where EMB, INH, RIF and PZA are given followed by a 
continuation phase of four months where INH and RIF are given (WHO, 2018). Directly 
observed treatment short course (DOTS) is a strategy used, where patients are observed 
swallowing their medication to ensure completion of therapy (Nahid et al. 2016).  
2.3.2 The treatment regimen for drug resistant TB, including RIF resistant TB (RR-TB), 
multi-drug resistant TB (MDR-TB) and extensively drug resistant TB (XDR-TB) is different from 
the standard TB treatment and includes second-line drugs. MDR-TB occurs when Mtb is 
resistant to RIF and INH and both RR-TB and MDR-TB requires treatment with second-line 




fluoroquinolones (Levofloxacin and Moxifloxacin (Mfx)) and a second-line injectable drug 
(Amikacin, Capreomycin or Kanamycin) (WHO, 2018). In 2018, the WHO convened a 
Guideline Development Group who is revising the guidelines of the drug resistant TB regimen 
including the use of the shorter nine months MDR-TB regimen (WHO, 2018). The new 
guidelines will be released late in 2018. Medicines to select as first priority include the later 
generation of fluoroquinolones (levofloxacin or moxifloxacin), bedaquiline and linezolid. Other 
agents are included based on their relative potency. The use of injectable drugs is not required 
anymore and longer oral-only regimens are still available for many patients. The older 
injectable drugs, kanamycin and capreomycin, are no longer recommended for use by the 
WHO due to their association with severe side effects such as nephrotoxicity and ototoxicity.
  
3. Latent Mtb infection and T2D 
Participants who are latently infected with Mtb and who have T2D are at a three times 
increased risk of developing TB compared to a healthy individual with LTBI (Jeon and Murray, 
2008). Therefore, screening TB contacts for T2D is effective for identifying new T2D cases at 
high risk of developing TB (Restrepo et al. 2018). We enrolled 95 contacts after screening 247 
individuals for T2D in South Africa and demonstrated that 17.4 % of TB contacts in our South 
African cohort have T2D and almost half of these individuals (43.9 %) are not aware that they 
have this disease (Restrepo et al. 2018). The factors associated with T2D such as 
hyperglycaemia and dyslipidaemia may play a role in the altered immune function associated 
with T2D, increasing the risk of TB development in individuals with LTBI and T2D (Restrepo 
et al. 2018). The immune profile of individuals with LTBI and T2D compared to LTBI without 
T2D have been characterized by reduced T helper 1 (Th1), Th17 and Th2 associated 
cytokines (Kumar et al. 2014; Figure 1.2). Cytokines associated with Th1 (interleukin-2 (IL-2), 
IFN-ү, Tumour necrosis factor- α (TNF-α) and Th17 (IL-17 A, IL-17F, IL-22) cells as well as 
the IL-1 family (IL-1α, IL-1β, IL-18) are important in resistance to TB (Cooper and Khader, 
2008; O’Garra et al. 2013). In plasma of individuals with LTBI and T2D (LTBI-T2D), IL-2, IFN-
y and TNF-α were significantly lower compared to LTBI (without T2D) (Kumar et al. 2014). IL-
17F was significanlty lower while IL-22 was significantly higher in LTBI-T2D compared to LTBI. 
IL-1 family cytokines such as IL-1β and IL-18 were lower in LTBI-T2D compared to LTBI and 
IL-1α was not different between the two groups (Kumar et al. 2014). The pro-inflammatory 
cytokines, IL-6, IL-12 and granulocyte macrophage-colony stimulating factor (GM-CSF) 
measured in plasma were the same in both groups (Kumar et al. 2014). Th2 (IL-4, IL-5, IL-13) 
associated and regulatory (IL-10, transforming growth factor-β (TGF-β)) cytokines, which play 
a role in the progression to TB disease (O’Garra et al. 2013), were not significantly different in 




in plasma of LTBI-T2D patients compared to individuals with LTBI. The concentration of IFN-
ү, TNF-α, IL-17A and IL-10 measured in whole blood stimulated with Mtb antigens (CFP-10, 
ESAT-6 and TB7.7), using the QFT-intube assay, are significantly lower in LTBI-T2D patients 
compared to individuals with LTBI (Kumar et al. 2014). 
 
        
Figure 1.2 The influence of T2D on the onset of TB, dysregulated immune response and clinical presentation of 
the TB during TB-T2D comborbidity (adapted from (Restrepo, 2016)). 
 
4. TB and T2D 
Globally, 790 000 TB cases were attributable to T2D and 880 000 people who had HIV also 
had TB (WHO, 2018). HIV infection is accountable for 8.7% and T2D for 7.5% of TB cases in 
the world in 2017 (WHO, 2018). However, since there are about 36 million HIV infected people 
and 460 million people with T2D (WHO, 2018), it is said that there will be more TB-T2D cases 
than TB-HIV (Lonnroth et al. 2014 ). About 75% of all people with T2D live in low- and middle-
income countries, where TB also flourishes (Kapur et al. 2016). About 25% of TB cases in 
India has T2D and 50% stress induced hyperglycaemia (Viswanathan et al. 2012). Among the 
TB patients with T2D, approximately 60% were previously diagnosed with T2D, which may 
have a negative effect on the immune response and could enhance TB morbidity 
(Viswanathan et al. 2012). In South India in 2011, T2D was a greater risk factor for TB (30.9%) 
than HIV (10.6%) (Gupta et al. 2011). A Mexican study showed that 39% of patients with T2D 
had TB, which is roughly five times more than TB cases attributable to HIV (Restrepo et al. 
2011). In SSA, where the TB incidence is high, little is known about how T2D affects the TB 




rise of T2D globally would avoid 6 million new incident cases and 1.1 million TB deaths during 
a 20 year period (Pan et al. 2015). Should interventions reduce the T2D incidence by 35%, 
7.8 million TB cases and 1.5 million TB deaths could be averted by 2035 (Pan et al. 2015). An 
estimated increase in T2D in TB endemic areas contributes to the challenge to control TB 
disease (International Diabetes Federation, 2015; Pereira et al. 2016). Patients with poorly 
controlled T2D, in particular, are at increased risk of developing active TB (Baker et al 2012) 
and are at increased risk of poor TB treatment outcome and death (Jeon and Murray, 2008; 
Dolley et al. 2009; Restrepo et al. 2011) (Figure 1.2).  
Although studies have generally identified T2D as a risk factor for TB disease development 
rather than TB disease as a risk factor for the onset of T2D (Stevenson et al. 2007; Harries et 
al. 2010), we cannot rule out this possibility, as a contributing factor to the increase in TB-T2D 
cases (Critchley et al. 2017), as TB (in absence of T2D) is well known to be associated with 
transient stress induced hyperglycaemia (Magee et al. 2018). T2D is not only associated with 
TB disease progression from LTBI, but is also linked to more severe clinical presentation of 
TB disease. Patients with TB-T2D are more likely to present with pulmonary and not extra-
pulmonary TB, have more cavities, increased TB severity scores, they are contagious for 
longer due to delayed culture conversion rates and at increased risk of MDR-TB (Fisher-Hoch 
et al. 2008; Gil-Santana et al. 2016; Liu et al. 2017) (Figure 1.2; Restrepo, 2016). The latter is 
somewhat controversial as some studies do not show an association between T2D and MDR-
TB (Magee et al. 2013; Chiang et al. 2015). TB-T2D patients compared to TB with no T2D are 
characterized by alterations in Th1 and Th17 cytokines (Kumar et al. 2013). Th1 (IL-2, IFN-y, 
TNF-α), Th17 (IL-17A, IL-22) and regulatory (IL-10 and TGF-β) cytokines were previously 
compared between TB-T2D and TB patients (Kumar et al. 2013). IL-22 was significantly lower 
in TB-T2D whereas IL-2, IFN-y, IL-17, IL-10 and IL-5 were significantly higher in TB-T2D in 
comparison to TB patients (Kumar et al. 2013a; Kumar et al. 2013b). There was no difference 
in the concentration of TNF-α and TGF-β between the two groups. In addition, IL-1 family 
members (IL-1β, IL-18) and other pro-inflammatory (IL-6) cytokines were higher and type 1 
interferon (IFN-β) lower in the plasma of TB-T2D patients compared to TB patients (Kumar et 
al. 2013). IL-12, GM-CSF, IL-1α, IFN-α, IL-8, Chemokine (C-C) motif ligand 11 (CCL11), 
CCL2, CCL4, granulocyte colony–stimulating factor (G-CSF), Chemokine (C-X-C) motif ligand 
CXCL10 and platelet derived growth factor (PDGF) were not significantly different between 
the two groups (Kumar et al. 2013).  
In unstimulated serum (obtained from the QFT in-tube assay), IFN-y, TNF-α, IL-17 and IL-1 
were significantly elevated in TB-T2D patients compared to TB patients. Similarly, the same 
was seen after measuring the cytokines in Mtb-antigen stimulated serum. IL-10 was also 




in this sample type (Kumar et al. 2013). When using broncho alveolar lavage (BAL), which is 
a representative sample of the site of disease, IFN-ү is higher and IL-10 lower in TB-T2D 
compared to TB (Sun et al. 2012). 
5. Innate immunity 
5.1 Innate immunity in TB 
The innate immune response during Mtb infection is important and some individuals are able 
to clear the infection without developing an adaptive immune response to Mtb, also referred 
to as early clearance (EC) (Verrall et al. 2013). After EC, the TST and/or IGRA tests remain 
negative because the T cells are not primed (Figure 1.3). If EC is not achieved, CD4+ T cells 
secreting IFN-ү are subsequently recruited and the adaptive response initiated (Verrall et al. 
2013). Once T cells are primed and effector memory T cells against Mtb antigens are in 
circulation, the TST or IGRA becomes positive (Figure 1.3). The major host innate immune 
cells that are important during Mtb exposure are macrophages, dendritic cells (DCs), 
neutrophils and the natural killer (NK) cells (Sia et al. 2015). Mtb interacts with the receptors 
expressed on the surface of these innate cells called pattern recognition receptors (PRRs) 
such as toll-like receptors (TLRs), Nod-like receptors (NLRs) and C-type lectin receptors 
(CLRs) (Killick et al. 2013). 
                                     
 
 
Figure 1.3: Possible outcomes after Mtb exposure: 1) Stage I and stage II showing early clearance which 
involves innate immune response, and no apparent adaptive immune response, resulting in IFN-y release assay 
(IGRA) and tuberculin sensitivity test (TST) negativity, 2) stage III involving adaptive immune response and delayed 





Macrophages are known to be the primary defence cell type during the initial encounter with 
Mtb. Mtb pathogen associated molecular patterns (PAMPs) such as glycolipids, lipoproteins 
and carbohydrates are recognized by PRRs on macrophages and induce a network of 
signalling pathways that will favour antimicrobial effector functions within macrophages (Sia 
et al. 2015). The mechanisms used by macrophages to eliminate Mtb involve inflammasome 
activation, production of oxygen and nitrogen components, phagosome acidification, 
autophagy of intracellular Mtb and apoptosis (Cadena et al. 2016). IFN-y plays an important 
role in host response against Mtb infection and activates macrophages to kill and restrict Mtb 
growth. In addition, IFN-γ induces the production of cytokines such as IL-12 and TNF-α by 
macrophages and other myeloid cells while inhibiting IL-10 production (Flynn et al. 1993; 
MacMicking et al. 1997; Liu et al. 2003; Mcnab et al. 2014). Type 1 interferons; IFN-α and IFN-
β are associated with unfavourable outcomes during Mtb infection (McNab et al. 2014) through 
inhibition of macrophages responsiveness to IFN-y and subsequent activation (Mcnab et al. 
2014). Studies have shown decreased bacterial load and increased survival of mice when 
IFN-α and IFN-β signalling are inhibited (Manca et al. 2005; Ordway et al. 2007; Stanley et al. 
2007). Mtb infected IFN-αR1 knock out mice had a significantly lower bacterial burden 
compared to wild type mice (Mcnab et al. 2014). When knock out mice were treated with both 
IFN-β and IFN-y, no change in bacterial load was observed, suggesting that type I IFNs inhibit 
macrophage restriction of Mtb growth and killing in response to IFN-y (Mcnab et al. 2014). 
Type I IFNs may therefore act to interrupt Th1 immune response, by making macrophages 
unresponsive to IFN-y and subsequently suppressing production of pro-inflammatory 
cytokines. Additionally, type I IFNs may act directly to prevent IFN-y mediated killing of Mtb by 
macrophages, allowing Mtb to replicate within these cells (Mcnab et al. 2014). The role of type 
1 IFNs is not universally observed, type 1 IFNs were shown to reduce the number of 
macrophages in the lung, reducing Mtb target cells in the lung, while addition of IFN-ү 
enhances their ability to restrict bacterial Mtb growth (Desvignes et al. 2012). It is speculated 
that the contradicting results are due to the different Mtb strain used and differences in study 
designs (Mcnab et al. 2014). 
DCs are key players in innate immunity during Mtb infection (Bhatt and Salgame, 2007) and 
are important for the transitioning from innate to adaptive immune response (Prendergast and 
Kirman, 2013). They are antigen presenting cells (APCs) and secrete cytokines that activate 
naive lymphocytes (Mellman et al. 2001; Sia et al. 2015). DCs secrete IL-12 (Giacomini et al. 
2001), which subsequently activate NK cells and T cells to produce IFN-y. DC-specific ICAM-
grabbing nonintegrin (DC-SIGN) is the predominant receptor on human DCs that recognises 
Mtb (Tailleux et al. 2003). The mycobacterial macrophage receptors such as complement 




mycobacterial ligand lipoglycan lipoarabinomannan (LAM) by DCs. This may be due to the 
greater abundance of DC-SIGN on DCs relative to CR3 and MR (Tailleux et al. 2003).  
Tailleux et al. investigated DC-SIGN trafficking in DCs infected with GFP-expressing Mtb 
H37Rv using confocal microscopy (Tailleux et al. 2003). During early phagocytosis (first hour), 
most bacilli were detected on the cellular membrane of DCs or co-localized with DC-SIGN in 
nascent phagosomes. DC-SIGN staining was not detected on phagosomes that had detached 
from the plasma membrane, indicating that it was excluded from the vacuoles immediately 
after phagocytosis (Tailleux et al. 2003). It is thus thought that DC-SIGN is rapidly expelled 
from the phagosome and recycled to the cell membrane (Tailleux et al. 2003). The intracellular 
trafficking pattern of DC-SIGN in Mtb infected DCs could also indicate that DC-SIGN 
transports the mycobacterial glycolipids from the bacterial vacuole to various subcellular 
compartments, where glycolipids could be loaded onto CD1 molecules for presentation to CD1 
restricted lymphocytes (Schaible et al. 2000). Mtb exploits this pathway to gain access to DCs 
via DC-SIGN. In doing so they can impair DC function and down-regulate DC mediated 
responses (Geijtenbeek et al. 2003; Mihret, 2012).  
NK cells form part of the innate immune response, and have been identified as inflammatory 
cytokine producing and cytotoxic lymphocytes and are largely known for their role in protection 
against viral infections and tumorigenesis (Sivori et al. 1997; Moretta et al. 2002), as well as 
controlling Mtb infection (Guerra et al. 2012). NK cells mediate their effector function indirectly 
by activating macrophages via IFN-ү and directly through the production of cytotoxic granules 
such as perforin, granzyme and granulysin (Liu et al. 2017). NK cells can also kill Mtb infected 
monocytes through direct contact and not via IFN-ү or cytotoxic granules (Brill et al. 2001). 
Additionally, it has been reported that NK cells can produce IL-22 and restrict intracellular Mtb 
growth by enhancing phagolysosomal fusion (Dhiman et al. 2003; Allen et al. 2015). 
Furthermore, IL-21 produced by T cells plays a role in the regulation of NK cell function and 
NK cells activated by IL-21 produce cytotoxic granules that lyse Mtb infected monocytes 
(Paidipally et al. 2018). NK cells are associated with early resistance against intracellular 
pathogens (Junqueira-kipnis et al. 2003). Mice infected with Mtb by aerosol, have an increased 
frequency of IFN-ү producing NK cells in their lungs (Junqueira–Kipnis et al. 2003). After 
depleting the NK cells, there was no difference in the lung bacterial burden, suggesting that 
removing NK cells do not necessarily have an impact in the early protective response to Mtb.  
Using cell-type deconvolution of transcriptomic data from several cohorts of different ages, 
genetic backgrounds, geographical locations and infection stages, an increase in the 
abundance of circulating NK cells in individuals with LTBI, with a corresponding decrease 
during active disease and higher levels upon clinical cure are features that are common to 




Neutrophils play an important role in TB immunity, they are the first, and most abundant cell 
type to be recruited to the lung after Mtb infection (Korbel et al. 2008). The role of neutrophils 
during Mtb infection is conflicting, for example, antimicrobial effectors from neutrophil granules 
such as elastase, collagenase, and myeloperoxidase can mediate both anti-mycobacterial 
activity and immunopathology in human TB (Dallenga and Schaible, 2016; Sia et al. 2015). 
One mechanism which leads to immunopathology involves the ESAT-6 mediated induction of 
an intracellular calcium overload in neutrophils which is followed by necrosis of the cells and 
the formation of neutrophil extracellular traps (NETs) (Francis et al. 2014). Death of neutrophils 
results in NETs which contain DNA, myeloperoxides and metalloproteinases (Parker et al. 
2012; Francis et al. 2014). A neutrophil-driven IFN-inducible gene profile, consisting of both 
IFN-y and type 1 IFN-α and -β signalling was reported to be a signature for TB disease and to 
be involved in the pathogenesis of TB (Berry et al. 2010). Absolute neutrophil counts are high 
in TB patients at diagnosis and reduce to levels compared to healthy controls at the end of TB 
treatment (Veenstra et al. 2006). In addition, this increase in blood neutrophils is associated 
with delayed sputum conversion (Martineau et al. 2011). Since the discovery of the IFN related 
gene signature, many investigated the role of type 1 IFN in innate immune responses during 
Mtb infection (Donovan et al. 2017). Type I IFN signatures in TB patients are associated with 
neutrophils and studies in mice with increased susceptibility to Mtb suggest that type I IFN 
signalling facilitates infection of permissive neutrophils resulting in damaging tissue pathology 
(Donovan et al. 2017). IFN-αR knock out in mice known to be susceptible to Mtb showed 
increased survival compared to wild type mice infected with Mtb H37Rv (Dorhoi et al. 2014). 
Furthermore, early depletion of neutrophils rescued TB-susceptible mice to levels observed in 
mice lacking IFN-αR1. It was concluded that type 1 IFN alters early innate events at the site 
of Mtb invasion leading to fatal immunopathology (Dorhoi et al. 2014). Despite the 
immunopathology aspect of neutrophils (Berry et al. 2010), they restrict Mtb growth in vitro 
(Korbel et al. 2008). Neutrophil peptides 1-3, cathelicidin LL 37 and lipocalin 2, have the ability 
to restrict Mtb growth and the depletion of neutrophils in whole blood results in poor Mtb control 
(Martineau et al. 2007). Loss of autophagy related gene 5 by neutrophils sensitizes mice to 
Mtb infection (Kimmey et al. 2015). Type 1 IFN controls Mycobacterium bovis and 
Mycobacterium smegmatis growth in infected mice (Kuchtey et al. 2006; Ruangkiattikul et al. 
2017). The exact role of neutrophils during Mtb infection is controversial and this has been 
attributed to the difficulties of working with the cells. They are short lived cells, easily activated 
and cannot be cryopreserved (Lowe et al. 2012). There is thus an urgent need for further 




5.2 Innate immunity in TB-T2D 
A study conducted by Gomez and colleagues showed that there is a reduced association of 
Mtb with  monocytes in T2D patients (Gomez et al. 2013), suggesting that the ability of the 
host cells to recognize Mtb is altered. The reduced association was likely due to the reduced 
expression of complement and Fc-gamma receptors (Restrepo et al. 2014). Initially, it was 
shown that alveolar macrophages (AMs) in TB-T2D patients are less activated compared to 
TB patients, which may contribute to susceptibility to Mtb infection (Wang et al. 1999; Lecube 
et al. 2011). TB patients have hypodense AMs which are also correlated to severity of disease, 
and activation. TB-T2D patients have low hypodense AMs suggestive of less activation (Wang 
et al. 1999). The level of activation was measured by the ability of cells to phagocytose E.coli 
bioparticles. Phagocytic capacity of AMs from TB-T2D is also lower compared to AMs from 
TB patients (Lecube et al. 2011). Furthermore, altered innate immunity was shown in TB-T2D 
using a mouse model (Vallerskog et al. 2011). Mice had reduced expression of chemokine 
CCL2 and CCL5, that stimulate migration of macrophages and DC to the lung (Vallerskog et 
al. 2011). The delay in macrophage recruitment results in delayed priming of the adaptive 
immune response that is necessary to restrict Mtb replication (Vallerskog et al. 2011).  
In the lung, DCs are highly represented but if DCs cannot migrate from the lung to the draining 
lymph nodes, their ability to activate antigen specific T cells is compromised (Khader et al. 
2006). T2D influences the phenotype and function of DCs in Mtb infected individuals and 
patients with TB (Kumar et al. 2015). The frequencies of DC are lower in Mtb infected 
individuals and TB patients with T2D compared to no T2D (Kumar et al. 2015). In addition, 
DCs were found to show a trend towards a negative correlation with hyperglycaemia during 
TB disease (Kumar et al. 2016). Kumar et al. investigated the influence of TB treatment on the 
frequency of DCs (kumar et al. 2016). TB patients without T2D did not show any difference in 
the frequency of DCs during TB treatment while TB-T2D showed a diminished DC frequency 
at baseline and at month two of TB treatment, which increased at month 6 (Kumar et al. 2016). 
The authors suggested that hyperglycaemia drives these alterations in the frequency of DCs 
in TB (Kumar et al. 2016).  
TB-T2D patients have altered NK cell responses with elevated frequencies of TNF-α, IL-17A 
and IL-17F secreting NK cells compared to TB patients, following stimulation of whole blood 
with Mtb antigens (ESAT-6 and CFP-10) (Kumar et al. 2015). The frequency of NK cells 
expressing the degranulation molecule, CD107a, was diminished in TB-T2D compared to TB 
during Mtb antigen stimulation (Kumar et al. 2015). Since T2D alters the NK cell response to 
Mtb, it was suggested that this alteration contributes to the increase in disease severity and/or 
immune-mediated pathology observed in TB patients with T2D ( Kumar et al. 2015). In whole 




between the groups (Guo et al 2012). The expression of natural killer group 2 (NKG2D) 
member was, however, positively correlated to body mass index and the CD107a produced 
by NK cells was higher in the T2D patients than controls. It was suggested that the activated 
NK cells may be involved in obesity dependent chronic inflammation associated with T2D 
pathogenesis (Guo et al. 2012). 
As previously mentioned, neutrophils play an important role in TB immunity (Korbel et al. 
2008). The role of neutrophils in recurrence and increased susceptibility to mycobacterial 
infection in T2D have been suggested before (Moutschen et al. 1992). TB-T2D have been 
associated with increased neutrophilic rich inflammation (Andrade et al. 2014; Prada-medina 
et al. 2017). There is a significantly higher number of neutrophils in blood of T2D patients, but 
they exhibit reduced capacity to phagocytose mycobacteria (Raposo-Garcia et al. 2017). 
Chemotaxis of neutrophils is lower in diabetic patients compared to healthy controls (Tater et 
al. 1987). Furthermore, activation of neutrophils and bactericidal activity was lower in 
neutrophils from diabetic patients compared to healthy individuals (Delamaire et al. 1997). In 
a streptozotocin (STZ) induced murine model of chronic diabetes (diabetes induced by STZ 
for more than three months) there was a higher Mtb burden in the lungs compared to normal 
non-diabetic mice (Martens et al. 2007), highlighting the inability of diabetic mice to control 
Mtb. Mycobactericidal activity of neutrophils did not differ between T2D patients and healthy 
individuals when their PBMCs were infected with Mtb (Raposo-Garcia et al. 2017). Although 
most reports show impaired phagocytic activity, chemotaxis and activation of neutrophils in 
T2D compared to healthy individuals (Delamaire et al. 1997; Raposo-Garcia et al. 2017), 
contradicting results in the ability of neutrophils to kill bacteria exist. C3Heb/FeJ mice are 
highly susceptible to Mtb and form hypoxic, neutrophilic driven, necrotic granulomas upon 
infection with Mtb (Vilaplana et al. 2013). Treatment with ibuprofen for three to four weeks, 
after infection, improved both pathology and mycobacterial loads. After one week of ibuprofen 
treatment, fewer and smaller lung lesions with intra-alveolar neutrophils were observed in 
treated mice, whereas untreated mice had central caseous necrotic areas. Treated mice also 
had reduced pulmonary mycobacterial burden and extended survival (Vilaplana et al. 2013). 
This study shows that repurposing this widely used drug, suitable for children, ameliorates 
massive neutrophilic-associated inflammation upon Mtb infection (Dallenga and Schaible, 
2016). The reported data shows that neutrophilic inflammation in T2D patients could also be 
targeted for host directed therapy  (HDT) for TB treatment in TB-T2D patients (Prada-Medina 
et al. 2017). 
6. Innate-like T cells 
Innate-like T cells can rapidly produce cytokines after exposure to an antigen and are 




major histocompatibility (MHC) class 1-like molecules (Huang, 2016). Innate-like T cells are 
mostly restricted by Cluster of differentiation 1 (CD1) and MHC-related protein 1 (MR1) 
(Huang, 2016). CD1 is restricted to invariant natural killer T (NKT) and MR1 is restricted to 
mucosal associated invariant T (MAIT) cells. Although innate-like T cells are known to be 
abundant in mucosal sites (Dusseaux et al. 2011; Kenna et al. 2003), MR1, CD1a and CD1c 
restricted T cells are also frequent in the periphery (Gold et al. 2010; de Lalla et al. 2011; Jong 
et al. 2014). The importance of innate-like T cells is due to their ability to express invariant T 
cell receptor α (TCRα) sequences (Porcelli et al. 1993). 
6.1 Innate-like T cells in TB 
NKT cells are predominantly CD8+ (Ho et al. 2002; Gumperz et al. 2002) and express an 
invariant TCRVα24 chain paired with the TCRVβ11 chain, which enables the recognition of 
glycolipid antigens such as α-galactosylceramide (α-GalCer) on the MHC-1 like molecule 
CD1d (Godfrey et al. 2004). NKT cells express the surface receptor NK1.1, which is also 
expressed on NK cells (Tudhope et al. 2010). NKT cells are not cytotoxic (Smyth et al. 2002), 
even though they express perforin, Fas ligand (FASL) and NKG2D (Godfrey et al. 2004). Upon 
activation, NKT cells upregulate CD40L and activate monocytes, DCs, NK, T and B cells by 
producing IFN-y and IL-4, showing their importance in the transition from innate to adaptive 
immunity (Kaer, 2005; Cerundolo et al. 2009). NKT cells can function as either regulatory or 
effector cells in different diseases (Godfrey et al. 2004; Wermeling et al. 2010). The low 
frequency of NKT cells in human peripheral blood mononuclear cells (PBMCs) (between 0.05-
0.92%) (Montoya et al. 2007), impacts the study of these cells in humans. The frequency of 
NKT cells can be expanded by alpha galactosaceramide and cultured for longer period with 
autologous irradiated mononuclear cells which can then change their surface receptors and 
may differ from unmanipulated resting NKT cells (Montoya et al. 2007). 
In a murine Mtb infection model, treatment with αGalCer improved infection outcome by 
activating T cells through NKT cell activation, similarly to mice that were treated with standard 
TB chemotherapy (Sada-ovalle et al. 2010). In another study, co-culturing splenocytes from 
uninfected mice with Mtb infected macrophages, showed suppressed bacterial load due to 
NKT cell function (Sada-ovalle et al. 2008). NKT cells have been reported to play a protective 
role in the immune response of mice against Mtb, but not much is known about their role in 
human Mtb (Kee et al. 2012). To address this, PBMCs were isolated and were phenotypically 
defined using flow cytometry. Patients with TB disease had a lower frequency of NKT cells 
compared to individuals with LTBI (Kee et al. 2012; Montoya et al. 2008; Snyder-cappione et 
al. 2007; Sutherland et al. 2009). NKT cell frequencies are similar in individuals with LTBI and 
healthy controls, but higher than TB patients (Snyder-cappione et al. 2007; Sutherland et al. 




TB patients was higher compared to healthy controls and correlated with a faster TB treatment 
response (Veenstra et al. 2006). When used in combination with NK cells they were identified 
as variables indicating the likelihood of culture conversion early during TB treatment (Veenstra 
et al. 2006). It was suggested that these cells hold promise to be considered as markers for 
TB treatment response (Veenstra et al. 2006).  
MAIT cells are predominantly CD8+, with a small subset being CD4+ (Reantragoon et al. 2016). 
These cells express an invariant TCRVα7.2, C-type lectin-like receptor CD161 and 
dipeptidase CD26 and produce IFN-ү, granzyme B, granulysin and IL-17 (Gold and 
Lewinsohn, 2013; Sharma et al. 2015). MAIT cells are activated by riboflavin precursor 
metabolites in an MR1 dependent manner (Kjer-Nielsen et al. 2012;Gold and Lewinsohn, 
2011). They can also be activated by cytokines in a MR1 independent manner owing to IL-
18R, IL-12R and IFNR that are expressed on the MAIT cells (Le Bourhis et al. 2011;Ussher et 
al. 2015). MAIT cells upregulate granzyme B and perforin following activation and greatly 
enhance their killing ability of the infected cells (Dusseaux et al. 2011; Kurioka et al. 2014). In 
addition, MAIT cells have chemokine receptors, CCR2, CCR5, CCR6 and CXCR6 that allows 
them to reside in mucosal tissues (Dusseaux et al. 2011; Le Bourhis et al. 2011) (Figure 1.4). 
They also express transcription factors including RAR-related orphan receptor γt (RORγt), T-
bet and pro-myelocytic leukemia zinc-finger (PLZF) at rest (Leeansyah et al. 2014; Walker et 
al. 2012) (Figure 1.4). 
MAIT cells predominantly reside in the gut where their accumulation is dependent on MR1 
expressing B cells and commensal flora (Martin et al. 2009). They also occur in the blood 
where 1-10% of the T cells are MAIT cells (Dusseaux et al. 2011). The frequency of MAIT 
cells in bacterial and viral infections, as well as in metabolic and autoimmune diseases vary 
(Billerbeck et al. 2010; Magalhaes et al. 2015; Loh et al. 2016; Petersone and Walker, 2017), 
implying that they play an important role in the regulation of immune responses in these 
diseases. Low frequencies of MAIT cells in the blood during TB disease is due to their 
migration to the site of disease (Gold et al. 2010). Wong et al. also demonstrated this after 
measuring MAIT cell frequencies in the broncho alveolar lavage fluid (BALF) and blood of TB 
patients and TB-HIV co-infected patients (Wong et al. 2012), higher frequencies of MAIT cells 
were found in the BALF than in the periphery. The addition of MAIT cells to BCG-infected 
macrophages resulted in the increased killing of the bacteria, demonstrating the protective 
role MAIT cells play during Mtb infection (Chua et al. 2012). MAIT cells not only assist in the 
control of bacterial infection, but also in the detection of bacterially infected cells (Gold et al. 
2010; Le Bourhis et al, 2010). Cytokines such as IL-12, IL-18 produced by activated 
macrophages during Mtb infection can activate MAIT cells to release IFN-ү and TNF-α (Le 




suggested that these cells can be used as biomarkers to differentiate between LTBI and active 
TB. In addition, MAIT cell frequencies can be used to monitor TB treatment outcomes (Sharma 
et al. 2015). 
 
Figure 1.4: MAIT cell phenotype and different cellular activation pathways. Mature MAIT cells in peripheral blood 
express the chemokine receptors CCR2, CCR5, CCR6, CXCR6, the C-type lectin-like receptor CD161, the 
dipeptidase CD26 and a CD45RO+CCR7− effector memory phenotype, with the majority of human MAIT cells 
expressing the CD8 co-receptor. MAIT cells also express the transcription factors RAR-related orphan receptor γt 
(RORγt), T-bet and promyelocytic leukemia zinc-finger (PLZF) at rest. During bacterial infection, derivatives of the 
riboflavin biosynthesis pathway are presented by MR1 on the surface of APCs. Alternatively, viruses can also 
rapidly activate MAIT cells in an MR1-independent manner due to the induction of IL-18, IL-12 and IFNα. Activated 
MAIT cells express IFN-γ, TNF-α, granzyme B, perforin and IL-17 (Reproduced from (Kurioka et al. 2016)). 
 
6.2 Innate-like T cells in TB and T2D 
Little is known about the role of NKT cells in the pathogenesis of T2D. To address this, blood 
from T2D patients and healthy controls were investigated for activated and inhibitory NKT cells 
by using flow cytometry (Guo et al. 2012). There was no difference in the frequency of NKT 
cells in T2D patients compared to healthy individuals (Guo et al. 2012). NKT cell frequency 
was also examined in PBMCs and BALF of TB patients with and without T2D (Zhang et al. 
2011). There were more NKT cells in blood and BALF from TB patients with T2D compared 
to TB without T2D (Zhang et al. 2011). Further analysis in PBMCs showed that NKT cells were 
higher in TB regardless of T2D status but lower in T2D patients with no TB and also in healthy 
controls (Zhang et al. 2011). This led to suggest that NKT cells measurements could be 




In a disease such as DM which is a risk factor for TB, the frequency of MAIT cells are altered 
(Magalhaes et al. 2015). MAIT cells were shown to be activated under changes in the make 
up of the gut microbiota, their activated form are associated with increased Th1 and Th17 
cytokines (Andreone et al. 2018). MAIT cells exhibiting high levels of granzyme B as well as 
proinflammatory cytokines are thought to directly kill beta cells in humans with T1D (Rouxel et 
al. 2017), which could have an effect on the production of insulin. In obesity, however, MAIT 
cells were correlated to fasting insulin levels in children (Carolan et al. 2015) and negatively 
correlated to body mass index (BMI) in adults (Carolan et al 2015). Furthermore, bariatric 
surgery improved metabolic parameters such as BMI, HbA1c, leptin, adiponectin and was also 
associated with increased MAIT cell frequency (Magalhaes et al. 2015). There is however, no 
information on the association of MAIT cell frequencies with hormones like cortisol or DHEA 
which are known to have immunomodulatory effects (Buford et al. 2008; Dong et al. 2016). In 
end stage renal disease (ESRD), a complication of DM, MAIT cells are diminished (Juno et al. 
2018). Individuals with LTBI suffering from ESRD have a 7-50 fold chance of developing TB 
(Hu et al. 2018; Mota et al. 2015). The MAIT cells in patients with ESRD have altered GM-
CSF responses to microbial stimulation (Juno et al. 2018). Aging has also been associated 
with a reduction in MAIT cells and their ability to produce IFN-ү (Geest et al. 2018), in addition, 
T2D is also common in elderly people (Kirkman et al. 2012). Whether the alterations in MAIT 
cells in T2D patients are associated with the susceptibility of these patients to develop TB is 
not known. What we do know is that they are diminished and less activated in T2D as shown 
by the reduced expression of CD69 and CD25 as well as reduced IFN-y and TNF-α production 
(Magalhaes et al. 2015). However, the exact role of MAIT cells in metabolic diseases is 
unclear. Furthermore, little is also known about MAIT cell frequencies and functions in TB-
T2D patients.  
7. Adaptive immunity 
7.1 Adaptive immunity in TB 
Adaptive immunity is an antigen specific response and has memory, to be able to mount an 
immune response during a second encounter with the same antigen. The ability of the host to 
recognize pathogens is important for the initiation of the adaptive immune response to an 
infection (Chackerian et al. 2002). The adaptive immune response is characterized by the 
activation of T (CD4+ and CD8+) and B lymphocytes. Infected innate cells, like macrophages 
and DCs, present antigens to the T lymphocytes (Dgeda et al. 2010). Upon recognizing the 
antigen, naïve T cells will differentiate into T cytotoxic lymphocytes (TCL (CD8+)), T helper 
cells (Th1, Th2, Th17) and T regulatory (Treg) cells, to name a few. Th17 cells are known to 
secrete cytokines, such as IL-17, IL-21 and IL-22, which are responsible for the recruitment of 




production of cytokines and T cell proliferation, and modulate Th1, Th2 and Th17 responses 
(Josten and Ottenhof, 2008). It is known that progressive TB disease is associated with low 
Th1 and high Th2 activity, whereas in close contacts (CCs) of TB patients there is a high 
Th1/Th2 ratio (Lienhardt et al. 2002). Patients who present with a favourable outcome at the 
end of TB treatment show a higher Th1/Th2 ratio as opposed to patients with poor clinical 
outcome (Lienhardt et al. 2002). Mtb infection induces IFN-y responses in both CD4+ and CD8+ 
T cells, which play a central role in the containment and killing of the bacterium (Kaufman and 
McMichael, 2005). The Th1 cells produce IFN-y, IL-2, TNF-α, IL-12, GM-CSF that incite the 
activation of Th1, CD8+ CTL, macrophages and neutrophils to kill the invading pathogen 
(Dgeda et al. 2010). Once activated, CD8+ cells secrete granulysin, granzyme and perforins, 
and directly kill the cells infected with Mtb (Ngai et al. 2007). 
Cytokines such as IL-4, IL-5, IL-10 and IL-13 are produced by Th2 cells and activate B 
lymphocytes. B cells are responsible for antibody production and antigen presentation (Dheda 
et al. 2010). The presence of B cells and antibody (Ab)-responsive immune cells in TB 
granulomas supports their involvement in immune responses against Mtb infection (Tsai et al. 
2006). The role of B cells have been studied in mice, where mice deficient in B cells showed 
higher splenic, lung and liver bacterial loads, six weeks after intravenous Mtb infection 
compared to mice without B cell deficiency. B cells can therefore exert beneficial effects on 
host responses to tuberculous infection (Vordermeier et al. 1996). In another study, B cell 
knock out mice were aerosol infected with a low dose of a clinical Mtb strain (CDC 1551) and 
compared to wild type mice (Bosio et al. 2000). B cell knock out (BKO) mice had less lesions 
in the lung and delayed dissemination of bacteria from lungs to peripheral organs. BKO mice 
in which naive B cells were reintroduced, but not mice given Mtb specific antibodies (before 
infection), developed pulmonary granulomas and dissemination patterns similar to wild type 
mice (Bosio et al. 2000). Mtb specific antibodies were obtained through cardiac puncture of 
mice that were infected with the Mtb CDC 1551 strain for 30 days, a period associated with 
the secretion of antibodies against a variety of mycobacterial antigens (Huygen et al. 1990). 
In this report, B cells were associated with increased cellular infiltration of the lungs by 
macrophages, neutrophils and CD8+ T cells in wild type mice (Bosio et al. 2000). Although 
there is contradicting reports on the role of B cells in TB, their functions, such as antibody 
production and antigen presentation, show that they are an important immune cell type that 
requires further exploring. 
7.2 Adaptive immunity in TB-T2D 
TB-T2D is characterized by increased levels of Th1 (IFN-y, TNF-α, and IL-2), Th2 (IL-5, IL-10) 
and Th17 (IL17-A) cytokine responses (Kumar, et al. 2013). Stimulation of whole blood from 




(Restrepo et al. 2008). Th1 and Th17 cytokines positively correlate with HbA1c which means 
that patients with poorly controlled DM have higher levels of these cytokines (Kumar et al. 
2013). These increased Th1 and Th17 mediated cellular responses are likely contributing to 
increased immune pathology in TB disease during T2D (Kumar et al. 2013). Recently, Wang 
et al. found that the proportion of Th2 and Th17 cells, but not Th1 cells, are significantly 
increased in TB patients with T2D after antigen stimulation of whole blood cells (Wang et al. 
2018). These findings were confirmed in a study where PBMCs were stimulated with Mtb 
antigens and TB-T2D patients showed lower Th1/Th2 cytokine ratios, and a higher Th2 bias 
(Al-Attiyah and Mustafa, 2009). The decrease in Th1/Th2 ratio noted by Wang et al. in TB 
patients with T2D suggests there is an anti-inflammatory or Th2 bias in these patients that 
could contribute to the increased susceptibility seen in these patients (Wang et al. 2018). 
However in our cytokine analysis we found that TB-T2D patients had higher Th2 cytokines (IL-
4, IL-5, IL-10 and IL-13) (Manuscript in preparation). 
High expression of IL-22 is beneficial to the host in many infectious and inflammatory 
disorders, and if produced in excess can cause immunopathology (Rutz et al. 2013). In TB-
T2D, this cytokine was reported to be expressed at lower levels compared to TB patients 
(Kumar et al. 2013). In addition, TB-T2D has also been associated with increased systemic 
levels of pro-inflammatory (IL-1β, IL-6 and IL-18) and anti-inflammatory (IL-10) cytokines 
(Kumar et al. 2013). Varying results have been reported with some showing no difference in 
Th1 cytokines in TB patients with and without T2D (Gan et al. 2014; Stalenhoef et al. 2008).  
The influence of T2D on immune cells were investigated by staining whole blood with 
monoclonal antibodies for various immune cell types using flow cytometry (Kumar et al. 2015). 
TB-T2D patients have lower frequencies of effector memory CD8+ T cells and higher 
frequencies of central memory T cells compared to TB patients. Classical memory B cells 
were higher in TB-T2D compared to TB patients (Kumar et al. 2015). TB-T2D patients also 
have a higher frequency of CD4+ T cells producing Th1 cytokines compared to TB patients 
after stimulation of whole blood with Mtb antigens (Kumaret al. 2013). This hyperactive antigen 
specific T cell response in TB-T2D that is significantly higher than responses in TB patients 
without T2D may be associated with increased lung pathology in TB patients with T2D (Kumar 
and Babu, 2017). CD8+ T cells in TB-T2D patients are characterized by diminished granzyme 
B, perforin and CD107a production compared to TB without T2D, which are important for killing 
of infected cells (Kumar et al. 2015).  
 
8. Gene expression analysis in TB 
Several studies have successfully shown that blood gene transcripts are capable of 




obtained from blood transcripts is fairly new and research in this field is increasing due to its 
contribution in identifying transcriptional signatures associated with diagnosing TB and TB 
treatment responses (von Both et al. 2015; Thompson et al. 2017). Transcriptional profiling of 
whole blood RNA revealed a 16-gene signature that predicts progression from LTBI to active 
TB diseases (Zak et al. 2016). This signature predicted progression to active TB, 12 months 
prior to diagnosis of TB disease (Zak et al. 2016). Following this study, it was thought that 16 
genes are too many to incorporate in a simple point of care test, and was further optimized to 
reduce the number of genes. A four-gene signature was identified that predicts which patients 
with LTBI will develop active TB two years prior to diagnosis (Suliman et al. 2018; Thompson 
et al. 2018). Gene expression studies in serum exosomes (Lv et al.  2017), specific immune 
cells such as DCs (Blischak et al. 2017) and PBMCs (Serrano et al. 2016) also identified gene 
profiles able to predict susceptibility to TB disease. The risk of TB progression in LTBI with 
HIV and T2D is much higher than compared to otherwise healthy LTBI positive individuals 
(Jeon and Murray, 2008; Murray et al. 2014). The question is whether the identified signatures 
are equally applicable to LTBI positive individuals with other diseases. For example, the 
signature identified by Zak et al. (2016) was in HIV negative individuals and is there a need to 
test the signature in HIV positive and T2D cohorts, because these groups are at greater risk 
of TB. To address this, Dawany et al. reported that the 393-gene signature from Berry et al. 
(2010), could not identify TB in patients co-infected with HIV (Dawany et al. 2014). However, 
a transcriptional profile identified by Prada-Medina et al. in patients with TB-T2D shared 
elements with the profiles in TB patients without T2D (Prada-Medina et al. 2017).  
In South Africa, preventative treatment is not given to LTBI positive individuals, because it 
would be too expensive and ineffective due to the high chance of re-infection in a TB endemic 
country. These signatures are therefore useful and can potentially be used to identify 
individuals with LTBI who are at increased risk of developing active TB and who can potentially 
be given prophylactic treatment in an attempt to reduce the TB burden (Cohn et al. 2000). In 
a whole blood transcriptomic study, Cliff et al. identified a transcriptional signature which 
correlated with the extent of TB disease in the lung as determined by radiography and 
concluded that immune responses in the blood can reflect the local reaction to Mtb in the lung 
(Cliff et al. 2015). Not only do blood transcript signatures identify individuals at risk of TB 
development, but can also inform of the severity of the disease in the lung. Thompson et al. 
further identified a five-gene signature that predicts TB treatment outcomes which correlated 
with the inflammatory state in the lungs of TB patients as measured by positron emission 
tomography–computed tomography (PET-CT) (Thompson et al. 2017). Bio-signatures to 
determine relapse and which can be applied to different ethnic groups and co-morbidities, 





9. Immune and endocrine interactions 
Cytokines produced by activated immune cells feed back to the central nervous system and 
induce neuroendocrine responses that, in turn, can modulate immune responses to infections 
(Webster et al. 2002). Chemical messengers produced by the immune cells facilitate the 
communication between the immune and neuro-endocrine system and also the immune and 
central nervous system (CNS) (Dantzer et al. 1998; Bottasso et al. 2012). Chronic, low-level 
inflammation that occurs during T2D travels to the brain and activate the hypothalamic-
pituitary-adrenal (HPA) axis, and the sympathetic system (Bottaso et al. 2012; Bouzaki and 
Zierath, 2007; Ottaviani and Francheschi, 1996; Chrousos, 2000). Activation of the HPA axis 
results in the production of corticotropin-releasing hormone (CRH) and vasopressin (VP), 
which travels via the portal vein to the pituitary gland and activate corticotropic cells, which 
subsequently produce adrenocorticotropic hormone (ACTH) (Antoni, 1986; Aguilera, 1994; 
Aguilera, 2012). ACTH travels to the adrenal gland which has two major zones; the cortex and 
the medulla, which will produce glucocorticoids (GCs) and catecholamines (CA), respectively 
(Rhen and Cidlowski, 2005; Aguilera, 2012). GCs inhibit Th1 responses by favouring Th2 
cytokine responses (Howard and Zwilling, 1999). Chronic stress, for example, leads to the 
activation of the sympathetic system and results in the upregulation of the CAs, adrenaline 
and noradrenaline (Figure 1.5) (Webster and Glaser, 2008; Tian et al. 2014). GCs and CAs 
bind to their receptors on immune cell and inhibit the secretion of pro-inflammatory cytokines 
such as IL-1β, IL-6, TNF-α and IFN-y, and enhances the production of anti-inflammatory 
cytokines such as IL-4, IL-13 and IL-10 (Figure 1.5) (Elenkov and Chrousos, 1999; Tracey 
2002). In addition, GCs will inhibit transcription factors such as nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-kB), activator protein 1 (AP-1), Janus kinase/signal 
transducers and activators of transcription (JAK-STAT), mitogen activated kinases, signal 
transducer and activator of transcription 3, which may in turn inhibit pro-inflammatory cytokine 






Figure 1.5: The activation of the HPA axis, sympathetic and immune system. Stress activates the HPA and 
Sympathomedullary axis which secrete (i) GC and (ii) CA hormones respectively, the hormones act on receptors 
on the surface or cytoplasm of the immune cells. (iii) Motor vagus secretes CAs, which in the end result in 
decreased pro-inflammatory cytokines while increasing anti-inflammatory responses. (iv) There is a shift to Th2 
opposed to Th1 responses. (v) In the cell, the hormones inhibit inflammation related pathways including NF-kB and 
further inhibit pro-inflammatory responses (Adapted from (Tian et al. 2014)). 
 
Serotonin, produced by nerve cells also has immune modulatory properties. Serotonin is 
stored in platelets and is released during platelet activation induced upon inflammation (Herr 
et al. 2017). The immunomodulatory effects of serotonin are mediated through binding to the 
serotonin receptors expressed on immune cells (Mossner and Lesch, 1998). Binding of 
serotonin to the 5 hydroxytryptamine-1 (5HT-1) receptor on monocytes, reduced the ability of 
the monocytes to suppress NK cell functions (Hellstrand and Hermodsson, 1993). In addition, 
the effect of serotonin on IFN-y-induced phagocytosis varies according to the concentration of 
IFN-y to which the macrophages are exposed (Sternberg et al. 1987). At low concentrations 
of IFN-y, serotonin augments phagocytosis, whereas at high concentrations of IFN-y, 
serotonin suppresses phagocytosis (Sternberg et al. 1987). Serotonin induces the production 




and lymphocyte (IL-2, IL-16 and IFN-ү), but supresses TNF-α production in monocytes, 
macrophages and DCs (Figure 1.6) (Duerschmied et al. 2014) supporting the notion of the 
bidirectional communication between central nervous and immune system. 
 
 
Figure 1.6: Immunomodulatory properties of serotonin. Blue - activated or upregulated, red - inhibited or 
reduced, question mark - unknown effect (Duerschmied et al. 2014). 
9.1 Immunendocrine changes during TB 
The pituitary gland produces ACTH (HPA axis), luteinizing hormone (LH) and follicle-
stimulating hormone (FSH) (HPG axis) as well as thyroid-stimulating hormone (TSH) (HPT 
axis) resulting in the production of cortisol by the adrenal gland, oestrogen and testosterone 
by the gonads as well as triiodothyronine and thyroxine by the thyroid gland. Activation of the 
HPA axis influences the behaviour of the immune system via GCs and 
dehydroepiandrosterone (DHEA), which counteracts the GC effects (Webster et al. 2002; 
Bottasso et al. 2007). GCs can both inhibit or stimulate the innate and adaptive immune 




hormones of the pituitary, adrenal, gonadal and thyroid glands in male patients with newly 
diagnosed TB and compared them to healthy controls (del-Rey et al. 2007). TB patients had 
increased plasma concentrations of the above mentioned cytokines and decreased 
concentrations of testosterone and DHEA (del-Rey et al. 2007). Growth hormone (GH) 
concentrations were higher in TB patients, higher concentrations were seen for cortisol, 
estradiol, thyroid hormones and no differences were observed in insulin like growth factor 1 
concentrations (del Rey et al. 2007). Immune responses during TB therefore affect endocrine 
functions (Turnbull and Rivier, 1999; Van den Berghe 2003). Since GCs favour Th2 
responses, elevated concentrations of GCs are not favourable for the development of the 
effective cell mediated response against Mtb (Bottasso et al. 2013). Supernatants from 
cultures of Mtb stimulated PBMCs of TB patients have been shown to inhibit DHEA secretion 
by a human adrenal cell line (del-Rey et al. 2007). Chronic persistence of decreased DHEA 
concentrations and of increased cortisol/DHEA ratios have harmful consequences for the host 
due to uncontrolled inflammatory processes that may affect the control of tissue damage and 
the development of protective immune responses (Imrich, 2002). TB patients have higher 
cortisol, estradiol, prolactin, GH, thyroid hormone and dopamine concentrations, as well as 
lower adrenaline and noradrenaline concentrations when compared to healthy controls (del 
Rey et al. 2007; Opolot et al. 2015). TB patients also have higher IFN-y, TNF-α, C-reactive 
protein (CRP), IL-1β, IL-6 and IL-10 levels compared to healthy controls (del Rey et al. 2007; 
Opolot et al. 2015). Kleynhans et al. showed that concentrations and treatment responses of 
various hormones were different in patients with different TB treatment outcomes (Kleynhans 
et al. 2017). Cortisol concentrations were higher in TB disease and decreased during 
treatment and remained lower in the cured group while it was higher in individuals who failed 
TB treatment (Kleynhans et al. 2017). Cortisol concentrations in patients with a failed TB 
treatment outcome correlated with immune markers such as CRP and serum amyloid protein 
–A (SAP-A) and interleukin 2 receptor subunit alpha (IL-2Rα) at baseline, matrix 
metalloproteinase 9 at week four of TB treatment and interferon inducible protein-10 (IP-10) 
at the end of treatment (Kleynhans et al. 2017). Increased inflammatory marker levels during 
TB results in increased cortisol concentrations as part of a feedback mechanism to prevent 
excessive inflammatory responses and immunopathology. These data provide evidence that 
there exists a relation between endocrine and immune systems during TB and the interaction 
between these systems need to be studied further and can potentially be used as biomarkers 
for TB disease progression, severity and even treatment responses. There is a dysregulation 
of the HPA, HPG and HPT axis, and the production of pituitary hormones during severe TB 
disease, and such dysregulation might be responsible for the aggravation of the disease 




9.2 Immune-endocrine changes in TB-T2D 
T2D is a known risk factor for TB and studies have shown that both diseases have altered 
endocrine responses, which are likely to play a role in certain immuno-endocrine-metabolic 
associated disorders (Fernandez et al. 2016). As mentioned previously, endocrine alterations 
can contribute to TB disease outcomes (Bottasso et al. 2013). The chronic inflammation 
contributes to the activation of the HPA axis and increases the severity of infections or lead to 
susceptibility to such infections through the suppressive ability rendered by GCs (Besedovsky 
and del-Rey, 1996; Bottasso et al. 2013). The occurrence of both TB and T2D may present a 
particular trend of immune and endocrine activation that is worth investigating in order to 
understand the association between the two diseases (Fernandez et al. 2016). In light of 
these, Fernandez and colleagues analysed blood levels of cytokines, hormones and immune 
responses to mycobacteria in TB-T2D patients. It was found that TB patients had higher 
concentrations of cytokines compared to healthy controls whereas TB-T2D patients had even 
higher IL-6 and IFN-y compared to TB patients (Fernandez et al. 2016). IL-10 levels remained 
the same between TB and TB-T2D but lower in healthy subjects (Fernandez et al. 2016). In 
the same study, the concentration of cortisol was found to be higher in individuals with TB-
T2D (Fernandez et al. 2016). Bottasso et al. showed that higher cortisol is associated with TB 
severity (Bottasso et al. 2013) and TB-T2D patients were previously reported to have more 
severe TB disease than patients with only TB (Baker et al. 2012; Gil-santana et al. 2016). 
Estradiol levels were high in patients with TB and significantly higher in patients with TB-T2D 
(Fernandez et al. 2016). Estradiol and cortisol were positively associated with IFN-y and IL-6 
(Fernandez et al. 2016). The adverse immune-endocrine profile observed in TB patients is 
more pronounced during TB concomitant with T2D characterised by more intense immune 
and endocrine inflammatory reactions, which shows the detrimental effects of T2D on Mtb 







10. Hypothesis, Aims and Objectives 
Central hypothesis  
We hypothesize that T2D causes a systemic dysregulation of the immune-endocrine 
networks which is associated with distinct blood bio-signatures and impaired monocytes and 
PBMCs function. 
Aim 1: 
The first aim of this project was to identify differentially expressed immune genes in 
unstimulated and Mtb-antigen stimulated whole blood of latently infected close contacts of TB 
patients as well as active TB patients with and without T2D. 
Specific objectives were to: 
1.1 Characterize messenger ribonucleic acid (mRNA) transcript signatures in unstimulated 
(nil) and Mtb-antigen stimulated whole blood collected from QFT tubes of individuals with 
LTBI with and without T2D. 
1.2 Characterize the mRNA transcript signatures in unstimulated (nil) and Mtb-antigen 
stimulated whole blood collected from QFN tubes of TB patients with and without T2D at 
baseline and month 6. 
Aim 2: 
To investigate immune and endocrine changes in the serum and plasma of individuals with 
LTBI as well as TB patients with and without T2D. 
Specific objectives were to: 
2.1 Characterize cytokine and hormone levels in individuals with LTBI and TB patients with 
and without T2D using luminex and ELISA. 
2.2 Determine whether any associations exist between cytokine and endocrine signatures 
with in vitro Mtb killing. 
2.3 Determine whether any associations exist between glycaemic control and in vitro Mtb 
killing. 
Aim 3: 
To determine the frequency of MAIT cells in TB patients with and without T2D. 
Specific objectives were to: 








Materials and methods 
2.1.1 Informed consent and ethical clearance 
This study was part of the ALERT and TANDEM studies. Ethical approval was obtained for 
the ALERT Study (Altered Immune-endocrine Axis in Type 2 diabetes and Tuberculosis 
risk:which was aimed at better understanding of the link between TB and T2D,  to identify 
individuals at increased risk for TB progression) and the TANDEM study (Concurrent 
Tuberculosis and Diabetes: aimed at improving Care through bi-directional Screening and 
Unravelling the Causal Link through Study of Genetic Susceptibility Factors) from the Human 
Research Ethics Committee of the University of Stellenbosch (N13/05/064, TANDEM and 
N13/05/064A, ALERT). The studies were conducted according to the Helsinki Declaration and 
International Conference on Harmonization guidelines (WMA, 2001). Written informed 
consent was obtained from all study participants. 
2.1.2 Study participants and sample collection 
Individuals with LTBI with and without T2D were screened and enrolled as part of the NIH 
funded ALERT study. Individuals with LTBI were defined as individuals sharing at least five 
hours per week in a house or closed space with a confirmed pulmonary TB case, test positive 
for Quantiferon IFN-ү assay and negative for active TB (discussed in II below). TB patients 
with and without T2D were enrolled in the EU FP7 funded TANDEM study, before TB 
treatment (baseline, BL), after completion of intensive phase treatment at month 2 (M2) and 
at the end of TB treatment (M6). TB patients were recruited at six TB clinics, Fisantekraal, 
Ravensmead, Uitsig, Adriaanse, Elsies River and Durbanville, in Cape Town, Western Cape, 
South Africa. TB patients gave permission for study personnel to visit their homes and to invite 
their family members and close friends to take part in the study. 
i. ALERT participants 
Forty CCs of TB patients who tested positive for LTBI on a Quantiferon TB-Gold in-tube (QFT) 
assay were included in this study. All the ALERT participants were fasted and the specimens 
collected before 09:00AM to control for circadian rhythm. At enrolment, clinical parameters 
such as insulin, cortisol, lipid profiles, complete blood count (CBCs) and anthropometric 
measurements were determined. T2D status was diagnosed based on a FBG and HbA1c 
(American Diabetes association, 2010). Patients were classified as LTBI without T2D (LTBI-
noT2D; n = 10; HbA1c < 5.6 %, FBG ≤ 100 mg/dL (5.6 mmol/L)), LTBI with preT2D (LTBI-
PreT2D; n = 10; HbA1c 5.7-6.49 %, FBG 100-125 mg/dL (5.6-6.9 mmol/L)), LTBI with T2D 
(LTBI-T2D; n = 10; HbA1c 6.5-7.9 %, FBG ≥ 126 mg/dL (7 mmol/L)) and LTBI with poorly 




ii. Inclusion and exclusion criteria for ALERT 
The inclusion criteria were LTBI (based on positive QFT assay) and the age of 30 to 65 years. 
Individuals were excluded if they were HIV positive, pregnant or breast-feeding, if they had 
active TB (confirmed by positive GeneXpert MTB/RIF (Cepheid, California, USA), sputum 
culture or abnormal chest X-ray (CXR), type 1 diabetes, and if they used steroids or any other 
medication that affects immunity (i.e. non-steroidal anti-inflammatories). 
iii. TANDEM participants 
HbA1c was measured at BL and at M6 for TB patients. TB patients were classified as TB only 
(n = 9), TB with transient hyperglycaemia (TB-THG; n = 5) and TB with T2D (TB-T2D; n = 7) 
using HbA1c cut-offs as follow: HbA1c <5.6 % for TB, HbA1c ≥ 6.5 % for TB-THG at BL but 
normal at M6, and HbA1c ≥ 6.5 % for TB-T2D at BL and M6. Four of the five TB-THG patients 
had a family history of diabetes, but were not taking diabetes medication during the course of 
the study. All TB-T2D patients were on standard TB treatment (Isoniazid (INH), RIF, 
Ethambutol (EMB) and Pyrazinamide (PZA) for the first two months, and INH and RIF for the 
following four months) as recommended by the South African National Tuberculosis program, 
and all seven were on T2D medication (Insulin and/or metformin). Twelve uninfected HCs and 
13 T2D patients without TB were included as controls. All the TANDEM participants were 
between the ages of 30 and 60 years and were age and gender matched.  
iv. Inclusion and exclusion criteria for TANDEM 
The inclusion criteria were TB disease confirmed by abnormal CXRs, positive GeneXpert 
MTB/RIF (Cepheid) and/or positive MGIT (BD BACTEC MGIT 960 system, BD, New Jersey, 
USA) culture. The TB patients received conventional TB therapy (described above). 
Participants were excluded if they were pregnant, HIV positive, had drug resistant Mtb and 
were using immunosuppressive drugs. All TB, TB-THG and TB-T2D patients used for this 
study adhered to and completed more than 80 % of their TB treatment and all were 
successfully cured at the end of treatment. 
2.1.3 Sample processing for ALERT study 
Blood collected in Sodium heparin (NaHep; BD), serum (Geiner bio-one, Kremsmunster, 
Austria), EDTA (Geiner bio-one) and Lithium heparin tubes (LiHep; BD)) and sputum were 








i. Plasma and serum isolation 
EDTA (1x 6 mL) and serum (2x 6 mL) blood tubes were spun down at 12 000 xg (Eppendorf 
centrifuge 5702, Merck-Millipore, Massachusetts, USA) for 10 minutes and the plasma and 
serum aliquoted and stored at -80°C for further use. 
ii. Quantiferon TB-gold in tube (QFT) processing 
One mL of blood, collected in a LiHep tube (1x 4 mL), was transferred to each of the three 
tubes of the QFT assay (Qiagen, Hilden, Germany). The nil tube contains no additives and 
serves to adjust for background IFN-y production, the TB-Ag tube is coated with an antigen 
cocktail including ESAT 6, CFP-10 and TB 7.7 specific for Mtb and the mitogen tube contains 
phytohaemogglutin-P (PHA) which is a positive control. After adding the blood, the tubes were 
inverted ten times and incubated at 37 °C for 16-22 hours. Blood was transferred from the 
QFT tubes into a 2 mL cryogenic vials (Sigma-Aldrich, Missouri, USA ) and centrifuged for 15 
minutes at 15 000 xg. The supernatants were stored at -80 °C and the pellet stored in 
RNALater (Thermo Fisher scientific, Virginia, USA) at 4 °C overnight, before being transferred 
to -80 °C. The preserved QFT pellets were used for RNA extractions and the supernatants 
used in an ELISA to measure IFN-y concentrations.  
iii. Peripheral blood mononuclear cells (PBMCs) isolation 
Blood collected in NaHep tubes (6x 9 mL) was used for PBMC isolations by density gradient 
centrifugation. Briefly, blood were transferred to 50 mL falcon tubes (Sigma-Aldrich) and 
centrifuged at 800 xg for 12 minutes at 20 °C (acceleration=9; brake=0). The plasma was 
transferred to a 15 mL falcon tube (Corning Science, Newyork, USA) and stored on ice. Care 
was taken not to disturb the white blood cell interphase. The remaining plasma, white blood 
cell interphase and top part of the red blood cell layer were transferred to a new 50 mL falcon 
tube (Corning Science) and mixed. PBS containing 1 mM EDTA (Sigma-Aldrich) and 1 % 
Human serum albumin (SEH) were added to the cells (up to 35 mL mark), to replenish the 
plasma, and mixed by pulse vortexing. The cells were layered onto 15 mL Ficoll-Paque-Plus 
(GE HealthCare Bio-science, Uppsala, Sweden) and centrifuged at 600 xg for 30 minutes at 
20°C (brake=0; acceleration=0). Plasma, including SEH, was removed except for 5-10 mL 
above the buffy coat. The buffy coat was transferred to a 50 mL tube and washed with cold 
RPMI-HEPES medium (Sigma-Aldrich). Cells were centrifuged at 4°C at 600 xg for four 
minutes (acceleration=9; brake=0) after which the supernatant was discarded. Cells were 
washed for a second time using RPMI-HEPES and spun down at 4°C at 150 xg for eight 
minutes (acceleration=9; brake=0) to remove excess platelets. The supernatant was 




supplemented with 2 mM glutamine (GLUT; Sigma-Aldrich) and 100U/mL penicillin (PEN; 
Sigma-Aldrich) (RPMI+GLUT+PEN). 
iv. Counting of PBMCs and overnight culturing: 
Ten µl of the cell suspension were added to 90 µl of 10 % Trypan blue (in PBS) and counted 
using a Countess Cell counter (Invitrogen, California, USA). The total cell count, live cell count, 
dead cell count and viability (%) were reported and the live cell count used to determine the 
number of cells needed for the downstream assays. Six hundred thousand cells were cultured 
overnight in RPMI+GLUT+PEN medium containing 20 % autologous plasma in 2 mL sterile 
screw cap tubes (Scientific specialists SSIBIO USA), in a final volume of 600 μl at 37 °C and 
5 % CO2. 
v. Monocytes (MNs) isolation 
MNs were isolated from PBMCs using the Miltenyi Pan Monocyte isolation kit and LS MACS 
separation columns (Miltenyi biotec, Bergisch Gladbach, Germany). PBMCs were spun down 
at 300 xg for 10 minutes at 4 °C and the supernatant discarded. FcR blocking reagent and 
biotinylated antibody (Ab) cocktail were added and the cells incubated for five minutes at 4 °C. 
MACS buffer was added as well as anti-biotin microbeads, the cells were again incubated for 
seven minutes at 4°C. During the incubation step, the columns were primed with MACS rinsing 
buffer (Miltenyi biotec) and the volume of the cell suspsension adjusted to a total volume of 
500 µl using the MACS rinsing buffer. The cell suspension was applied to the column and the 
flow-through containing the monocytes collected in a 15 mL tube. The column was washed 
three times with 3 mL rinsing buffer. The cells collected as part of the flow-through was 
centrifuged at 300 xg for seven minutes at 4 °C, the supernatant discarded and the pellet 
resuspended in 1 mL RPMI+GLUT+PEN media. The MNs were counted, as mentioned above, 
and 130 000 cells/well were seeded in poly-D-lysine coated flat bottom plates (Corning 
Sciences, USA) in a final volume of 200 μL and incubated overnight at 37 °C and 5 % CO2. 
Purity checks were performed for the first participants and we confirmed the purity to be > 90 
% with all of the isolations. Due to the limited number of cells, we did not do it for all 
participants. Purity check was performed by staining a fraction of the isolated MNs using 
monoclonal antibodies anti-human CD14 and anti-human CD16. The MNs were centrifuged 
at 400 xg for five minutes and the media was discarded. MNs were incubated with the 
antibodies for 30 minutes at 4°C. After washing with FACS buffer, MNs were fixed with 4 % 
formalin for 15 minutes in the dark. Formalin was washed off with 1 mL FACS buffer and the 
cells resuspended in 100 µl FACS buffer prior to acquisition. Stained cells were kept at 4°C 





vi. PBMCs and MNs infection with Mtb H37Rv to determine Mtb uptake and killing 
After overnight culturing, the PBMCs were centrifuged at 400 xg for five minutes, the 
supernatant discarded and the cells washed with 600µl RPMI-HEPEs. MNs adhered to the 
poly-D lysine coated flat bottom plates, therefore no centrifugation was required before 
aspirating the media and washing the cells with 200 µl RPMI-HEPES. PBMCs and MNs were 
infected for two hours with Mtb H37Rv at an MOI of 3.25:1 and 1:1 respectively, washed and 
further incubated for one day and three days (for MNs) or six days (for PBMCs) in RPMI+GLUT 
media supplemented with 20 % autologous plasma at 37 °C and 5 % CO2. Culture 
supernatants collected from PBMC (after two hours, day one, day three and day six) and MNs 
(after two hours, day one and day three) were filter sterilized using Millex 4 mm syringe filters 
(Merck-Millipore) and stored at -80°C until cytokine profiling. 
At each of the time points, PBMCs and MNs were washed and lysed using 0.05 % SDS for 
five minutes. The SDS was diluted out by adding an equal volume (300μL) of Middlebrook 
7H9 broth (BD). The lysates were serially diluted and plated on 7H11 Middlebrook (BD) plates. 
The plates were monitored weekly for contamination and the colony forming units (CFU) 
enumerated after three weeks. Additional PBMCs were removed from the tubes using 2 mM 
EDTA (Sigma-Aldrich) and stored in RNALater (Invitrogen) at 4 °C overnight and transferred 
to -80 °C the following day until RNA was isolated.  
Some MNs were treated with 100 µl of Cetyltrimethyl ammonium bromide (CTAB; Sigma-
Aldrich) for 10 minutes to lyse the cells. Nuclei were then counted using a haemocytometer to 
determine the number of viable cells.  
2.1.4 Sample processing for the TANDEM study 
Serum, plasma, whole blood (stored in RNALater) and cryopreserved PBMCs were previously 
collected and stored as part of the TANDEM study and analysed as mentioned below. 
2.1.5 RNA extraction study 
RNA was extracted from the QFT assay cell pellets for both the ALERT and TANDEM study. 
The pellet, which was stored in RNALater (as mentioned above), was thawed and total RNA 
extracted using the Ribopure Ambion RNA isolation kit (Life Technologies, Carlifornia, USA). 
The extraction was done according to the manufacturer’s instruction. Briefly, samples were 
thawed and spun down at 14 000 xg (Eppendorf centrifuge 5415C, Merck-Millipore) for one 
minute. The supernatants were discarded and lysis buffer added to the pellets. Sodium acetate 
solution was added and the samples vortexed to ensure all the cells were lysed. Chloroform 
(350 μl) was added to the cell lysates and the samples vortexed to remove DNA and proteins, 
followed by five minutes incubation at RT. The mixture was centrifuged for a minute at 14 000 




grade ethanol (600 µl) was added to the aqueous phase and the samples vortexed. The 
samples were transferred to a column, centrifuged and the flow through discarded. The 
column was washed with buffer 1 and again with buffer 2/3 and centrifuged for 10 seconds at 
14 000 xg after each wash step. The RNA was eluted in a total volume of 100 µl elution buffer. 
The eluted RNA was treated with 8 U/ µl DNase I, which is included in the Ribopure Ambion 
isolation kit (Life Technologies), for 30 minutes, to remove DNA. DNase activity was halted by 
adding the inactivation reagent and incubating the samples for two minutes at RT. After 
centrifuging the sample, the supernatant was collected into a new tube and quantified (see 
below). RNA samples were divided into 20 µl aliquots, to avoid multiple freeze-thaw cycles, 
and stored at -80 °C. 
2.1.6 RNA quantification, gene expression assay and data analysis 
Total RNA was quantified using the Nanodrop 2000c spectrophotometer (Thermo Fisher 
Scientific) and the RNA Qubit kit (Life technologies, Oregon, USA). Samples with a 
concentration of ≥ 20 ng/µl and a 260/280 and 260/230 ratio of ≥ 1.7 were included in the 
NanoString analysis. Eighty-four TANDEM and 80 ALERT samples were shipped to 
NanoString Technologies in Seattle Washington through their Cape Town supplier, Anatech, 
to determine the gene expression of 594 genes included in the nCounter GX Human 
Immunology kit V2 (supplementary Table 1). The nCounter analysis platform from NanoString 
is a direct digital detection assay of individual target molecules and does not require any 
amplification or reverse transcription step. Briefly, 100 ng of each RNA sample was added to 
the hybridization buffer containing the Codeset and incubated at 65 °C for 16 hours. The 
CodeSet consists of reporter and capture probes that hybridize to the target sequences of 
interest, forming a tripartite complex. The complexes were purified and immobilized onto the 
surface of a sample cartridge on the prep station using the high sensitivity protocol pre-set. A 
microscope with CCD camera was used to capture images of the surface of the sample 
cartridge where the barcodes were bound and gene transcripts were counted. The barcodes 
were decoded and cross-referenced to a specific target resulting in actual counts of specific 
target molecules in a particular sample (Gene expression assay user manual, NanoString 
Technology, Seattle, WA). Zipped RCC files were received from NanoString Technology. 
NanoString RCC data files were imported into the nSolver 3 software (nSolver Analysis 
software, v3.0) where they were normalized to housekeeping genes. The housekeeping genes 
had an average read count four fold higher than the negative controls and any gene with 
counts less than 20 was reported to be negative. The analysis was done, in consultation with 
a biostatistician at the University of Queensland, using JMP statistical software (SAS Institute 
for comparing gene expression) and the nil and Ag/nil ratio of the gene expression between 




2.1.7 Enzyme linked immunosorbent assay (ELISA) in ALERT samples 
Stored plasma samples were thawed on the day the ELISA was done and all the reagents 
were brought to RT before being used. 
i. Elabscience® ELISA kit: Serotonin (5-hydroxytryptamine) ELISA 
The serotonin competitive ELISA (Biocom, California, USA) was performed following the 
manufacturer’s instructions. Briefly, 50 µl of the samples, standards and blank were added in 
duplicate to the pre-coated plate to the positions indicated on the template. Fifty µl of 
biotinylated detection antibody was added to the wells and the plates incubated for 45 minutes 
at 37 °C. After the incubation step, the plates were washed three times. Hundred µl Avidin-
Horseradish Peroxidase (HRP) was added to each well and the plates incubated for 30 
minutes. The plates were washed five times before 90 µl of Tetramethylbenzidine (TMB) 
substrate was added. The plates were again incubated for 15 minutes after which 50 µl sulfuric 
acid was added to stop the reaction. Colorimetric changes were detected at 450 nm using an 
Imark microplate reader (Bio-rad Laboratories, California, USA). A standard curve ranging 
from 15.63-1000 pg/mL was used and the Microplate manager 6 software, (Bio-rad 
Laboratories) used to calculate the serotonin concentrations in the samples.  
ii. Abnova 3 kit Catecholamine ELISA: Adrenaline/Noradrenaline/Dopamine ELISA kit 
The hormones in question were first extracted before the samples were analysed using the 
catecholamine ELISA kit (Abnova, Taipei City, Taiwan). Extractions were done according to 
the manufacturer’s instruction and using the extraction plates provided. Briefly, 10 µl of the 
standards, controls and 300 µl of the plasma samples were added to the plates followed by 
250 µl of deionized water. Assay and extraction buffer were then added to each well and the 
plates incubated for 30 minutes at RT while shaking at 600 rpm (all subsequent incubation 
steps were done at RT while shaking). Each well was washed twice and the plates incubated 
for five minutes between each wash step. Acylation buffer (150 µl) and acylation reagent (25 
µl) were added to each well followed by a 15 minute incubation. After washing and drying the 
plate, hydrochloric acid (0.025 M; 175 µl) was added to all the wells and the plate incubated 
in the dark for 10 minutes. Thereafter, the samples were ready to be loaded onto the three 
different ELISA plates: 
For the dopamine ELISA, 25 µl of the Catechol-o-methyltransferase enzyme solution was 
added to the microtiter strips of the dopamine ELISA plate followed by 50 µl of the isolated 
samples and 25 µl of the controls and standards, to allow for the formation of methyldopamine. 
Hydrochloric acid (0.025 M; 25 µl) was added to all the wells and the plate incubated for 30 
minutes. Fifty µl rabbit anti-dopamine antibody was added and the plate incubated for two 




peroxidase conjugate was added. Thereafter the plate was incubated for 30 minutes. After the 
30 minutes incubation step, the plates were washed and 100 µl TMB substrate solution added. 
After 25 minutes, 100 µl of sulfuric acid was added to the plate to stop the reaction. The plates 
were read at 450 nm using an Imark microplate reader (Bio-rad Laboratories) and the 
concentrations calculated using the Microplate manager 6 software (Bio-rad Laboratories). A 
4-parameter logistic regression standard curve was used and ranged from 57.4-15054 pg/mL. 
The measured concentrations were divided by 60 (as recommended by the manufacturer) to 
obtain the actual dopamine concentration. 
For the noradrenaline ELISA, 25 µl of enzyme solution (Catechol-O-methyltransferase) was 
added in the noradrenaline microtiter strip. Twenty µl of the extracted standards, controls and 
samples were added to appropriate wells and incubated for 30 minutes. Fifty µl of rabbit anti-
noradrenaline antibody was added in all wells and the plates incubated for two hours. 
Subsequent steps were done similarly as for dopamine. A standard curve ranging from 51-
14251 pg/mL was used, and the measured concentration divided by 30 (as recommended by 
the manufacturer) to obtain the actual noradrenaline concentration. 
Lastly, for the adrenaline ELISA, 25 µl of enzyme solution (Catechol-O-methyltransferase) 
was pipetted into the adrenaline microtiter strips. Hundred µl of the isolated samples, controls 
and standards were added to their respective wells followed by a 30 minute incubation. Fifty 
µl rabbit anti-adrenaline antibody was added in all wells and the plates incubated for two hours. 
Subsequent steps were performed as previously described for dopamine and noradrenaline. 
The standard curve with the lowest detection limit of 9.1 and highest detection limit of 426 
pg/mL was used and the measured concentrations divided by 30 to obtain the actual 
concentration. All quality controls (QCs) were within the expected ranges.  
iii. Elabscience® ELISA kit: Interferon inducible T cell alpha chemoattractant (I-TAC) 
sandwich ELISA 
Hundred µl of neat serum samples, standards and blank were added to the pre-coated I-TAC 
ELISA plate (E-EL-H0051, Elabscience) and incubated for 90 minutes at 37 °C. The plates 
were washed three times. After the wash steps, 100 µl of Avidin-HRP conjugate was added 
to the wells and the plate incubated for 30 minutes. After washing the plates five times, 90 µl 
of substrate solution was added and again incubated for 15 minutes. Fifty µl of sulfuric acid 
was used to stop the reaction and the optical densities read at 450 nm using the Imark 
microplate reader (Bio-rad Laboratories). A standard curve ranging from 62.5-4000 pg/mL was 
used to calculate the unknown concentrations using the Microplate manager 6 software (Bio-




iv. Elabscience® ELISA kit: Interleukin 22 (IL-22) ELISA in ALERT and TANDEM 
samples  
Serum samples from both the ALERT and TANDEM study were included in the IL-22 ELISA 
(E-EL-H0106, Elabsciences). The ELISA plates were pre-coated with an Ab specific to human 
IL-22. Standards and neat samples were added to the plates in duplicate and the plates 
incubated for 90 minutes at 37 °C.  One hundred µl of the biotinylated capture antibody was 
added after removing the samples and the plate incubated for one hour. The plates were 
washed three times with wash buffer and 100 µl of Avidin-HRP conjugate added to the wells. 
After a 30 minutes incubation step, the plates were washed five times and 100 µl of substrate 
reagent was added. The plate was again incubated for 15 minutes, after which the 50 µl 
sulfuric acid was added to stop the reaction. The colorimetric changes were immediately 
detected at 450 nm using the Imark microplate reader (Bio-rad Laboratories) and a 4 
parameter logistic regression standard curve ranging from 15.63-1000 pg/mL was used. The 
Microplate manager 6 software (Bio-rad Laboratories) was used to calculate the IL-22 
concentrations in the samples. 
2.1.8 Luminex in ALERT samples 
A customized multiplex screening assay from RnD Systems (Qiagen) was used to determine 
the concentration of 14 immune proteins namely; IFN-ү, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-13, IL-
18, IL-21, IL-22, IL-23, IL-27, IL-33, and TNF-α. Two single-plex assays were used to measure 
the concentrations of Oncostatin (OSM) and IL-35 both from Merck (Merck- Millipore). 
i. Human Magnetic Luminex®: RnD Screening assays (14-plex) 
Serum samples were diluted (1:2) and the assay done according to the manufacturer’s 
instructions. Fifty µl of the micro particle cocktail was added into each well in the 96-well plate 
followed by 50 µl of the samples and standards. The plates were sealed and incubated for two 
hours at RT in the dark while shaking at 800 rpm. The plates were washed three times. Fifty 
µl of biotinylated antibody cocktail was added and the plates incubated for one hour, followed 
by three wash steps. The plates were incubated for 30 minutes after the addition of 50 µl of 
streptavidin-phycoerythrin (PE) conjugate and washed three times. Finally, wash buffer was 
added and the plates left on the shaker for two minutes to re-suspend the beads. The sample 
was read immediately on the Bio-Plex 200 instrument (Bio-rad Laboratories) and a four 
parameter logistic regression standard curve was used to determine concentrations of all the 
cytokines in the samples using the Bio-Plex Manager software, version 6 (Bio-rad 
Laboratories). The standard curve for each analyte was ranging from; IFN-ү 43.2-11220 
pg/mL, IL-1β 15.8-3840 pg/mL, IL-13 454.8-110520 pg/mL, IL-33 47.8-11500 pg/mL, IL-8 4.4-




7140 pg/mL, IL-23 228.8-55600 pg/mL, IL-6 4.8-1180 pg/mL, IL-18 54.6-13260 pg/mL, IL-
27 375.7-91290 pg/mL and IL-4 15.4-3750 pg/mL. 
ii. Milliplex® Map Kit: IL-35 and Oncostatin luminex 
Luminex plates were primed with assay buffer for 10 minutes at RT while shaking at 600 rpm. 
The contents were discarded and 25 µl of standards and quality controls added to the wells 
as indicated on the plate template. Twenty five µl of assay buffer was added to all the sample 
wells and 25 µl of serum matrix to the wells containing the standards and quality controls. The 
diluted serum sample for IL-35 (1:4) and for OSM (1:2) were added to the sample wells 
containing assay buffer. Twenty five µl of beads were added to all the wells and the plates 
incubated for 16 hours, at 4 °C while shaking. After the incubation step, the plates were 
washed three times. Twenty five µl of detection antibody was added to each well and the 
plates incubated for one hour at RT (shaking). Following incubation, 25 µl of streptavidin-PE 
conjugate was added, without removing the contents of the wells, followed by a 30 minute 
incubation step. After washing the plate three times, 150 µl of sheath fluid was added and the 
plate left on the shaker for five minutes to re-suspend the beads. The mean fluorescent 
intensities were read on the Bio-Plex 200 instrument (Bio-rad Laboratories). The standard 
curve ranging from 6.9 to 5000 pg/mL for OSM and 0.8 to 800 ng/mL for IL-35 was used to 
calculate unknown cytokine concentrations using the Bio-Plex Manager software, version 6. 
The actual concentrations were obtained by multiplying by the dilution factor. All QCs were 
within the expected ranges. 
2.1.9 Flow cytometry: TANDEM study 
i.  Thawing of peripheral PBMCs 
Thawing media (TM), prepared by adding 10% of heat inactivated FBS (HyClone; BD) in RPMI 
(Biowest) with L-Glutamine (Sigma-Aldrich), was heated to 37 °C in a water bath prior to 
adding it to the cells. Cryopreserved PBMCs were thawed in a 37 °C water bath. One ml of 
the TM was added in a dropwise manner to the cells. The cells were gently mixed with the TM 
and transferred to a 15mL tube containing 8 mL of TM. The cells were centrifuged at 250 xg 
for 10 minutes, the media discarded and the cells again washed with 10 mL TM. After the 
second wash step, the cells were resuspended in 1 mL TM. PBMCs were counted, as 
described in section 2.1.3 iv, to determine the cell number and viability. 
ii.  Surface staining of PBMCs 
PBMCs (2.5x105 cells) were centrifuged at 250 xg for five minutes and washed with 1 mL of 
PBS (All wash steps were followed by centrifugation). PBMCs were first stained with the 
Live/dead (Zombie aqua; BD) stain, diluted to 1:100 in PBS, and incubated for 15 minutes at 




1 mL of FACS buffer (2 % FBS in PBS). A MAIT cell antibody panel was used to stain the cells 
and included pre-titrated anti-human antibodies purchased from BD and BioLegend 
(Cambridge, UK). The panel include CD26-FITC (1:5 dilution, 10 µl; BD), anti-human CD8-
APC-Cy7 (1:20 dilution, 2.5 µl; BD), anti-human CD4-BV412 (1:20 dilution, 2.5 µl; BD), anti-
human CD3-Per-Cp (1:40 dilution, 1.25 µl; BD), anti-human TCR Vα7.2-APC (1:10 dilution, 5 
µl; BioLegend), and anti-human CD161-PEcy7 (1:20 dilution, 2.5 µl; BioLegend) monoclonal 
antibodies. Cells were incubated with the antibody panel for an hour at 4 °C. The cells were 
washed after 30 minutes with FACS buffer. After washing with FACS buffer, PBMCs were 
fixed with 4 % formalin for 15 minutes in the dark. Formalin was washed off with 1 mL FACS 
buffer and the cells resuspended in 100 µl FACS buffer. Samples were kept at 4 °C until the 
samples were acquired on the FACSCanto II flow cytometry instrument with FACS Diva 
software, version 10 (BD). The results were analysed on FlowJo v10.1 software (TreeStar, 
Ashland, OR). 
2.1.10 Statistical analysis 
For the multiplexing data, values below and above the standard curve range, were 
extrapolated by the Bio-Plex Manager Software. Statistical analysis of clinical data was done 
using GraphPad PRISM version 6 (GraphPad Software Inc., California, USA). For more than 
two groups a Kruskal-Wallis analysis of variance (ANOVA) with a Dunn’s post hoc test to 
correct for multiple comparisons was used. When testing for significant differences between 
two groups a non-parametric Mann-Whitney U test was used. Statistical analysis of MAIT cell 
frequencies, cytokine, hormone and CFU data was done using Statistica version 13 (StatSoft, 
Ohio, USA). The data were analysed using a repeated measures ANOVA with a Fisher LSD 
post hoc test. Correlations between groups were determined by Spearman correlations on 
GraphPad PRISM version 6 (GraphPad Software). Gene expression analysis was done using 
JMP statistical software version 13.2 (SAS institute, North Carolina, USA) and significance 
was assessed using repeated measures ANOVA and Dunns correction Ingenuity pathway 







Identification of distinct immune gene expression signatures in active TB patients and 
close contacts with and without type 2 diabetes 
3.1. Introduction 
Progression from LTBI to active TB disease occurs when the immune system fails to control 
the infection (Sutherland et al. 2014). Transcriptional analysis of whole blood and Mtb antigen 
stimulated blood has become an important tool to study the expression of immune system 
related genes and shows promise in identifying possible biomarkers for TB progression and 
treatment responses (Cliff et al. 2013; Zak et al. 2016; Thompson et al. 2017). Transcriptomic 
analysis of healthy controls, patients with T2D and TB patients with and without T2D showed 
there are shared elements with published TB signatures in TB patients without T2D (Prada-
Medina et al. 2017; Berry et al. 2010). In the same study, increased neutrophil counts were 
associated with TB disease severity in patients with TB-T2D as previously reported in TB 
patients (Prada-Medina et al. 2017; Berry et al. 2010). Interestingly, pathways correlating to 
diabetic associated complications including several epigenetic reprogramming pathways were 
overexpressed in patients with TB-T2D, compared to patients with T2D only (Prada-Medina 
et al.2017). In this study, differentially expressed genes in TB-T2D patients included the four 
genes of the Maertzdorf TB diagnostic signature (Maertzdorf et al. 2015) as well as nine of the 
16 genes of the Zak signature predicting TB progression within two years of infection (Zak et 
al. 2016). the fact that a gene expression profile exists which predicts which individuals who 
are LTBI positive will develop TB disease, our aim was to identify altered gene expression 
profiles in individuals with LTBI as well as TB patients with and without T2D and to describe 
the underlying molecular mechanisms that could contribute to the increased susceptibility to 
TB observed in these participants. In addition, we aimed to describe changes in gene 
expression profiles at the end of TB treatment. Pathway analysis was done in an attempt to 
understand alterations in immune responses in the different patient groups.  
3.2 Methods 
The detailed methods were discussed in chapter 2. Ex-vivo and Mtb antigen stimulated whole 
blood gene transcripts from CCs with LTBI with, and without T2D and TB patients with and 
without T2D (BL and M6) were measured using the NanoString Technology. CCs of TB 
patients with and without T2D were recruited as part of the ALERT study and TB patients with 
and without T2D were enrolled as part of the EU FP7 funded TANDEM study. Briefly, whole 
blood was added to the three tubes of the QFT assay, incubated overnight and the supernatant 
and cells harvested. The supernatants were stored at -80°C, and the pellet resuspended in 
RNALater, which preserves RNA and then stored in -80°C. The pellet stored in RNA later was 




manufacturer’s instructions. Total RNA was quantified using the Nanodrop as well as the RNA 
Qubit kit. 
RNA of unstimulated (nil) and Mtb antigen stimulated (antigen tube) whole blood of TB patients 
(TB n=9, TB-THG n=5 and TB-T2D n=7; BL and M6) and individuals with LTBI (LTBI-noT2D 
n=20, LTBI-T2D n=20) were shipped to NanoString Technologies (in Seattle Washington) to 
determine the gene expression of 594 genes (579 immunological genes and 15 housekeeping 
genes) as part of the nCounter GX Human Immunology kit V2. Statistical significance was 
assessed using repeated measures ANOVA and Hochberg’s correction between three groups 
and student T-test used to determine differences between two groups. 
3.3 Results  
3.3.1 Demographic and clinical characteristics 
Participants with LTBI (n=20) and LTBI-T2D (n=20) and 21 TB patients (TB n=9, TB-THG n=5 
and TB-T2D n=7) were included in this study. No significant differences were seen in age 
between the groups (Table 3.1). The clinical parameters for the LTBI and LTBI-T2D groups 
were taken at a single time point and for TB, TB-THG and TB-T2D at BL and M6. At BL, the 
median BMI in LTBI and LTBI-T2D was significantly higher compared to TB and TB-THG. The 
median BMI at M6 was significantly higher in the TB-T2D group compared to both the TB and 
TB-THG groups, as shown in (Table 3.1). The median HbA1c was significantly higher in the 
LTBI-T2D and TB-T2D groups compared to LTBI and TB (Table 3.1), respectively. At BL, there 
were differences in HbA1c between TB-THG and TB-T2D although not significant, however, 
significant differences were observed in TB-THG and TB-T2D at M6 (Table 3.1). Even though 
the HbA1c is much higher in the TB-T2D group it did not reach significance due to the low 
power because of the small sample size. We measured High density lipoprotein (HDL), Low 
density lipoprotein (LDL), triglycerides and total cholesterol (CHL) in LTBI and LTBI-T2D at 
BL. Triglycerides were significantly higher in LTBI-T2D (vs. LTBI), but no significant 
differences were observed in HDL, LDL and total CHL. In TB-THG and TB-T2D, the lipid 
measurements were performed at week 2 and at M6 and no significant differences were 
observed. Generally, the lipid concentrations were elevated in individuals with T2D 
irrespective of LTBI or TB status, with the exception of HDL, which was lower. With respect to 
medication, 50 % of the LTBI-T2D patients were on metformin, 25 % on insulin and 80 % were 
on a combination of medication and none of them were on prophylactic LTBI treatment in line 
with TB treatment policies in South Africa. All TB-T2D patients were on TB standard treatment, 
100 % were on metformin, 71% on insulin and 57% taking a combination of medication. The 
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Data expressed as n (column %) unless specified. BMI-Body mass Index, RBG-Random blood glucose, Bold 
number indicates a significant ANOVA, P-value of <0.05 was considered significant using Kruskal-Wallis and 
Dunns post-hoc test. Letters indicate statistical significance if different from each other. Values with the same letter 
are not significantly different from each other. #- 2 participants in that particular group 
3.3.2 Overall transcript expression in unstimulated and stimulated blood from LTBI, 
LTBI-T2D, TB, TB-THG and TB-T2D at BL 
Gene expression analysis of a total of 594 immune genes was performed using the NanoString 
Technology platform to identify differentially expressed transcripts. The differential transcripts 
were investigated in the unstimulated and stimulated blood from individuals with LTBI with and 
without T2D and also in the TB, TB-THG and TB-T2D patients. The individuals with LTBI with 
and without T2D were compared to each other and TB, TB-THG and TB-T2D patients 
compared to one another. Gene transcripts data were reported as unstimulated, from the nil 
tube and stimulated, from the antigen tube divided by the value from the nil tube. 
Figure 3.1A shows the number of total transcripts that were differentially expressed in TB 
compared to TB-THG in both stimulated and unstimulated samples, shown as stim TB-THG 
and unstim TB-THG, respectively. Figure 3.1A also shows total differentially expressed 
transcripts inTB compared to TB-T2D in both stimulated and unstimulated samples, shown as 
stim TB-T2D and unstim TB-T2D, respectively. Two hundred and fifty genes were upregulated 
and 329 downregulated in the unstimulated blood of individuals with LTBI compared to LTBI-
T2D (Figure 3.1C). In the stimulated blood, 263 genes were upregulated and 315 




differences in the transcripts from unstimulated blood in TB patients compared to TB-THG and 
TB-T2D, shows that ex-vivo differences exist in the RNA of the investigated patients. 
Furthermore, the differentially expressed genes are shown on Venn diagrams to highlight the 
overlap of any of the differentially expressed transcripts between TB-THG and TB-T2D 
compared to TB. We found 182 and 187 of stimulated gene transcripts to be similarly 
downregulated and upregulated in TB-THG and TB-T2D compared to TB, respectively. 
Interestingly, 86 of the gene transcripts from stimulated whole blood were upregulated in TB-
THG and downregulated in TB-T2D, in addition, 123 were downregulated in TB-THG and up 
regulated in TB-T2D (Figure 3.1B). The Venn diagram was also done for LTBI and LTBI-T2D 
to determine the unique and shared genes between them (Figure 3.1D). A total of 211 gene 
transcripts which were upregulated in unstimulated blood of LTBI-T2D individuals were 
downregulated in stimulated blood from LTBI-T2D compared to LTBI. Two hundred and twenty 
four gene transcripts were downregulated in unstimulated blood and upregulated in stimulated 
blood from LTBI-T2D. Furthermore, 104 gene transcripts downregulated in unstimulated blood 
from T2D patients were also downregulated in the stimulated blood, and 39 genes were 
similarly upregulated in unstimulated and also in RNA from stimulated blood of LTBI-T2D 
(Figure 3.1D). There is a contrast between TB compared to both groups with high glucose 
(TB-THG and TB-T2D) leading to upregulation of more genes (than downregulation), while 
individuals with LTBI compared to LTBI with high glucose shows more downregulated than 





Figure 3.1 Overall transcriptomic gene expression in TB, TB-THG and TB-T2D. RNA was isolated from whole 
blood stimulated with Mtb specific antigen using QFT assay (nil, unstimulated and Ag, stimulated). Gene expression 
analysis of 594 genes as part of the nCounter GX Human Immunology kit V2 was done on the extracted RNA. 
Column graphs were generated on excel and Venny 2.0 software was used to generate Venn diagrams. Column 
graph showing the number of all upregulated and downregulated transcripts from RNA isolated from unstimulated 
and stimulated blood of TB patients compared to TB-T2D and TB-THG (A).  A Venn diagram showing the number 
of all differentially expressed transcripts and the transcripts that are shared between the groups (B). Column and 
Venn diagrams showing the number of all upregulated and downregulated transcripts from RNA isolated from 
unstimulated and stimulated blood of LTBI individuals compared to LTBI-T2D (C and D).+ means upregulated and 
- means downregulated, unstim is forunstimulated, stim is for stimulated. 
  
3.3.3 Differentially expressed blood transcripts in unstimulated whole blood of TB-
THG and TB-T2D (vsTB) at baseline 
To determine differentially expressed whole blood gene transcripts from TB, TB-THG and TB-
T2D patients, heatmaps were used to determine the clustering of the gene expression data in 
the different groups. Gene expression was considered significantly different when the p value 
was < 0.01 and FDR-value was < 0.05 when compared to another group. Sixty-three genes 
were significantly different between TB-T2D and TB, of which, 25 were upregulated and 38 
downregulated in the TB-T2D group (Figure 3.2A and C). Twenty-nine genes were 
differentially expressed between TB-T2D and TB-THG, of which, 25 were downregulated and 
four upregulated in the TB-T2D patients (Figure 3.2B and D). TB compared to TB-THG 
showed significant differences in the five genes (P selectin glycoprotein ligand 1 (SELPLG), 





subcomponent binding protein (C1QBP) and  B cell lymphoma like protein 11 (BCL2L11), 
(data not shown). Two genes were upregulated in TB-THG vs TB (SELPLG and MME) and 
three downregulated genes (ITLN1, C1QBP and BCL2L11). We used the Ingenuity pathway 
analysis (IPA) software to analyse differentially expressed genes from unstimulated blood 
between the TB and TB-THG, and found that pathways associated with innate immune 
responses including the complement system and apoptosis pathway were highly represented.  
All significantly downregulated and upregulated genes from unstimulated blood at BL were 
analysed using Venn diagrams to enable visualization of shared and unique gene transcripts 
(Figure 3.2E, F). Twenty-two genes were exclusively downregulated in the TB-T2D (vs TB), 
two were significantly downregulated in TB-THG (vs TB) and 10 were specific to TB-T2D (vs 
TB-THG). BCL2L11, an apoptotic marker, was similarly downregulated in TB-THG and TB-
T2D compared to TB. Fifteen gene transcripts (CCL2, CCL4, CCL3, IL-1A, cluster of 
differentiation 163 (CD163), CXCL2, plasminogen activator urokinase (PLAU), CXCL1, IL-
1R1, tumour necrosis factor receptor superfamily member 8 (TNFRSF8), CCRL2, NF-KB1, 
proteasome non-ATPase regulatory subunit 7 (PSMD7), proteasome subunit beta type 
5(PSMB5) and B cell lymphoma 2 associated X protein (BAX)) were downregulated when TB-
T2D was compared to both TB and TB-THG (Figure 3.2E). The 15 gene transcripts may be of 
significance particularly, since these genes were downregulated in TB-T2D vs. TB and also 
found downregulated in TB-T2D vs. TB-THG. The genes that are altered by higher glucose 
appear to be in part similar between TB-T2D and TB-THG, but not ignoring the fact that 
differences between both groups exists which are not driven by excessively high blood glucose 
as shown by the distinct 15 gene signature between TB-T2D vs TB and TB-T2D vs TB-THG. 
These result shows the uniqueness of the 15 gene transcript profile to TB-T2D and may have 
impact in the pathogenesis and clinical outcomes associated with T2D during TB-T2D 
comorbidity. Twenty-four genes were exclusively upregulated in TB-T2D (vs TB), three were 
upregulated in TB-T2D (vs TB-THG) and two were specific to TB-THG (vs TB). One gene 
transcript (mitogen activated protein kinase activation protein kinase 2 (MAPKAPK2) was 
similarly upregulated in TB-T2D and TB-THG compared to TB (Figure 3.2F). Fewer gene 
transcripts were differentially expressed after stimulation, between patinets with TB-T2D 
compared to patients with TB. Results demonstrating changes in stimulated whole blood at 
BL are shown in supplementary Figure 1 A-C and month 6 gene expression shown in 







Figure 3.2: Differentially expressed gene transcripts between TB, TB-THG and TB-T2D. RNA was isolated 
from whole blood of TB-T2D, TB-THG and TB stimulated with Mtb specific antigen using QFT assay (nil, 
unstimulated only represented in the figure). Gene expression of 594 genes as part of the nCounter GX Human 
Immunology kit V2 was done on the extracted RNA. Down and upregulated transcripts from unstimulated blood of 
TB compared to TB-T2D (n= 14, A and C), and TB-THG vs. TB-T2D (n=12, B and D). Downregulated and 
upregulated genes commonly and exclusively expressed between the TB-T2D vs TB, TB-THG vs TB and TBT2D 
vs TBTHG (E and F). JMP SAS was used to generate heatmaps and volcano plots, Venny 2.0 software was used 
to generate Venn diagrams and used Student T test to determine statistical difference between the groups. Genes 
with a p value was < 0.01 and FDR < 0.05 was statistically significant. - downregulated, + upregulated. Figure A 
Red TB-THG, Blue TB-T2D, Figure B red TB, blue TB-T2D.  
 
3.3.4 Differentially expressed gene transcripts in blood from LTBI with and without 
T2D 
Analysis of differentially expressed genes was done to identify distinct genes associated with 
LTBI-T2D. Genes have been described showing differences between LTBI and TB, however, 
there is no published data on LTBI-T2D gene expression. There were 26 genes, 16 
significantly upregulated and 10 significantly downregulated in unstimulated blood from LTBI-
T2D compared to LTBI (Figure 3.3A). Stimulating with Mtb antigens increased the 
transcriptomic differences that we saw since stimulated blood resulted in 42 genes significantly 
expressed, and 36 of those were downregulated in LTBI-T2D patients compared to LTBI 
(Figure 3.3B).. There were seven genes exclusively upregulated in the unstimulated blood of 
LTBI-T2D patients (Figure 3.3E i) and nine that were exclusively downregulated in the LTBI-
T2D patients (Figure 3.3E ii) compared to LTBI. After stimulation, there were five genes 
uniquely upregulated (Figure 3.3E iii) and 27 downregulated (Figure 3.3E iv) in the individuals 
with LTBI-T2D (vs LTBI). Interleukin-18 plays a critical role in immune response against Mtb 




one that was downregulated in the unstimulated and upregulated in the stimulated blood of 
LTBI-T2D (vs LTBI). Nine of the gene transcripts were upregulated in the unstimulated and 
downregulated in stimulated blood of individuals with LTBI-T2D (vs LTBI) (Figure 3.3E vi). 
 
Figure 3.3: Differentially expressed gene transcripts in LTBI and LTBI-T2D. RNA was isolated from whole 
blood of LTBI-T2D and LTBI stimulated with Mtb specific antigen using QFT assay (nil, unstimulated and Ag, 
stimulated). Gene expression of 594 genes as part of the nCounter GX Human Immunology kit V2 was done on 
the extracted RNA. Significantly down and upregulated transcripts from unstimulated blood of LTBI-T2D compared 
to LTBI (A and C). Downregulated transcripts from stimulated blood of LTBI-T2D and LTBI (B and D). 
Downregulated and upregulated genes commonly and exclusively expressed between the LTBI-T2D vs LTBI are 
shown in 3E: I-VI. JMP SAS was used to generate heatmaps and volcano plots, Venny 2.0 software was used to 
generate Venn diagrams and used Student T test to determine statistical difference between the groups. Genes 
with a p value < 0.01 and FDR < 0.05 was statistically significant. – means downregulated, + means upregulated, 
unstim is for unstimulated, stim for stimulated, Red LTBI, Blue LTBI-T2D. 
3.3.5 A core gene signature in whole blood differentiates TB-THG from TB-T2D 
patients at baseline 
Differentially expressed genes were used to run a recursive partitioning analysis (RPA) to 
identify gene transcripts that can categorize patients in a group that describes their condition, 
either as TB, TB-THG or TB-T2D. The partition is created in such a way that gene expression 
with similar response values are grouped. After the partition is completed, a constant value of 
the response variable is predicted within each patient group (Sun et al. 2011). Figure 3.4A is 
a representative cubic cluster of patients depending on the expression levels of the following 
genes; PSMB5, complement component receptor 1 (C1R) and C1QBP from unstimulated 
blood at BL. PSMB5 with a log2 expression value of less than 6.1 predicted all TB-T2D patients 
with an area under the curve (AUC) of 1.00 (Figure 3.4B). To further characterize TB and TB-
THG, C1QBP with a log2 expression value of < 6.7 was able to predict all five TB-THG patients 




addition of C1R, with a log2 expression value of < 0.2, could separate all TB from TB-THG 
patients with an AUC of 0.99 (Figure 3.4B). The gene signature consisting of PSMB5, C1QBP 
and C1R were therefore able to accurately discriminate the three patient groups. A univariate 
analysis was done on the three genes to describe their expression in the different test samples 
as shown in Figure 3.4C to F. PSMB5 was significantly lower in TB-T2D compared to both TB 
and TB-THG (p=0.0001). C1QBP was significantly higher in TB compared to both TB-THG 
and TB-T2D (p=0.0069) (Figure 3.4C-D). C1R was not different among the groups (p=0.7328; 
data not shown).  
Furthermore, the RPA was done for the stimulated blood at BL and three genes differentiating 
TB-THG from TB-T2D were identified, LILRB4, LGALS3 and ABCB1. When the level of 
expression of LILRB4 was ≥ 1.02, the genes were able to identify all TB-THG, however at an 
expression level of ≤ 1.02 the gene was not able to discriminate between TB and TB-T2D. To 
further characterize TB and TB-T2D patients, the addition of galectin 3 (LGALS3) with the 
expression value of ˃  0.08 was able to identify all TB-T2D patients but included one TB patient 
in this group. Subsequently, the addition of ATP binding cassete subfamily B member 1 
(ABCB1) with a log2 expression ˃ -0.39 could separate all TB from TB-T2D patients with an 
AUC of 0.99. Using this approach we found a transcript signature in Mtb-antigen stimulated 
whole blood that can differentiates patients with TB-THG from TB-T2D (LILRB4, LGALS3 and 
ABCB1). A univariate analysis on these transcripts showed that leukocyte immunoglobulin like 
receptor B4 (LILRB4) was significantly higher in TB-THG compared to both TB and TB-T2D 
(p=0.0003) and that LGALS3 was significantly higher in TB-T2D compared to both TB and TB-
THG (p<0.0001) (Figure 3.4E-F). ABCB1 was not different between the groups (p=0.5601) 





Figure 3.4: Gene signature distinguish between TB-THG and TB-T2D. (A) Cubic clustering from recursive 
partition analysis (RPA) of gene transcripts from RNA isolated from unstimulated blood of patients at baseline 
showing three markers accurately categorizing patients in either TB (red), TB-THG (green) and TB-T2D (blue). (B) 
Receiver operating characteristics curve showing the accuracy of the three markers to predict any of the patients 
as either TB, TB-THG or TB-T2D patients. Diamond plots showing differences in the expression of PSMB5, C1QBP 
in unstimulated blood (C and D) and LILRB4 and LGALS3 transcripts in stimulated blood (E and F). Mean 
expression was reported and ANOVA used to determine statistical significance. *p<0.01, **p<0.001, ***p<0.0001. 
3.3.6 Gene signatures in whole blood could be associated with dysregulated 
pathways in LTBI-T2D that may increase susceptibility to TB 
A group of differently expressed genes from unstimulated whole blood were used in RPA to 
identify a gene signature that would accurately classify LTBI with (n=20) and without T2D 
(n=20). Three genes cluster of differentiation (CD59), tumour necrosis factor ligand 
superfamily member 11 (TNFSF11) and cluster of differentiation (CD247) were able to 
distinguish between LTBI and LTBI-T2D. CD59 with a log2 expression value of ≥ 8.25 could 
identify 12 of the 20 patients as T2D.  TNFSF11 (at a cut off < 3.85) and CD247 (at cutoff < 
9.52) were added to the model to further distinguish the eight remaining T2D patients and by 
doing so, a three gene signature, could discriminate all LTBI from LTBI-T2D with an AUC of 




also used for the RPA modelling. TNFRSF8, LILRA6 and PSMB7 were identified as good 
predictors for either LTBI or LTBI-T2D individuals. TNFRSF8 at a log2 expression value of ≥ 
0.85, LILRA6 with a log2 value of ≤ 0.06 and PSMB7 with a log2 value of ≤ 0.12 were able to 
accurately classify patients as LTBI or LTBI-T2D with an AUC of 1.00 (data not shown). Most 
importantly, these gene signatures could be involved in immunological pathways that may 
render patients with T2D susceptible to TB.  
A univariate analysis of the RPA predictive genes was done for both signatures from 
unstimulated and stimulated blood. CD59 was significantly higher in the LTBI-T2D compared 
to LTBI (p=0.0059) (Figure 3.5C). TNFSF11 (p=0.1573) and CD247 (p=0.7727) were not 
significantly different between the two groups in unstimulated blood (data not shown). From 
the stimulated samples, TNFRSF8 was significantly higher in the LTBI-T2D compared to LTBI 
(p=0.0097) (Figure 3.5D). Leukocyte immunoglobulin like receptor A6 (LILRA6) (p=0.3137) 
and PSMB7 (p=0.6046) were not significantly different (data not shown). 
 
Figure 3.5: Gene signature distinguishing between LTBI and LTBI-T2D. (A) Cubic clustering from recursive 
partition analysis (RPA) of gene transcripts from RNA isolated from unstimulated blood of study participants 
highlighting three markers that shows distinct immune signature in LTBI-T2D (blue) compared to LTBI (red) (B) 
Receiver operating characteristics curve of unstimulated blood at baseline showing the accuracy of the three 
markers to identify altered immune genes in LTBI-T2D compared LTBI. Diamond plots showing differences in the 






3.3.7 The number of differentially expressed gene transcripts was reduced in TB-T2D 
patients at month 6 
The transcript expression profile at M6 was investigated to determine how TB treatment would 
affect immune gene expression in the different patient groups. When comparing the gene 
expression between BL and M6, seven genes were differentially expressed in TB-THG 
(compared to TB). Platelet and endothelial cell adhesion molecule 1 (PECAM1), integrin 
subunit alpha 6 (ITGA6), CCR7, membrane spanning 4 domains A1 (MS4A1) and transcription 
factor 7 (TCF7) were significantly upregulated, while toll interleukin 1 receptor domain 
containing adapter molecule 1 (TICAM1) and IL17A were downregulated (data not shown).  At 
M6, however, none of the genes were differentially expressed between TB-THG and TB 
(Figure 3.6A). In TB-T2D (vs TB) we observed a drastic reduction in differentially expressed 
genes at M6 compared to BL. There were now eight genes downregulated (TICAM1, PSMD7, 
chromosome 14 open reading frame 166 (C14orf166), BCL2L11, PSMB7, mothers against 
decapentaplegic homolog 5 (SMAD5), Interleukin enhancer binding factor 3 (ILF3) and 
CXCL10) and two genes upregulated (PECAM1 and B cell linker protein (BLNK)) in TB-T2D 
(vs TB) at M6 (Figure 3.6B). Even after the decrease in the total number of differentially 
expressed genes in TB-T2D from BL to M6, there were four genes (ILF3, PSMD7, PSMB7 
and BCL2L11) which were downregulated at both time points. At M6, five genes (TP53, 
SMAD5, PSMC2, C14orf166 and C1QBP) were downregulated in TB-T2D compared to TB-
THG (Figure 3.6C).  PECAM1 was upregulated and TICAM1 downregulated in TB-T2D 
compared to TB at M6, the same was seen when comparing TB-THG to TB at M6. At the end 
of treatment, the reduction in gene transcripts and loss of differential expression is expected 
as the patients are cured. It is possible that the immune response is returning to normal, while 





Figure 3.6: Differentially expressed gene transcripts between TB, TB-THG and TB-T2D at month 6. RNA was 
isolated from whole blood of TB-T2D, TB-THG and TB stimulated with Mtb specific antigen using QFT assay (nil, 
unstimulated only represented in the figure). Gene expression of 594 genes as part of the nCounter GX Human 
Immunology kit V2 was done on the extracted RNA. Down and upregulated transcripts from unstimulated blood of 
TB compared to TB-THG (A), TB vs. TB-T2D (B) and TB-THG vs TB-T2D. JMP SAS was used to generate 
heatmaps and used Student T test to determine statistical difference between the groups. Genes with a p value < 
0.01 and FDR < 0.05 was statistically significant. Figure A Red TB, Blue TB-THG, Figure B red TB, blue TB-T2D 
and Figure C red TB-THG and blue TB-T2D.  
3.3.8 Antigen presentation and Th1 activation and glucocorticoid signalling pathways 
are dysregulated in whole blood from LTBI, LTBI-T2D, TB, TB-THG and TB-T2D 
participants 
To investigate the role of the genes that were differentially expressed in the study groups, we 
performed an IPA analysis. Genes from unstimulated and stimulated whole blood, which were 
significantly different between LTBI-T2D and LTBI revealed alterations in immune responses 
such as antigen presentation and Th1 activation pathway (Table 3.2). From the stimulated 
whole blood of TB compared to TB-T2D at BL, the differentially expressed genes were 
involved in the regulation of triggering receptor expressed on myeloid cells (TREM-1) 
signalling which is critical for innate immune responses including activation of inflammatory 
responses (Colonna and Facchetti, 2003). TREM-1 is poorly expressed in Mtb infection, and 
correlates with inflammatory response rather than with bacterial proliferation (Colonna and 
Facchetti, 2003). In our results, TREM-1 could be induced by T2D in TB patients. 
Glucocorticoid receptor signalling was also among the overrepresented pathways in TB-T2D 
patients compared to TB. This could be associated with the IL-10 production that is seen in 




enhance the secretion of other anti-inflammatory molecules (Schaaf and Cidlowski, 2003). 
The complement and apoptosis pathways were observed when genes differentially expressed 
between TB and TB-THG from unstimulated whole blood at BL were investigated. After 
stimulating whole blood with Mtb-antigens, pathways involving IL-22 signalling, IL-15 
production and type 1 interferon signalling were overrepresented in TB-THG at BL (Table 3.2). 
The identified pathways are critical for immune response during TB and their differential 
expression shows that there are major differences between patients with and without T2D, 
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Humans infected with Mtb can clear the pathogen, become latently infected or develop active 
TB disease (Lu et al. 2011) and the risk of progression is significantly increased in T2D patients 
(Jeon and Murray, 2008). However, the factors influencing pathogen clearance and disease 
progression from latent infection are poorly understood (O’Garra et al. 2013). Our study 
investigated gene expression data from unstimulated and Mtb-antigen stimulated whole blood 
to identify distinct gene signatures in individuals with LTBI with and without T2D, and TB with 
and without T2D. We identified differential gene expression profiles, which may contribute to 
increased susceptibility of T2D patients to TB and increased disease severity in TB-T2D 
comorbidity, as well as delayed treatment response and unfavourable treatment outcomes.  
T2D is a risk factor for poor TB treatment outcomes including treatment failure and relapse 
(Dooley et al. 2009; Critchely et al. 2017) and the WHO recommends that all active TB patients 
be screened for T2D. This is however not broadly implemented. The TB-THG group is 
characterised by high HbA1c prior to TB treatment which decreases during the first three 
months of treatment (Tabarsi et al. 2014). It is therefore advised to monitor HbA1c of TB 
patients during treatment in order to confirm their T2D status. Our study was able to identify a 
signature that could differentiate between TB-THG and TB-T2D, which could be useful in 
preventing the unnecessary treatment in those who would have been incorrectly diagnosed 
as having T2D. Most importantly, T2D screening of TB patients is recommended by the WHO 
(Restrepo et al. 2011), however HbA1c testing using a cut-off of 6.5% will not be able to 
distinguish patients with THG from T2D. Therefore, our gene signature could complement 
standard T2D screening of TB patients and also support a re-evaluation of HbA1c cut-offs for 
T2D diagnosis in TB patients. 
We identified 15 gene transcripts that were dysregulated in unstimulated whole blood from 
TB-T2D patients compared to TB and TB-THG. It is possible that the products of these 15 
gene transcripts (CCL2, CCL4, CCL3, IL-1A, CD163, CXCL2, PLAU, CXCL1, IL-1R1, 
TNFRSF8, CCRL2, NFKB1, PSMD7, PSMB5 and BAX) contribute to immunopathology in TB-
T2D because their expression was unique to TB-T2D. Our unpublished data revealed that 
serum CCL2 protein is highly upregulated in TB-T2D patients, and could mean that high CCL2 
in TB-T2D negatively feeds back to downregulation of CCL2 at the mRNA level. It is also 
possible however that the high CCL2 concentrations in the serum are a spill-over from the site 
of disease and produced by immune cells recruited to the lung and not by immune cells in the 
circulation. Others also showed that serum of TB-T2D patients have elevated CCL2 protein 
levels (Panee, 2013). It has been shown that downregulated proteins are well correlated with 
their mRNA gene transcripts, however this trend was not reported for upregulated proteins, 




expression (Fournier et al. 2010). This could be why we observe downregulated CCL2 
transcripts while its protein has been reported to be upregulated in TB-T2D patients (Panee, 
2013). Insufficient CCL2 mRNA expression in diabetic wounds were reported to be primarily 
responsible for the delay in macrophage response in these wounds (Wood et al. 2014). We 
believe that the downregulation of the products of the gene transcripts mentioned above may 
favour altered recruitment of immune cells to the site of inflammation and affect immunity. Our 
results show that the TNFRSF8, BAX and NF-kB1 gene transcripts which are important for 
triggering apoptosis are inhibited in TB-T2D patients (Donath et al. 2003). Furthermore, 
Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2), a protein kinase 
downstream of the p38 mitogen-activated protein kinase pathway, is involved in pathological 
conditions by upregulating various inflammatory pathways (Fiore et al. 2015). MAPKAPK2 
was found to be upregulated in TB-T2D compared to TB and TB-THG patients, in our study, 
and could be involved in promoting dysregulated inflammatory processes that are seen in TB-
T2D patients. Complement system C1q transcript is highly expressed in early stages of TB 
disease (Esmail et al. 2018). Interestingly, compliment c1q binding protein (C1QBP) was 
downregulated in our unstimulated sample of TB-THG (vs TB). C1QBP was also 
downregulated after stimulation in T2D compared to LTBI. C1QBP and SERPING, also 
downregulated in T2D compared to LTBI, were highly abundant in whole blood of TB patients 
compared with LTBI (Esmail et al. 2018). Since the complement pathway is upregulated during 
Mtb infection and gets downregulated during TB treatment (Cliff et al. 2013), Suliman et al. 
speculated that c1q is involved in TB pathology (Suliman;  Thompson et al. 2018). In keeping 
with this, its expression is strongly associated with active TB disease and disease severity 
(Cai et al. 2014). Even though the exact role of C1QBP is still unknown, it has been shown to 
play a role in regulating apoptosis and inflammatory processes in the mitochondrial matrix 
(Feichtinger et al. 2017). The downregulation of this transcript in our results was seen along 
with the downregulation of BCL2L11, which is an apoptotic gene. The inhibition of BCL2L11 
is associated with inhibition of apoptosis as well as autophagy (Dai and Grant, 2015). In our 
unstimulated blood from TB-T2D patients compared to TB, BCL2L11 gene transcript was 
downregulated.  
Immunity to TB requires effective innate and adaptive immune responses (Cooper and 
Khader, 2008; Beisiegel et al. 2009). NF-kB is a mediator of pro-inflammatory gene 
development and functions in both innate and adaptive immunity (Liu et al. 2017). NF-kB 
induction was high in TB compared to TB-T2D, this was accompanied by the induction of 
CD14 found on monocytes, CD163 expressed on macrophages and natural killer cell receptor 
2B4 (CD244) which are important players of the innate immune response. As part of this study, 




as perforin (PRF1), granulysin (GNLY) and granzyme B (GZMB) were also elevated and 
corresponded to the expression of CD244 in unstimulated samples. Kumar et al. showed that 
the frequency of CD8+ T cells producing PRF1 or GZMB or CD107a were decreased in TB-
T2D group compared to TB in unstimulated whole blood and even after stimulation with Mtb-
antigens (CFP-10 or ESAT-6) (Kumar et al. 2015). NK cells producing PRF1 or GZMB were 
not significantly different between TB-T2D and TB at baseline and after stimulation with Mtb-
antigens, however, CD107a produced by NK cells was significantly lower in TB-T2D compared 
to TB after Mtb-antigens stimulation (Kumar et al. 2015). Kumar’s finding is different from our 
gene expression results since we saw similar results in the unstimulated blood and not after 
Mtb-antigens stimulation. However, this is not surprising since the gene expression and its 
protein abundance has been shown to be poorly correlated (Maier et al. 2009). The key 
transcription factor NF-kB of M1 macrophages is essential for the development of the Th1 
responses such as IL-12, IFN-ү, IL-23, and IL-27 which are required to control Mtb replication 
(Cooper and Khader, 2008), as well as IL-1β, TNF-α, and IL-6 (Wang et al. 2014). Blood 
transcriptional assays that enable early accurate TB diagnosis could have an important impact 
on control of the global TB epidemic (Walter et al. 2016). The immunological factors involved 
in the host immune response network in Mtb infection and TB reactivation have not yet been 
clearly elucidated. Identifying the host genes responsible for TB susceptibility and resistance 
may be the key towards better understanding the mechanisms leading to the development of 
the disease, and also identify pathways for targeted HDT. The genes that were differentially 
expressed in unstimulated LTBI-T2D compared to LTBI were associated with activation of 
necrosis and cell death of tumour cells, inhibition of immune response of leukocytes, 
maturation of blood cells, which may be implicated in the regulation of the immune response 
during Mtb infection. CCL2, CD163, TNFRSF8, cytokine inducible SH2 containing protein  
(CISH), guanylate binding protein 5(GBP5), promyelocytic leukemia (PML) and transporter 
associated with antigen presentation (TAP1) were differentially expressed in LTBI-T2D 
compared to LTBI and TB-T2D compared to TB patients which implies that these genes could 
have some significance in promoting TB susceptibility in LTBI and pathology in TB patients 
with T2D.  
A gene signature unique to LTBI-T2D patients was identified and includes CD59, TNFS11 and 
CD274. Only CD59 was significantly higher in individuals with LTBI-T2D compared to LTBI. 
CD59 is a membrane glycoprotein which protects host cells from the membrane attach 
complex mediating lysis (Koski et al. 1996). The membrane attack complex can result in tissue 
injury during dysregulated complement activation that occurs during chronic inflammatory 
conditions (Huang et al. 2006). This can result in overexpression of CD59, which, in tumour 




patients, it is possible that CD59 protects the Mtb infected cells from complement mediated 
lysis which favours replication within the cells. A process which is perhaps exploited by Mtb. 
Zak et al. identified a 16 gene signature that could predict development of TB two years prior 
to diagnosis (Zak et al. 2016). Suliman et al. also identified a RISK4 gene signature that 
identifies those at risk for TB progression within two years (Suliman et al. 2018). In our study, 
TAP1, SERPING-1 and GBP5 genes were downregulated in T2D compared to LTBI after 
stimulation with Mtb antigens. The mentioned genes are also in the 16 gene signature 
identified by Zak et al. Before Mtb antigens stimulation, these genes were upregulated in LTBI-
T2D compared to LTBI, and were downregulated after stimulation. This shows that LTBI-T2D 
patients express some of the signature genes associated with progression to TB. Whether this 
is associated with an increased risk to progress to TB in T2D patients is not yet known. The 
complete signatures identified by Zak et al. (2016) and Suliman et al. (2018) could not be 
detected in our study. This was expected since a published 393-gene TB signature identified 
previously could not identify TB in patients co-infected with HIV (Dawany et al. 2014). The 
other reason was that our study used a specific immunological panel, which only looked at a 
subset of genes unlike the mentioned studies which used more in depth techniques such as 
RNA-seq. Due to T2D, the expression of genes is likely to differ.  
The IL-18 gene transcript was downregulated in the RNA isolated from unstimulated blood 
and upregulated in the Mtb antigen stimulated blood of individuals with LTBI-T2D compared 
to LTBI. In our unpublished data, we showed higher serum protein levels of IL-18 in LTBI-T2D 
compared to LTBI. This means that there is an inverse relationship between IL-18 protein and 
mRNA (similarly to what we observed for CCL2), which could feedback to suppress the IL-18 
transcript. In a study where IL-18 knock out mice were infected with Mtb, the IL-18 knock out 
mice had more CFUs in their lungs, compared to wildtype mice, and the CFUs were reduced 
after treating the mice with IL-18 (Sugawara et al 1999). In this study, the authors concluded 
that IL-18 is important for the development of protective immunity during Mtb infection 
(Sugawara et al. 1999). IL-18 increases FASL expression and NF-κB activation and its 
downregulation has been associated with increased Mtb susceptibility (Dinarello, 1999). The 
IL-18 gene has been studied in TB and LTBI models. We found it to be differentially expressed 
in LTBI-T2D compared to LTBI. Interestingly, in unstimulated LTBI-T2D samples, this gene 
transcript was downregulated and upregulated after Mtb antigen stimulation. This could be as 
a means of immune activation, and implies that IL-18 expression is affected during LTBI-T2D. 
These results have not been reported elsewhere, however, the inflammatory gene profile 





Transforming growth factor beta (TGF-β) is an anti-inflammatory and immunosuppressive 
cytokine, it antagonizes the activation of NF-kB in lymphocytes, on the one hand, NF-kB also 
inhibit activities of TGF-β (Geiser et al. 1993). TGF-β receptor-1 transcript was increased in 
our results in the TB-T2D compared to TB, and we think that this increase could underlie or 
result in irregular TGF-β production. If it does influence TGF-β production, it could explain the 
increased Th2 responses that have been reported in other studies (Al-Attiya and Mustafa, 
2009; Wang et al. 2018). However, in LTBI-T2D the upregulation of TGF- β is associated with 
the down regulation of Th1 (Kumar et al. 2014). 
Generally, the immune responses (especially the NF-kB signalling pathway) against Mtb were 
downregulated in the unstimulated blood from TB-T2D patients which could be a contributing 
factor in delayed Mtb clearance and unfavourable TB treatment outcomes. Interestingly, 
TNFRSF8 or CD30 which is expressed by activated lymphocytes (T and B cells), was 
downregulated in TB-T2D and one of its major functions is to arbitrate the signal transduction 
that leads to the activation of NF-kB (Liu et al. 2017). TNFRSF8 was also down-regulated in 
unstimulated LTBI-T2D compared to LTBI and as we know, TNF-α suppressors have been 
associated with progression to TB disease in LTBI individuals (Cantini et al. 2016).  
We were able to perform gene expression assay on both TANDEM and ALERT samples and 
found that there are unique gene profiles among our study patients. These gene profiles will 
be useful to characterize the biological composition and the immune response profile during 
different disease states. We identified a 15 gene signature that was downregulated in TB-T2D 
patients when compared to both TB and TB-THG and suggested that it could be involved in 
the immunopathology associated with TB-T2D. In addition, we also identified a biosignature 
using RPA (C1QBP, C1R and PSMB5) that could distinguish between TB-THG and TB-T2D 
in unstimulated blood. We were able to identify novel gene signature in unstimulated blood 
(CD59, TNFSF11 and CD247) from individuals with LTBI-T2D compared to LTBI which should 
be further evaluated in functional assays to elucidate their involvement in the increased 
susceptibility to TB observed in individuals with T2D. We were not able to perform a direct 
comparison for our 594 gene expression between the participant groups of the two different 
studies as the gene expression analysis was batched and run at different times. The first gene 
expression analysis was performed on the TANDEM patients, and a year later we ran the 
same gene expression panel on ALERT patients. We further acknowledge that we had a 






Immune-endocrine changes in the serum and plasma of individuals with LTBI and TB 
patients with and without T2D, association with glycaemic control and Mtb control in 
phagocytic mononuclear cells. 
4.1 Introduction 
T2D is increasing in low and middle income countries where TB is also endemic (Harries et 
al. 2011). T2D is considered a risk factor for TB; apart from hyperglycaemia, altered 
phagocytosis by monocytes, dysregulated T cell immune response, altered hormone and 
cytokine production have been reported in TB-T2D patients (Restrepo and Schlesinger, 2013; 
Gomez et al. 2013; Kumar et al. 2014). Individuals with LTBI-T2D exhibit diminished circulating 
levels of type 1 (IFN-ү, IL-2 and TNF-α) and type 17 (IL-17F) cytokines (Kumar et al. 2014). 
Furthermore, decreased systemic levels of other pro-inflammatory cytokines such as IL-1β 
and IL-18, and the anti-inflammatory cytokine IL-10 have been reported (Kumar et al. 2014). 
Moreover, inflammatory cytokine production can activate the HPA axis (Fernandez et al. 
2016). The activation of the HPA axis leads to secretion of ACTH, ultimately resulting in the 
production of cortisol from the adrenals (Burford et al. 2017). Dysregulated cortisol production 
is associated with inhibition of immune cell functioning, such as antigen presentation leading 
to reduced Mtb control (Angerami et al. 2013), and has also been associated with TB severity 
(Santucci et al. 2011). The immune-endocrine profile is dysregulated in TB and more so in TB-
T2D comorbidity (Fernandez et al. 2016). Little is known about the dysregulation of the 
immune-endocrine interaction in LTBI-T2D, although this may contribute to the susceptibility 
of T2D patients to TB disease. We therefore aimed to characterize cytokine and hormone 
levels in latently infected individuals and TB patients with and without T2D and evaluate if 
there is correlation among the cytokines, hormones and Mtb association and control by 
PBMCs and MNs from these participants. 
4.2 Methods 
The detailed methods are discussed in Chapter 2. Forty close contacts of TB patients with and 
without T2D (enrolled as part of the ALERT study) and 21 TB patients with and without T2D 
at BL and M6 (enrolled as part of the TANDEM study) were included. The blood collected in 
NaHep tubes was used for PBMC isolation using the density gradient centrifugation method 
(for ALERT patients). Subsequently, MNs were isolated using Miltenyi Pan Monocyte isolation 
kit and LS MACS separation columns (Miltenyi biotec). The PBMCs and MNs were infected 
with H37Rv Mtb for two hours. Mtb uptake was determined, and cells were further incubated 
for one and three days (for MNs) or six days (for PBMCs), to determine the ability of the MNs 
and PBMCs to control and kill the Mtb in both the LTBI (noT2D) and LTBI-T2D (T2D). 
Differential blood cell counts and clinical parameters (HbA1c, FBG, lipids, weight and height) 




serum and plasma samples that were previously stored at -80°C were thawed and ELISAs 
used to measure adrenaline, noradrenaline, dopamine, (Abnova) serotonin, I-TAC and IL-22 
(Biocom). Luminex was used to simultaneously measure IFN-ү, TNF-α, IL-1β, IL-4, IL-6, IL-8, 
IL-10, IL-13, IIL-18, IL-21, IL-22, IL-23, IL-27, IL-33, (Qiagen), IL-35 and oncostatin (OSM) 
(Merck-Millipore) in the same samples. The CFU data were correlated with the cytokines, 
hormones, blood glucose levels, lipids and differential blood cell counts. IL-22 ELISA was 
performed on serum samples from both the ALERT and TANDEM study. Repeated measures 
ANOVA with a Fisher LSD post hoc test as well as Kruskal-Wallis with Dunn’s post hoc test 
were used to determine statistical differences between the groups. Spearman correlation 
analysis was used to determine association between variables. 
4.3 Results 
4.3.1 Study participants and characteristics 
The participants included in this chapter are the same as in the previous chapter. Their 
demographics and clinical parameters are summarized in Table 3.1. The ALERT participants 
were latently infected individuals with and without T2D, and in this particular chapter, 
participants were divided into four subclasses; noT2D (HbA1c 4.0-5.69%, n=10), PreT2D 
(HbA1c 5.7-6.49%, n=10), T2D (HbA1c 6.5-7.9%, n= 10) and poorly controlled T2D (pT2D) 
(HbA1c ≥8%, n=10). TANDEM participants were TB patients with and without T2D, and were 
grouped as follow, TB (HbA1c ≤5.7%), TB with transient hyperglycaemia (TB-THG; HbA1c 
≥6.5% at BL only and not on DM medication) and TB-T2D (HbA1c ≥6.5% at BL and M6, and 
taking DM medication). 
4.3.2 Cytokine responses in latently infected individuals with and without T2D 
T2D is characterised by chronic inflammation and dysregulated immune response (Xia et al. 
2017). LTBI-T2D have low circulating levels of IFN-ү, IL-2, TNF-α and IL-17F (Kumar et al. 
2014), as well as IL-1β, IL-18, IL-10 (Kumar et al. 2014). In this study, we measured the 
circulating concentrations of Th1 (IFN-ү and TNF-α ), Th2 (IL-4, IL-10, IL-13, IL-33, IL-35 and 
IL-27), Th17 (IL-22) as well as a range of other pro-inflammatory cytokines (IL-1β, IL-6, IL-18, 
IL-21 and IL-23) and chemokines (IL-8 and I-TAC) in the serum and plasma of individuals with 
LTBI with and without T2D.  
In this section we first compared the cytokine concentrations in the two groups, LTBI (including 
noT2D and preT2D) and LTBI-T2D (includingT2D and pT2Ds). Serum concentrations of IL-6 
were significantly higher in individuals with LTBI-T2D compared to LTBI-noT2D (Figure 4.1A). 
IL-18 showed a trend towards higher concentrations in LTBI-T2D compared to LTBI-noT2D 
(Figure 4.1B). There was no significant difference in concentrations of the following cytokines; 




T2D and LTBI-noT2D. IFN-ү, TNF-α, IL-10, IL- 21, IL-22, IL-23, IL-33 and IL-35 were not 
detected in majority of the study participants and therefore were not included in the analysis. 
 
 
Figure 4.1 Circulating cytokine levels in LTBI-noT2D compared to LTBI-T2D. IFN-ү, TNF-α, IL-1β, IL-4, IL-6, 
IL-8, IL-10, IL-13, IL-18, IL-21, IL-22, IL-23, IL-27, IL-33, IL-35, OSM were measured using luminex and I-TAC and 
IL-22 using ELISA in serum samples of LTBI-noT2D (HbA1c 4.0-6.4%, n=20) and LTBI-T2D (HbA1c ≥6.5%, n=20) 
patients. (A) IL-6 concentrations were significantly higher in LTBI-T2D compared to LTBI-noT2D. (B) IL-18 
concentrations were also higher in LTBI-T2D patients compared to LTBI-noT2D participants, but did not reach 
statistical significance. (C) IL-27 concentrations were not significantly different between LTBI-noT2D and LTBI-
T2D. Data are represented as LS means with 95% confidence intervals (CI). The significant difference between 
the groups was calculated using the Mann-Whitney U T test and a p-value < 0.05 was considered significant. 
4.3.3 IL-22 and IL-18 concentrations are higher in pT2D patients  
IL-22 has been shown to induce antimicrobial peptides, promotes epithelial repair and inhibits 
intracellular growth of Mtb in macrophages (reviewed in Domingo-gonzalez et al. 2016). IL-
18, produced by monocytes and macrophages, is associated with protection against Mtb 
infection (Schneider et al. 2010). When further subdividing the study participant into LTBI with 
preT2D, T2D and pT2D, we found that IL-18 concentrations were significantly higher in LTBI-
pT2D compared to LTBI-noT2D (p=0.02; Figure 4.2A). There was a trend towards higher 
levels of IL-18 in LTBI-pT2D when compared to LTBI-preT2D (p=0.06; Figure 4.2A). IL-22 was 
significantly higher in LTBI-pT2D compared to LTBI-T2D (p=0.04; Figure 4.2B). IL-22 was also 
higher in LTBI-pT2D compared to LTBI-noT2D, however, this difference failed to reach 
significant difference (p=0.09). IL-6 did not show any significant difference when comparing 






Figure 4.2 IL-18, IL-22 and IL-6, concentrations compared among LTBI-noT2D, preT2D, T2D and LTBI-pT2D 
patients. Serum samples from LTBI-noT2D (HbA1c% 4.0-5.69, n=10), PreT2D (HbA1c% 5.7-6.49, n=10), T2D 
(HbA1c% 6.5-8, n= 10) and pT2D (HbA1c%≥8, n=10) were used to measure IFN-ү, TNF-α, IL-1β, IL-4, IL-6, IL-8, 
IL-10, IL-13, IL-18, IL-21, IL-22, IL-23, IL-27, IL-33, IL-35 and OSM using the luminex technology and  IL-22 and I-
TAC  using ELISA. (A) IL-18 is significantly higher in LTBI-pT2D (vs noT2D). (B) IL-22 is higher in LTBI-pT2D 
compared to LTBI-T2D (p=0.02) and LTBI-preT2D (p=0.09). (C) No statistical significant difference in IL-6 is 
observed among the four groups. The data were analysed using an ANOVA with a Fisher LSD Post-hoc test. Data 
are represented as LS means with 95% CI, ANOVA p value is shown on the graph. Letters (a-b) are used to indicate 
significant differences, groups with the same letter are not statistically different from each other. 
4.3.4 IL-22 cytokine is higher in TB-T2D  
The role of IL-22 in TB is contradicting, with some studies suggesting a pathological role, while 
other studies suggest a protective role for IL-22 during TB  (Treerat et al. 2017). Given the 
importance of IL-22, we measured its concentration in TB, TB-THG and TB-T2D patients at 
BL and M6 using an ELISA. IL-22 concentrations were significantly lower in TB-THG patients 
compared to TB-T2D at BL (Figure 4.3A) and this trend was also seen at M6, although not 
statistically significant   (Figure 4.3B). To determine if TB treatment has an effect on IL-22 
levels, we compared IL-22 expression at BL and M6 in the three groups and no differences 
were observed, however, TB-T2D showed a trend towards decreased IL-22 at M6 compared 
to BL (Figure 4.3C).  
Furthermore, we wanted to compare the concentration of IL-22 in TB, TB-THG and TB-T2D 
patients before and after TB treatment to that of individuals with LTBI with and without T2D. 
There was an overall significant difference in IL-22 concentration at BL (ANOVA), however, 
after correcting for multiple comparisons with the Dunn’s post hoc test, there were no 
significant differences detected among any of the groups (Figure 4.3D). When comparing the 
end of treatment (M6) IL-22 concentrations of the TB patients to those measured in the LTBI 
groups, we found that the end of treatment, IL-22 concentrations were significantly higher in 





Figure 4.3 IL-22 concentrations in LTBI-T2D compared to TB-T2D. Serum from individuals with LTBI with 
noT2D (HbA1c 4.0-5.69%), preT2D (HbA1c 5.7-6.49%), T2D (HbA1c 6.5-8%) and pT2D (HbA1c ≥8%) was used 
for measuring IL-22 using ELISA. (A) IL-22 measurement in TB, TB-THG and TB-T2D at BL. (B) IL-22 
measurement in TB, TB-THG and TB-T2D at M6. (C) IL-22 measurements to determine treatment effect in TB, TB-
THG and TB-T2D at BL and M6. (D) IL-22 measurement in LTBI-noT2D, LTBI-preT2D, LTBI-T2D, LTBI-pT2D, TB, 
TB-THG and TB-T2D at BL. (E) IL-22 measurement in LTIB-noT2D, LTBI-preT2D, LTBI-T2D, LTBI-pT2D, and M6 
of TB, TB-THG and TB-T2D. The ANOVA p-value is shown on the graph and differences between the groups 
indicated with a *. The data was analysed using the Kruskal-Wallis test with a Dunn’s post hoc test to determine 
difference between the groups. *P <0.05, **P<0.01. 
4.3.5 No differences in catecholamines, vitamin D, cortisol and insulin concentrations 
in LTBI participants with and without T2D  
Cytokines produced during Mtb infection and T2D may alter endocrine responses which in 
turn could have an effect on theprogression of the disease (Webster et al. 2002). We therefore 
wanted to investigate the plasma concentrations of some hormones (mentioned below) in LTBI 
participants with and without T2D. We measured catecholamine (dopamine, adrenaline and 
noradrenaline) and serotonin concentrations with ELISA, while measurements of insulin, 
cortisol and Vitamin D levels were done at the national health laboratory services for these 
participants. We were unable to measure Noradrenaline due to technical problems 
encountered in the laboratory. No differences were observed in the circulating concentrations 
of the measured hormones between LTBI-T2D and LTBI-noT2D. Figures comparing the levels 




4.5D), between T2D and noT2D, are shown below. Dopamine and Vitamin D data were not 
included. 
 
Figure 4.4 Hormone concentrations in LTBI-T2D compared to LTBI-noT2D. Measurements of cortisol (A) and 
insulin (B) were assessed by clinical laboratory testing through the national health laboratory services (NHLS). 
Adrenaline (C) and serotonin (D) were measured with ELISA. All the hormones were not significantly different 
between LTBI-T2D and LTBI-noT2D. Data was analysed using Mann-Whitney U T test and represented as LS 
means with 95% CI. P <0.05 was considered significant. 
4.3.6 Insulin was higher in LTBI with pT2D compared to LTBI with noT2D 
It is known that T2D patients are characterized by hyperglycaemia and insulin resistance 
(Taskinen and Boren, 2015), therefore we wanted to determine if subdividing our participants 
according to glycaemic levels would result in differences in hormones associated with T2D. 
After subdividing the participants into the four groups, there was a significant difference in 
insulin levels between LTBI-pT2D and LTBI-noT2D (p=0.03; Figure 4.5A). This is not 
surprising as high insulin observed in the LTBI-pT2D patients is driven by the insulin treatment 
some of the patients received (5 of the 10 pT2D patients reported using insulin) or could be 
due to hyperinsulineamia. There were no differences observed in any of the hormones; vitamin 
D, cortisol, serotonin and catecholamines measured when comparing the four patient groups 






Figure 4.5. Hormone levels in patients with LTBI and noT2D, preT2D, T2D and pT2D. Insulin (A) and serotonin 
(B) concentrations were measure in the plasma samples of LTBI-noT2D (HbA1c 4.0-5.69%), LTBI-preT2D (HbA1c 
5.7-5.64%), LTBI-T2D (HbA1c 6.5-8%) and LTBI-pT2D (HbA1c ≥8%) patients by ELISA. The data was analysed 
using an ANOVA with a Fisher LSD post hoc test. Data are represented as LS means with 95% CI. Letters (a-b) 
indicate significance differences. Groups with the same letter are not statistically different from each other. 
4.3.7 Triglycerides were higher in LTBI-T2D compared to LTBI-noT2D 
Dyslipidaemia is one of the best described characteristics of T2D (Taskinen and Boren, 2015), 
and is involved in the regulation of chronic inflammation (Wellen and Hotamisligil 2005). Since 
T2D is characterized by low grade chronic inflammation (Huang et al. 2014), we wanted to 
investigate the lipid profile in our study participants. We, therefore, investigated total CHL, 
triglycerides, LDL and HDL levels in the plasma of participants with LTBI with and without T2D. 
As shown in Figure 4.6A, the LTBI-T2D patients had significantly higher triglyceride 
concentrations in their blood compared to LTBI-noT2D. The total CHL (Figure 4.6B) and LDL 
(data not shown) were higher and HDL (data not shown) was lower in LTBI-T2D patients, but 
the differences were not significant. 
 
 
Figure 4.6 Triglycerides and cholesterol in LTBI-T2D compared to LTBI-noT2D. Lipids concentrations were 
assessed by clinical laboratory testing through the national laboratory services (NHLS). (A) Triglycerides were 




the two groups. Data were analysed using Mann-Whitney U T test. Data are represented as LS means with 95% 
CI. P <0.05 was considered significant. 
4.3.8 Poorly controlled glycaemia drives the increase in lipids in T2D patients 
To determine if the differences between the participants were dependant on the glycaemic 
control, the analysis was done in the four subgroups. Triglycerides were significantly higher in 
LTBI-pT2D compared to all the other groups (Figure 4.7A). Total CHL was significantly higher 
in LTBI-pT2D in comparison to LTBI-noT2D (p=0.01; Figure 4.7B). LDL was significantly 
higher in LTBI-pT2D compared to LTBI-noT2D (p=0.01; Figure 4C) and showed a trend 
towards higher levels compared to LTBI-preT2D (p=0.06; Figure 4.7C). HDL concentration 
was significantly higher in LTBI-noT2D compared to LTBI-PreT2D and LTBI-T2D (p=0.03; 
Figure 4.7D). Overall, all lipids measurements were higher in LTBI-pT2D compared to LTBI-
noT2D, with the exception of HDL, which was the highest in the LTBI-noT2D. 
 
 
Figure 4.7 Lipid concentrations in LTBI-noT2D, LTBI-preT2D, LTBI-T2D and LTBI-pT2D participant groups. 
Lipids were measured in serum from LTBI-noT2D (HbA1c 4.0-5.69%, n=10), LTBI-PreT2D (HbA1c 5.7-6.49%, 
n=10), LTBI-T2D (HbA1c 6.5-8%, n= 10) and LTBI-pT2D (HbA1c ≥8%, n=10). (A) Triglycerides were significantly 




to LTBI-noT2D. (C) LDL was also significantly higher in LTB-pT2D (compared to LTBI-noT2D) and there was a 
trend for it to be higher in than LTBI-preT2D. (D) HDL was significantly lower in LTBI-noT2D (compared to LTBI-
T2D). The obtained concentrations were analysed using an ANOVA with a Fisher LSD post hoc test. Data are 
represented as LS means with 95% CI. Letters (a-b) are used to indicate significance. Groups with the same letter 
are not statistically different from each other. 
4.3.9 No difference in complete blood cell counts in LTBI with and without T2D 
To determine the effect T2D might have on the full and differential blood cell counts, we 
compared the absolute number and frequency of blood cells in LTBI participants with and 
without T2D. Total red and white blood cells, as well as platelet counts were measured. In 
addition, neutrophil, monocyte, basophil and lymphocyte numbers were determined. No 
significant changes in the full and differential cell counts were observed between LTBI-T2D 
and LTBI-noT2D (data not shown). 
4.3.10 Individuals with LTBI and pT2D have increased white blood cell and 
lymphocyte counts 
Differential blood cell counts in our participants after stratification according to HbA1c was 
determined and we found higher white blood cell counts in LTBI-pT2D compared to LTBI-
noT2D (p=0.01; Figure 4.8A) and a trend towards higher levels in LTBI-pT2D when compared 
to preT2D (p=0.08 Figure 4.8A). The lymphocyte counts were higher in the LTBI-pT2D 
compared to LTBI-noT2D (p=0.01), preT2D (p=0.02) and T2D (p=0.02) as shown in (Figure 
4.8B). The neutrophil absolute counts did not show any differences, however, there was a 
trend towards higher counts in both LTBI-pT2D and LTBI-preT2D compared to LTBI-noT2D 
(p=0.07) (data not shown). There was no difference among the absolute counts of monocytes, 
eosinophils and basophils, and there was also no significant changes in the frequency of all 
the different blood cell counts among the four groups. 
 
Figure 4.8. Absolute counts of white blood cells and lymphocytes in participants with LTBI and noT2D, 
preT2D, T2D and pT2D. Whole blood from LTBI-noT2D (HbA1c 4.0-5.69%, n=10), LTBI-preT2D (HbA1c 5.7-
6.49%, n=10), LTBI-T2D (HbA1c 6.5-8%, n= 10) and LTBI-pT2D (HbA1c ≥8%, n=10) was used to measure the 
blood cell counts. (A) Illustrates significantly higher white blood cell count in LTBI-pT2D compared to LTBI-noT2D. 
(B) Lymphocyte counts are significantly higher in LTBI-pT2D compared to noT2D, preT2D and T2D. The obtained 




Data are represented as LS means with 95% CI. Letters (a-b) are used to indicate significance. Groups with the 
same letter are not statistically different from each other. P <0.05 was considered significant. 
4.3.11 PBMCs from participants with LTBI and T2D show poor association and control 
of Mtb  
Innate responses are compromised in patients with chronic hyperglycaemia and macrophages 
from these patients have impaired association as well as bactericidal activity (Llorente et al. 
2000). In this study, the PBMCs from individuals with LTBI with and without T2D were infected 
with Mtb H37Rv to determineassociation and killing activity. The CFU count at two hours was 
used as a measure of the number of Mtb associated with MNs, and the CFU counts at day 
one (D1), day three (D3) (MNs) or day six (D6) (PBMCs) as a measure of controlling Mtb 
growth, and decreasing CFU over time is a sign of Mtb killing. There was no correction made 
for the differential blood cell counts. 
PBMCs from LTBI-T2D patients had significantly lower CFUs at two hours suggesting 
poorassociation of Mtb when compared to LTBI-noT2D (p=0.04; Figure 4.9A). Fold changes 
in CFU counts at D1 and D6 were calculated by dividing the CFU counts of each of these time 
points with the corresponding two-hour CFU counts. Fold changes were used to control for 
variations in Mtb uptake. PBMCs from LTBI-T2D and LTBI-noT2D had significantly higher CFU 
counts at D6 compared to D1 (p=0.01 and p=0.02, respectively; Figure 4.9B). No difference 
in killing ability of the PBMCs were observed when LTBI-T2D were compared to LTBI-noT2D. 
It is important to note that these findings vary to those of the entire ALERT cohort showing no 
difference in phagocytosis between the two groups and also showing significantly higher Mtb 
fold growth in LTBI-T2D compared to LTBI-noT2D. The differences are most likely due to the 
small number of participants included in this substudy. The analysis for the larger parent study 
is still ongoing. 
It has been shown that pT2D increases TB risks (Leung et al. 2008). For that reason we further 
classified and analysed the data of the participants in the four subclasses depending on 
HbA1c. We found that after two hours the CFU counts from PBMCs isolated from LTBI-T2D 
were significantly reduced compared to LTBI-noT2D (p=0.02), LTBI-preT2D (p<0.01) and 
interestingly to LTBI-pT2D (p=0.01) (Figure 4.9C). There was a trend towards higher CFU in 
PBMCs of LTBI-T2D compared to PBMC from LTBI-noT2D, at D6 (p=0.06; Figure 4.9D). 
Furthermore, the four subclasses were investigated to determine Mtb containment. PBMCs 
from LTBI-noT2D (p=0.03), LTBI-preT2D (p=0.02) and LTBI-T2D (p<0.01) had a significant 
increase in CFUs from D1 to D6 (Figure 4.9D), whereas, a trend towards an increase from D1 





Figure 4.9 The influence of T2D on the containment of Mtb by PBMC of latently infected participants. PBMCs 
from LTBI-noT2D (HbA1c 5.7-6.4%, n=20) and LTBI-T2D (HbA1c ≥6.5%, n=20) (A and C) and PBMC from LTBI-
noT2D (HbA1c 4.0-5.6%9, n=10), LTBI-PreT2D (HbA1c 5.7-6.49%, n=10), LTBI-T2D (HbA1c 6.5-8%, n= 10) and 
LTBI-pT2D (HbA1c≥8, n=10) (B and D) were infected with Mtb for two hours. Cells were lysed immediately after 
the infection as well as one and six days post infection. The data were analysed using ANOVA with a Fisher LSD 
post hoc test. Data are represented as LS means with 95% CI. Letters a-d indicate statistical significance with the 
same letter indicating no difference between or among groups. 
4.3.12 MNs from T2D have poor Mtb control 
MNs from patients with T2D have decreased phagocytic activity (Komura et al. 2010), and 
lower association with Mtb (Gomez et al. 2013) which could result in poor Mtb control. To 
determine the phagocytic capacity of MNs in our study cohort, MNs were isolated from PBMCs 
and infected with Mtb. Although our study showed that MNs from LTBI-noT2D had higher Mtb 
uptake compared to LTBI-T2D, the difference observed was not significant (Figure 4.10A). We 
further determined the Mtb killing capacity of the MNs from LTBI-noT2D and LTBI-T2D. CFUs 
increased in both groups from D1 to D3 with D3 CFU counts of LTBI-T2D reaching statistical 
significance (p=0.02; Figure 4.10B). In LTBI-noT2D the increase in CFUs from D1 to D3 
remained a trend (p=0.06; Figure 4.10B). There was no significant difference in CFU between 
LTBI-T2D and LTBI-noT2D at D1 (p=0.47) and D3 (p=0.24) post infection (Figure 4.10B). 
We further analysed the MNs CFU results according to the four subclasses and did not see 
any differences in the association of Mtb with MNs (Figure 4.10C). We continued to determine 
the growth and the ability of the MNs to control Mtb in these patients. Fold changes from D1 




increase in CFU from D1 to D3 (p=0.04 and p<0.01, respectively; Figure 4.10D). The CFU fold 
growth from MNs of LTBI-preT2D and LTBI-pT2D did not significantly change from D1 to D3 
(Figure 4.10D). There was no significant difference in CFU among the four groups at D1 and 
D3 (Figure 4.10D). 
 
Figure 4.10 The influence of T2D on the containment of Mtb by MNs. MNs from LTBI-noT2D (HbA1c 5.7-6.4%, 
n=20) and LTBI-T2D (HbA1c ≥6.5%, n=20) (A and C) and MNs from LTBI-noT2D (HbA1c 4.0-5.69%, n=10), LTBI-
preT2D (HbA1c 5.7-6.49%, n=10), LTBI-T2D (HbA1c 6.5-8%, n= 10) and LTBI-pT2D (HbA1c ≥8%, n=10) (B and 
D) were infected with Mtb for two hours. CFUs counts were determined for uptake at two hours and Mtb burden 
and control at D1 and D3. The CFU data was analysed using ANOVA with a Fisher LSD post hoc test. Data is 
represented as LS means with 95% CI. Letters a-c indicate statistical significance with the same letter are not 
statistically different from each other. 
4.3.13 No association between FBG and HbA1c with Mtb uptake by PBMCs 
There was poor Mtb association with PBMCs from T2D patients. Following that observation, 
we did a spearman correlation between the clinical characteristics associated with T2D. We 
found a negative correlation between BMI and Mtb uptake by PBMC (p=0.07, r=-0.29) of 
patients with LTBI and T2D, however this was only a trend. There was no correlation between 
FBG and Mtb uptake by MNs (p=0.14; r=0.25; Figure 4.11A) and PBMCs (p=0.14, r=0.25; 
Figure 4.11B). There was also no relationship between Mtb uptake by MNs (p=0.12, r=0.27; 
Figure 4.11C) and PBMCs (p=0.82, r=-0.04; Figure 4.11D) with HbA1c. 
When the participants were further divided into the four groups according to HbA1c (LTBI-




in PBMCs of LTBI-noT2D (p=0.03, r= 0.68) as well as in LTBI-T2D (p=0.01, r= 0.75; data not 
shown). There was no correlation between FBG and Mtb uptake by PBMC of LTBI-preT2D 
(p=0.25, r=0.40) and LTBI-pT2D (p=0.73, r=0.13; data not shown). 
 
 
Figure 4.11 Correlation of glycaemic control with Mtb uptake. FBG was correlated to Mtb uptake by MNs (A) 
and PBMCs of (B). HbA1c was correlated to Mtb uptake by MNs (C) and PBMCs (D). The associations were 
determined using Spearman correlations. 
4.3.14 Correlations between Mtb killing and cytokines  
We observed that IL-6, IL-18 and IL-22 serum concentrations were high in T2D patients and 
investigated further whether there were associations between the cytokine concentrations and 
the Mtb uptake and killing. Firstly, we did correlations of cytokines and CFU data in all 
participants. IL-6 did not shown any significant correlation with Mtb uptake by MNs (p=0.19, 
r=-0.23; Figure 4.12A) or PBMCs (p=0.63, r=-0.08; Figure 4.12B) and the same was seen for 
IL-18 and IL-22. I-TAC showed a trend towards a positive correlation with Mtb uptake by 
PBMCs (p=0.06, r=0.30; data not shown) and IL-4 a trend towards a negative correlation with 
D1 CFU fold change in PBMCs (p=0.09, r=-0.27; data not shown). I-TAC was negatively 




In the analysis of the four groups, we found that IL-6 was positively correlated with Mtb uptake 
by PBMCs in the LTBI-noT2D group (p=0.03, r=0.68; data not shown) while IL-22 showed a 
trend towards a negative correlation with Mtb uptake by PBMCs in the same group (p=0.06, 
r=0.71). IL-6 was negatively correlated to D1 CFU fold growth in PBMCs (p<0.01, r=-0.91). In 
addition, I-TAC revealed a trend towards a negative correlation with D6 CFU fold growth in 
PBMCs (p=0.05, r=-0.64).  
In LTBI-preT2D, IL-6 was not significantly correlated to Mtb uptake by PBMCs (p=0.13, r=-
0.52; data not shown). IL-4 was positively correlated to D3 CFU fold growth in MNs (p=0.03, 
r=0.59) and a similar association was found with IL-18 and D3 CFU fold change in MNs 
(p=0.04, r=0.76). A trend towards a positive correlation was seen between IL-8 and D3 CFU 
fold change in MNs (p=0.07, r=0.69). IL-4 (p=0.08, r=-0.66) and IL-8 (p=0.07, r=-0.71) revealed 
a trend towards a negative association with Mtb uptake by MNs. 
IL-6 was positively correlated with Mtb uptake by PBMCs in LTBI-T2D patients (p=0.02, 
r=0.72; data not shown). Furthermore, IL-6 showed a trend towards negative correlation with 
D6 CFU fold change in PBMC (p=0.06, r=-0.61). IL-13 (p=0.04, r=-0.65) and I-TAC (p=0.02, 
r=-0.73) negatively correlated with fold change in PBMCs at D6. IL-18 on the other hand was 
trending towards a negative correlation with Mtb uptake by MNs (p=0.05, r=-0.74)  
There was a negative correlation between IL-6 and Mtb uptake by PBMCs of LTBI-pT2D 
(p=0.01, r=-0.75; data not shown), similarly, OSM was also negatively correlated to Mtb uptake 
by PBMC (p=0.04, r=-0.72).  
 
Figure 4.12 Correlation of serum cytokines with Mtb uptake by PBMCs. (A) IL-6 correlated to Mtb uptake by 
MNs (A) and PBMCs (B). The associations were determined using Spearman correlations. 
4.3.15 Correlations between Mtb killing and measured catecholamines, cortisol, 
insulin and vitamin D  
A correlation analysis was done to determine whether plasma hormone concentrations are 
associated with differences in CFU. This is relevant as PBMCs and MNs were cultured in 20% 




(p=0.78, r=0.-0.05; Figure 4.13A) and PBMCs with vitamin D (p=0.66, r=-0.08; Figure 4.13B) 
and other measured hormones. There was a weak positively correlated between Vitamin D 
and D1 CFU fold growth in PBMCs (p=0.02, r=0.39).  
When groups were subdivided according to HbA1c, vitamin D in LTBI-noT2D did not correlate 
with Mtb uptake by PBMC (p=0.50, r=0.29). A trend towards a positive correlation between 
cortisol and Mtb uptake by MNs (p=0.09, r= 0.58) was shown in the same group. Adrenaline 
measured in LTBI-noT2D also showed a trend to negatively correlate with D3 CFU fold change 
in MNs (p=0.08, r=-0.63).  
Vitamin D concentrations from LTBI-preT2D correlated negatively with Mtb uptake by PBMCs 
(p=0.02, r=-0.73). There was a trend for adrenaline to positively correlate with Mtb uptake by 
PBMC (p=0.06, r=0.62). In addition, in LTBI-preT2D there was a negative correlation between 
cortisol and CFU fold change in PBMC at D1 (p=0.01, r=-0.77) and a trend for a positive 
correlation between adrenaline and D1 fold change in PBMCs (p=0.08, r=0.59). 
Adrenaline measured in T2D patients was negatively correlated to Mtb uptake by PBMCs 
(p<0.01, r=-0.81). Vitamin D had a positive correlation with Mtb uptake by PBMC (p=0.04; 
r=0.72, Figure 4.13C). Serotonin showed a positive association with the CFU fold change from 
PBMCs at D1 (p=0.04; r= 0.62). Adrenaline was negatively correlated to Mtb uptake by MNs 
(p=0.02, r=-0.81) in T2D patients. 
Furthermore, dopamine positively correlated with D1 fold change in MNs in pT2D patients, 
however this was not statistically significant (p=0.07, r=0.69). 
Figure 4.13 Correlation of plasma hormones with Mtb uptake by PBMCs. Vitamin D was correlated to Mtb 
uptake by MNs (A) and PBMCs (B). The associations were determined using Spearman correlations. 
4.3.16 Correlations between Mtb killing and lipids 
Most of the patients with T2D are characterised by dyslipidaemia and it is believed that this 
dyslipidaemia play a role in susceptibility to TB disease (Martens et al. 2008). We wanted to 
determine the association between lipids and Mtb uptake and killing. In all the participants, 




Figure 4.14A) or PBMCs (p=0.10, r=-0.26; Figure 4.14B), total CHL is shown as a 
representative of the hormone data. A trend for a positive correlation between LDL and D1 
CFU fold change in PBMC. 
When the participants were subdivided according to HbA1c, lipids of LTBI-noT2D did not 
correlate with CFUs. 
In LTBI-preT2D there was a trend towards negative correlation between triglycerides and D1 
CFU fold change in PBMCs (p=0.06, r=-0.61) of the same group.  
Total CHL was negatively correlated with Mtb uptake by PBMCs in LTBI-T2D (p=0.02, r=-0.73; 
data not shown). There was a trend for a negative correlation between LDL and Mtb uptake 
by PBMCs (p=0.06, r=-0.62). In MN cultures, there was a negative correlation between total 
CHL and Mtb uptake in LTBI-T2D (p=0.05, r=-0.75). LDL showed a trend for a negative 
correlation with Mtb uptake by MNs (p=0.08, r=-0.67). Triglycerides were trending towards a 
negative correlation with D3 CFU fold change in MNs in the same group (p=0.05, r=-0.74).  
In LTBI-pT2D, there is a trend towards a negative correlation between LDL and Mtb uptake 
by MNs (p=0.09, r=-0.71). 
This shows that there are some interplay between the lipids in the plasma and the ability of 
cells to control Mtb. In our ALERT cohort, we found that LDL was associated with reduced Mtb 
growth (manuscript in preparation), which we did not find in the smaller subset of individuals 
in this study. 
 
Figure 4.14 Correlation of lipids with Mtb uptake by PBMCs. Total CHL was correlated to Mtb uptake by MNs 
(A) and PBMCs (B). The associations were determined using Spearman correlations. 
4.3.17 Correlations between Mtb killing and complete blood counts 
We observed that there was poor association of Mtb with PBMC from T2D patients, therefore, 
we investigated whether correlations exist between the frequency and the absolute counts of 




Mtb uptake by MNs (p=0.42, r=-0.15; Figure 4.14A) or PBMCs (p=0.84, r=0.03; Figure 4.14B) 
and white cell counts.  
Whole blood cell counts from LTBI-noT2D showed a trend to positively correlate with Mtb 
uptake by PBMCs (p=0.08, r=-0.70; Figure 4.15A). Lymphocyte frequency was negatively 
correlated with Mtb uptake by PBMCs (p=0.03, r=-0.69). Still in LTBI-noT2D, the lymphocyte 
frequency also showed a trend towards a positive correlation to D1 fold change in PBMCs 
(p=0.07, r=0.60) and D6 fold change in PBMCs (p=0.09, r=0.57). The MN absolute count was 
also negatively correlated with D6 CFU fold change in PBMCs (p<0.01, r=-0.81). 
In LTBI-preT2D, white blood cell counts had no correlation with Mtb uptake by PBMC (p=0.39, 
r=0.33; Figure 4.15B). MN frequency was positively correlated to D6 PBMC CFU fold growth 
(p=0.04, r=0.73). White blood cell counts (p=0.09, r=0.71) only showed a trend towards a 
positive correlation with Mtb uptake by MNs, additionally, white blood cell counts were 
inversely correlated to D3 MN CFU fold growth (p=0.03, r=-0.82). 
In LTBI-T2D, the whole blood cell count was not correlated to Mtb uptake by PBMC (p=0.61, 
r=0.19). MN frequency had a trend towards negative correlation with Mtb uptake by PBMC 
(p=0.08, r=-0.57). MN frequency was negatively associated with Mtb uptake by MNs at two 
hours (p=0.04, r=-0.73). Lymphocyte frequency from T2D patients was negatively correlated 
to D1 MN CFU fold growth (p<0.01, r=-0.90). 
In LTBI-pT2D, there was no association between white blood cell counts and Mtb uptake by 
PBMC (p=0.41, r=0.30). MN frequency from pT2D patients had a trend to a negative 
correlation with D1 PBMC fold growth (p=0.05, r=-0.63), further we showed a trend for a 
negative correlation between MN count and D6 PBMC fold growth (p=0.08, r=-0.59).  
 
Figure 4.15 Correlation of differential blood counts with Mtb uptake. White blood cell counts correlation to Mtb 







The chronic inflammation accompanying TB disease is associated with altered cellular 
immunity, as well as altered cytokine production (Kumar et al. 2014; Kumar et al. 2015; 
Pearson-stuttard et al. 2015; Kumar et al. 2016). Studies have been conducted in an attempt 
to understand the influence of T2D in the control of Mtb infection (Restrepo et al. 2008; Alim 
et al. 2017; Raposo-Garcia et al 2017; Boillat-Blanco et al. 2018). With this in mind, we studied 
the immune profile in patients with T2D residing in a high TB burden area in SA. Therefore, 
we investigated the influence of T2D on the immune response during Mtb infection of PBMCs 
and MNs isolated from LTBI individuals with and without T2D and further analysed the 
cytokines, hormones, lipids and differential blood cell counts in these participants. 
TNF-α is an important cytokine for the immune response during Mtb infection (Shim, 2014). 
Individuals with LTBI receiving TNF-α antagonists are at high risk of developing TB disease 
(Tobin et al. 2011). In a study that investigated immunological responses to Mtb infection in 
T2D patients and healthy controls, the levels of TNF-α were higher in the T2D patients 
(Raposo-Garcia et al. 2017). TNF-α was however, not detected in the serum of our 
participants. TNF-α was reported to be low in Mtb antigen stimulated whole blood and Mtb 
infected PBMCs of T2D patients (Kumar et al. 2015; Alim et al. 2017). The fact that TNF-α 
was below the detection limit in our study participants could be due to the nature of samples 
we used, which was serum while other studies measured this cytokine in either Mtb stimulated 
or infected samples. IFN-ү is also a crucial cytokine in anti-mycobacterial immunity (Tascon 
et al. 1998). IFN-ү plays a central role in Th1 responses required to clear Mtb infection. Mice 
incapable of producing IFN-ү presented with a high Mtb burden in the spleen and lungs after 
intraperitoneal Mtb infection (Tascon et al. 1998). In a recent study investigating the 
immunological responses to Mtb infection in T2D patients and healthy controls, IFN-ү could 
not be detected in T2D patients (Raposo-Garcia et al. 2017). In our study we also saw similar 
results where the concentration of IFN-ү was undetectable in plasma of LTBI-T2D. 
IL-23 along with IL-1β and IL-6 are essential for Th17 differentiation (Annunziato et al. 2012) 
and inducing IL-22 production (Rutz et al. 2013). Low concentration of IL-22 in LTBI-T2D 
patients in our study could be associated with the low levels of IL-23 and IL-1β cytokines 
especially since they were undetected, with the exception of IL-6. Dhiman et al. showed that 
high IL-22 is associated with protection in infectious diseases (Dhiman et al. 2009). Contrary 
to our finding, Kumar et al. reported higher IL-22 in the serum of LTBI-T2D patients compared 
to LTBI-noT2D (Kumar et al. 2015). This difference could be attributable to ethnicity since 
Kumar and colleagues investigated this in Chennai, India, and it has been shown that patients 
with T2D have metabolic differences depending on where they are from (Restrepo et al. 2018), 




IL-22 promotes lung repair, the release of pro-inflammatory chemokines and cytokines, and 
antimicrobial proteins (Rutz et al. 2013; Ronacher et al. 2018). 
Despite its protective role and wound healing properties, excessive production of IL-22 can be 
harmful and induce necrosis. IL-22 further reduces blood glucose levels, restores insulin 
sensitivity and modulate lipid metabolism in mice (Hasnain et al. 2014). In humans, Kumar et 
al. reported low IL-22 in PPD stimulated whole blood and in plasma of TB-T2D patients 
compared to TB patients (Kumar et al. 2013; Kumar et al. 2015) which could be associated 
with the disease progression of T2D in TB disease (Treerat et al. 2017) or can favour Mtb 
control in TB. IL-22 concentrations in our TB-T2D patients was not significantly different 
compared to TB-THG but was higher compared to TB patients. This was contrary to what 
Kumar et al. found in their study where IL-22 was significantly lower in TB-T2D compared to 
TB patients (Kumar et al. 2015). Higher IL-22 concentration in our study may be a way of the 
immune system to promote metabolic balance and control of TB disease. However, the 
differential expression of IL-22 in our patients and varying results in previous studies supports 
the importance of IL-22 in the regulation of the immune response, and warrants further 
investigation to understand the exact role of IL-22.  
IL-18 production is low in Mtb antigen stimulated whole blood of LTBI-T2D compared to LTBI 
without T2D (Kumar et al. 2014). We however found higher IL-18 in the LTBI-pT2D compared 
to LTBI only. IL-18 plays a critical role in inducing Th1 responses during Mtb infection 
(Schneider et al. 2010; Ponnana et al. 2017), without IL-18, the Th1 responses are decreased 
and mycobacterial replication increases (Schneider et al. 2010). In our study, we expected 
lower IL-18 expression in LTBI-T2D compared to LTBI since T2D is associated with increased 
susceptibility to TB progression. However, due to chronic inflammation in T2D, increased IL-
18 may be due to dysregulated immune responses associated with T2D. In our mycobacterial 
infection assay, we found a negative correlation between IL-18 and Mtb uptake by MNs in 
LTBI-T2D and positively correlated to Mtb burden in MNs at D3. Our finding therefore show 
that IL-18 was associated with poor association of Mtb with MNs in T2D patients and with poor 
control of Mtb by MNs.  
IL-6 is a pro-inflammatory cytokine and its upregulation is associated with inflammatory 
diseases such as TB (Martinez et al. 2013) and T2D. IL-6 is required for the rapid expression 
of an initial IFN-ү response during Mtb infection (Saunders et al. 2000). This is because IL-6 
knock out mice showed increased bacterial growth in the lung within 14 days of Mtb infection 
compared to wild type mice (Saunders et al. 2000). In TB-T2D, IL-6 plasma concentrations 
are high compared to TB (Kumar et al. 2013). We measured IL-6 in LTBI-T2D, and we found 
high IL-6 compared to LTBI. IL-6 has the ability to impair insulin signalling in insulin-sensitive 




inflammation and could be associated with insulin resistance since it is one of the 
characteristics of T2D patients. Lower IL-6 production by macrophages from diabetic mice 
infected with Mycobacterium fortuitum contributed to increased bacterial growth in the infected 
macrophages which suggests that IL-6 is required for better control of bacteria (Abdul Alim et 
al. 2017). Despite the fact that IL-6 is a pro-inflammatory cytokine, its high expression in our 
study was associated with poor Mtb uptake by PBMCs from T2D patients. As previously 
mentioned in our findings, T2D patients had lower Mtb uptake by PBMCs compared to noT2D, 
with that in mind, we also think that IL-6 may promote immune suppression in T2D patients 
(Zhang et al. 2014).  
Vitamin D inhibits intracellular growth of Mtb by interfering with the accumulation of infection 
induced lipid droplets (Salamon et al. 2014). Contrarily, vitamin D can suppress pro-
inflammatory cytokines and induce anti-inflammatory cytokine responses (Penna and Adorini 
2000; Unger et al. 2009). Bhatt et al. investigated whether administration of vitamin D could 
affect immunity against Mtb in mice and found that vitamin D affected granuloma formation 
and failed to contain the bacteria (Bhatt et al. 2016). In our study, there was a trend that T2D 
patients had higher levels of vitamin D compared to noT2D. Banerjee et al. however found 
that vitamin D concentration were lower in the serum of T2D patients compared to noT2D 
(Banerjee et al. 2017). We further found that vitamin D was positively correlated to Mtb uptake 
in PBMCs. This is consistent with previous reports that vitamin D significantly enhances the 
phagocytic potential of macrophages isolated from healthy individuals (Chandra et al. 2004). 
In a study where TB patients were given vitamin D while on intensive phase of TB treatment, 
the bacterial load was reduced in vitro as measured by reduced time to sputum conversion 
(Martineau et al. 2014).  
T2D is characterized by hyperglycaemia due to insulin resistance and also associated with 
severe dyslipidaemia (Taskinen and Boren, 2015). Dyslipidaemia is characterized by high 
levels of triglycerides, and/or cholesterol as well as low HDL (Vrieling et al. 2018). In our study 
LTBI-pT2D patients had higher triglycerides and total CHL compared to noT2D, preT2D and 
T2D patients. LDL was also higher in LTBI-pT2D compared to LTBI-noT2D, followed by higher 
HDL in LTBI-noT2D compared to LTBI-T2D. Mtb has been shown to depend on host-derived 
lipids for replication and survival (Lee et al. 2013; Tsai et al. 2017; Walpole et al. 2018). Several 
studies have identified high cholesterol as a risk factor for TB disease (Martens et al. 2008; 
Soh et al. 2016) and reducing cholesterol levels using statins were beneficial in reducing the 
risk of TB disease (Lai et al. 2016; Su et al. 2017). In our study, total CHL in T2D patients was 
negatively correlated to association of Mtb with PBMCs, which shows the interplay between 
lipids and Mtb uptake. A potential therapy targeting cholesterol catabolism can effectively 




investigating the use of CHL lowering drugs in conjunction with TB treatment to prevent TB 
disease especially in LTBI-T2D. 
The leukocytes (white blood cells, neutrophils, lymphocytes, MNs and eosinophils) counts are 
elevated in patients with T2D (Shim et al. 2006; Nakhjavani et al. 2014). Higher white blood 
cell and lymphocyte counts are characteristics of T2D development in obese patients 
(Vatcheva et al. 2014). In support of that, we found higher white blood cell counts in 
uncontrolled T2D (pT2D) patients compared to noT2D. Our study found lymphocyte counts 
significantly higher in the pT2D patients compared to noT2D, preT2D and T2D. This was 
similar to other reports where pT2D patients had elevated lymphocyte counts (Ali et al. 2018). 
T2D exerts adverse effect on neutrophils and MNs functions (Geerlings and Hoepelman 1999; 
Raposo-Garcia et a. 2017). Although higher in T2D patients, no significant difference was 
observed in neutrophil counts in our study participants, however, Ali et al. found significantly 
elevated neutrophil counts in T2D compared to noT2D (Ali et al. 2018). The negative 
correlation observed in our study for neutrophils and MNs with Mtb uptake in T2D patients has 
been shown before (Lecube et al. 2011; Gomez et al. 2013; Raposo-Garcia et al. 2017). 
It is well established that T2D is associated with altered MN and neutrophil functions 
(Hatanaka et al. 2006; Alba-Loureiro et al. 2007; Restrepo et al 2014). Despite the evidence 
that MNs from TB naïve T2D patients are altered (reduced phagocytosis) (Restrepo et al. 
2014; Raposo-Garcia et al. 2017), we cannot say for sure that these alterations are the only 
factors contributing to the altered immune responses observed in T2D patients, because in 
our study, the MNs did not show any difference in H37Rv Mtb uptake between T2D and noT2D 
participants. Additionally, in a recent study, the lipid profile was shown to vary in T2D patients 
from different ethnic groups, and we believe that this variation could also affect the function of 
the phagocytic cells (Restrepo et al. 2018). The killing ability of MNs from both noT2D and 
T2D was not different, as shown by a significant increase in CFU at D3 in each group. Our 
results supported previous studies where no difference in Mtb killing by MNs derived 
macrophages, and blood were observed (Reyes-Ruvalcaba et al. 2008; Raposo-Garcia et al. 
2017).  
Our results adds to the small body of knowledge that is available on the immune profile, 
including cytokine production, hormone production and the ability to contain bacteria by 
immune cells from individuals with LTBI with and without T2D. We have shown that there is a 
need for more studies to define the immune profile of these individuals, to help us learn and 
understand the immune mechanisms during Mtb infection and influence of plasma soluble 






Investigation of MAIT cells in TB patients with and without T2D 
5.1 Introduction 
MAIT cells predominantly occur in the gut where their accumulation is dependent on MR1 
expressing B cells and commensal flora (Martin et al. 2009). They also occur in the blood 
where 1-10% of T cells are MAIT cells (Dusseaux et al. 2011). The frequency of MAIT cells in 
bacterial and viral infections, as well as in metabolic and autoimmune diseases vary 
(Billerbeck et al. 2010; Magalhaes et al. 2015; (Loh et al. 2016; Petersone and Walker, 2017), 
implying that they might play an important role in the regulation of immune responses in these 
diseases. It is said that low frequencies of MAIT cells in the blood during Mtb infection is due 
to their migration to the site of infection (Gold et al. 2010). Wong et al. also demonstrated this 
after measuring MAIT cell frequencies in the Broncho alveolar lavage fluid (BALF) and blood 
of TB patients and TB-HIV co-infected patients (Wong et al. 2012). Higher frequencies of MAIT 
cells were found in the BALF than in the periphery. The addition of MAIT cells to BCG-infected 
macrophages resulted the increased killing of the bacteria demonstrating the protective role 
MAIT cells play during Mtb infection (Chua et al. 2012). MAIT cells not only assist in the control 
of bacterial infection, but also in the detection of bacterially infected cells (Gold et al. 2010; Le 
Bourhis et al, 2010).  
In the context of T2D, it has been shown that patients with T2D have a reduced peripheral 
MAIT cell frequency when compared to HCs (Magalhaes et al. 2015). This is in part due to the 
alterations in the gut microbiota in T2D patients (Vaarala and Atkinson, 2008.), which affects 
the riboflavin pathway which is essential in MAIT cell activation (Treiner et al. 2003). The exact 
role of MAIT cells in metabolic diseases is, however, unclear. The aim of this study, therefore, 
was to determine the frequency of MAIT cells in the South African Coloured population 
residing in a high TB burden area in Cape Town, South Africa. The frequency of MAIT cells 
were determined in the following groups; HCs, T2D, TB, TB-THG and TB-T2D using flow 
cytometry. In addition, MAIT cell frequencies were monitored before, during and after TB 
treatment in TB subgroups. 
5.2 Study participants and methodology  
Cryopreserved PBMCs from 64 participants (TANDEM); were retrieved, thawed and stained 
with a MAIT cell flow cytometry antibody panel. The flow cytometry panel consisted of the 
following anti-human monoclonal antibodies; CD3, CD4, CD8, CD161, CD26 and TCR Vα-7.2 
as well as a live/dead (Zombie aqua) stain. PBMCs from HCs, T2D, TB, TB-THG, and TB-
T2D patients were stained and the frequency of MAIT cells compared at baseline (BL). In 
addition, PBMCs from TB, TB-THG and TB-T2D patients were stained at month 2 (M2) and 




PBMCs were stained for one hour at 4°C in 2% FACs buffer. Cells were acquired using a 4 
laser, 8 colour FACS Canto II flow cytometry instrument (Becton Dickson). The results were 
analysed using FlowJo v10.1 (TreeStar, Ashland, OR). At first, lymphocytes were selected 
using SSC-A and FSC-H, doublets were excluded using FSC-A and FSC-H and live cells 
selected using SSC-A and the live/dead stain (Figure 5.1). CD8+TCR Vα7.2+ T cells were 
selected and from this population CD26++ CD161++ cells were selected. Flow data was 
analysed using ANOVA and LSD Fishers post hoc test were used to determine differences 
between the groups. Differences between clinical information was determined in GraphPad 
prism version 6 using the Kruskal Wallis with Dunns post hoc to determine differences 
between the groups. A p-value < 0.05 was considered significantly different. Spearman 
correlation was performed to determine correlations between MAIT cells and blood glucose 
levels.  
5.3 Results 
5.3.1 Study participants and clinical parameters  
Among the 64 participants that were selected for this study, 17 were TB patients, 9 were TB-
THG, 13 were TB-T2D and 13 were T2D only patients. Twelve HCs were also included. 
Patients with T2D were using metformin or metformin in combination with insulin and other 
T2D medication (Table 5.1). There were no significant differences in the ages of the different 
patient groups (Table 5.1). The BMI at BL was significantly higher in T2D and TB-T2D patients 
compared to the HCs, TB and TB-THG patients (Table 5.1). Both at M2 and M6, there was 
significantly higher BMI in the TB-T2D group compared to TB and TB-THG. RPG was 
significantly higher in the TB-T2D patients compared to T2D and HCs. HbA1c was significantly 
higher in the TB-T2D and T2D patients compared to TB patients, whereas HbA1c in T2D was 
also significantly higher than the HCs. At M6 however, HbA1c in the TB-T2D patients was 




Table 5.1. Demographic and clinical information of all study participants. 
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Female 
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#- 2 participants in the TB-T2D group 
5.3.2 TB-T2D have significantly low CD3+CD8+TCR Vα7.2+ CD26++ CD161++ MAIT cells 
at baseline 
MAIT cells were defined as CD3+ CD8+TCR Vα7.2+ CD26++CD161++ and reported as a 
percentage of CD8+ T cells (Figure 5.1). HCs had significantly higher MAIT cell frequency than 
TB-T2D at baseline (p=0.02). TB-T2D patients also had significantly lower MAIT cell frequency 
compared to TB-THG at BL (p=0.02; Figure 5.2 A, B and C). TB-T2D had lower MAIT cell 
frequencies compared to TB-THG at M2 (p=0.01; Figure 5.2 A and B). There was no significant 
difference in MAIT cell frequency between TB-T2D and TB at M2 (p=0.64). There was a trend 
in MAIT cell frequency at M2 between TB-THG and TB (p=0.08; Figure 5.2 A and B). There 
was no observed significant difference in MAIT cell frequency at M6 in all groups, despite a 





5.3.3 CD3+CD8+TCR Vα7.2+ CD26++ CD161++ MAIT cell frequency increases at month 2 
of TB treatment 
We further investigated whether TB treatment will have an effect on the frequency of CD8+TCR 
Vα7.2+ CD26++ CD161++ MAIT cells in the three TB patient groups. The frequency of MAIT 
cells in TB patients did not change during TB treatment. There was a trend towards increase 
in MAIT cell frequency from BL to M2 (p=0.05) and a significant decrease from M2 to M6 
(p=0.01) in the TB-THG group (Figure 5.2A and B). In the TB-T2D group there was a 
significant increase in the frequency of MAIT cells from BL to M2 (p=0.003), however, MAIT 
cell frequency from M2 to M6, was not significantly different (p=0.15) (Figure 5.2A and B). 
MAIT cell frequencies in this group was significantly lower at BL when compared to the end of 
treatment (p<0.0001; Figure 5.2A and B).These results show that TB-THG patients have 
varying MAIT cell frequency compared to TB and TB-T2D. The different treatment responses 
observed in the frequency of CD8+TCR Vα7.2+ CD26++ CD161++ cells in these two group 
suggest that the TB-THG and TB-T2D are more different from one another than previously 
thought. 
5.3.4 The frequency of CD3+CD8+TCR Vα7.2+ CD26++ CD161++ MAIT cells of TB-T2D 
patients at month 6 is comparable to T2D  
We determined whether the frequency of MAIT cells in TB patients at M6, recovers to the 
levels seen in HCs. The frequency of CD3+CD8+TCR Vα7.2+ CD26++ CD161++ MAIT cells in 
the TB-T2D, which was lower at BL, recovered at M6 compared to frequencies similar to HCs 
(at BL) and all the other groups, Figure 5.2 A, C and D. 
 
Figure 5.1. Characterization of circulating peripheral MAIT cells (CD3+CD8+TCR Vα7.2+ CD26++ CD161++). 
PBMCs from HC, T2D, TB, TB-THG and TB-T2D were thawed and stained using anti-human antibodies for CD3, 




laser, 8 colour FACS Canto II flow cytometry and analysed on flowJo v10.1. We gated on lymphocytes using SSC-
A and FSC-H, doublets were excluded using FSC-A and FSC-H. Live cells were selected using SSC-A and the 




Figure 5.2: CD8+TCR Vα7.2+ CD26++ CD161++ MAIT cell frequencies. CD8+TCR Vα7.2+ CD26++ CD161++ MAIT 
cell frequencies from 64 participants (HCs n=13, TB n=17, T2D n=12, TB-THG n=9, TB-T2D n=13) were 
determined in PBMCs. Figure A and B illustrate the changes in MAIT cell population during TB treatment. Figure 
C and D show pie charts displaying the MAIT cell frequencies from T2D and HCs as well as TB, TB-THG and TB-
T2D at BL and M6, respectively, ANOVA with a LSD post hoc test was used to determine differences in the 
frequencies of MAIT cells between the groups, the pie chart was drawn in GraphPad prism version 6. And a p-
value <0.05 was considered significant. BL baseline, M2 month2, M6 month6. 
5.3.5 Association of T2D parameters with CD8+TCR Vα7.2+ CD26++ CD161++ MAIT cells 
HbA1c and RBG were measured in the study groups and was correlated with the MAIT cell 
frequencies. There was no correlation between MAIT cells and blood glucose levels (Figure 





Figure 5.3 Correlation plots of MAIT cells with glycaemic parameters. There was no significant correlation 
between (A) MAIT cell frequencies and HbA1c (r=-0.04; p=0.74) or (B) MAIT cell frequencies and RBG (r=-0.09; 
p=0.51) using the Spearman ranks correlation test in Graphpad Prism version 6. 
 
5.4 Discussion  
MAIT cell frequencies range from 1-10 % of T cells in peripheral blood of healthy people 
(Kurioka et al. 2016). In this study an average of 1.14 % of MAIT cells (CD8+TCR Vα7.2+ 
CD26++ CD161++) were found in cryopreserved PBMCs. Such low frequencies have previously 
been reported from PBMCs. Paquin-Proulx et al. reported 1.07% in thawed PBMCs of HCs 
(Paquin-proulx et al. 2018). Lee et al. reported different MAIT cell frequencies in blood of HCs; 
1.17%, 2.12% and 3.99 % according to the age of the study participants (Lee et al. 2014). The 
highest frequency was observed in the younger age group (21-40 years), followed by middle 
age (41-60 years) and elderly (61-92 years) (Lee et al. 2014). Since the depletion in MAIT cell 
frequencies is negatively associated with age (van der Geest et al. 2018), our study 
participants were matched by age. Therefore, in our study the association between MAIT cells 
and age was not observed.  
There were differences in MAIT cell frequencies in our study compared to other reports (Gold 
et al. 2010; Le Bourhis et al. 2011; Jiang et al. 2014; Sakala et al. 2015). The reason could be 
attributable to the various phenotypes used to define the MAIT cell population. In this study 
we used the following phenotype CD3+CD8+TCR Vα7.2+ CD26++ CD161++ (shared with us by 
David Lewinsohn). Many gating strategies have been used to describe circulating MAIT cell 
population. Eberhard et al. used CD3+CD4-CD161+TRC7.2+, Magalhaes et al. used CD3+CD4-
CD161++TCR Vα7.2+, and Wong et al. used CD3+CD8+CD161++CCR6 and 
CD3+CD8+CD161++CCR5 (Wong et al. 2013; Eberhard et al. 2014; Magalhaes et al. 2015). 
The use of the different markers in varying combinations to describe MAIT cells could be the 
reason for large variations in the findings from different reports.  
MAIT cells play a key role in protection against several pathogens, including Mtb (Gold et al. 
2010). Previous studies show that MAIT cell frequencies in the periphery decrease during TB 




et al. 2014; Sharma et al. 2015). Contrarily, people with LTBI were shown to have higher MAIT 
cell frequencies compared to TB patients or uninfected controls. In addition to that, the authors 
also found no difference in MAIT cells in TB patients compared to uninfected controls (Paquin-
Proulx et al. 2018). Our study supports the latter results since the reduction of MAIT cells in 
our TB patients were lower than the HCs who were all LTBI positive. In our data set, however, 
this difference did not reach statistical significance. 
In a study investigating MAIT cells in obese and T2D patients before and after bariatric 
surgery, the MAIT cell frequency increased in the blood of patients who did not initially show 
any MAIT cells before surgery (Magalhaes et al. 2015). However, when MAIT cells were not 
in the blood, they were detected in adipose tissue and it was hypothesized that MAIT cells 
migrate to the site of inflammation (Magalhaes et al. 2015). What we found was in agreement 
with this since in uninfected T2D patients, the MAIT cells were lower than that of HCs, however 
not significant. The difference became apparent when MAIT cells were lower in TB-T2D 
patients. This result may be explained by the migration of MAIT cells to the adipose tissue 
(Magalhaes et al. 2015) or to the lung (Gold et al. 2010) as previously showed. There are no 
other published results on MAIT cells in TB-T2D co-morbidity. 
TB is associated with increased insulin resistance and stress-induced hyperglycaemia or TB-
THG, which may lead to over diagnosis of T2D during the early stages of TB disease (Boillat-
Blanco et al. 2016). There was a trend towards higher frequency of MAIT cells in TB-THG 
compared to TB at M2. In addition, there was a significantly higher MAIT cell frequency in TB-
THG compared to TB-T2D at M2 confirming that this subgroup of TB patients is unique from 
TB and TB-T2D. It could be that the high MAIT cell frequency in TB-THG patients is associated 
with protection from acquiring T2D in these patients. This would however, require a 
longitudinal study to determine if TB-THG patients develop T2D and if MAIT cell frequency 
plays a role. 
TB patients, after TB treatment (M6), had a lower frequency of MAIT cells to that of the HCs 
(although not significant). It is possible that the residual infection, at M6, might still result in the 
recruitment of MAIT cells to the lung. In line with this finding, Paquin-proulx et al. reported that 
MAIT cells in individuals with LTBI was significantly higher compared to TB patients and 
speculated that high MAIT cells may be associated with Mtb control and protection from TB 
disease progression (Paquin-proulx et al. 2018). TB-T2D patients at M6 of TB treatment 
however had comparable frequency of MAIT cells to that in T2D patients. This is possible due 
to the clearance of Mtb and cause MAIT cells to redistribute to the periphery. 
We investigated whether TB treatment will have an impact on the frequency of MAIT cells in 




different from what was previously reported by Sharma et al. who showed that MAIT cells are 
restored in the blood of TB patients undergoing TB treatment (Sharma et al. 2015). It has been 
shown that the lack of MAIT cells in the blood during TB is due to redistribution to the lung 
(Gold et al. 2010; Wong et al. 2013). All the TB patients included in our study converted to 
sputum negative for Mtb at M2. We believe that due to the decrease in the bacterial load in 
the lung, some of the MAIT cells would be restored in the blood and some would be killed 
along with the bacteria at the lung. This could explain why there was no significant change in 
MAIT cells during the course of TB treatment. There are no other studies reporting MAIT cells 
treatment response during TB. 
During the course of TB treatment, TB-THG patients showed a trend towards increased MAIT 
cell frequency from BL to M2. This increase would also be explained by the lower bacteria at 
the site of disease during treatment (Sharma et al. 2015). Interestingly, in TB-THG, the MAIT 
cell frequency significantly decreased from M2 to M6. This is different from what has been 
reported in the context of TB (Sharma et al. 2015). The fact that the patients are TB-THG and 
not TB only could be reason for this unexpected result. Gérart et al. reported that over 
activation of MAIT cells may result in activation induced cell death (Gérart et al. 2013), 
therefore, MAIT cells in the lung die due to apoptosis before they are restored to the blood. 
The impact of TB treatment on MAIT cells was also investigated in TB-T2D patients. MAIT 
cells increased significantly from BL to M2 and are lower at BL compared to M6. Despite 
having T2D, the MAIT cell frequency in TB-T2D were restored in the periphery and this is in 
agreement with what was previously discussed by Sharma et al. in the context of TB patients 
(Sharma et al. 2015).  
Chua et al. co-cultured MAIT cells with BCG-infected macrophages from TB patients and 
found fewer mycobacteria compared to macrophages without MAIT cells (Chua et al. 2012; 
Lepore et al. 2014).  It is not known how T2D will affect the function of MAIT cells therefore 
more studies are required to understand their behaviour in different disease states, especially 
in a population where both TB and T2D poses a major problem. Moreover, MAIT cells play a 
role in setting a stage for establishing coordinated adaptive immune response to infection 
(Wong et al. 2016). Our patients with TB-T2D presented with reduced MAIT cells. Lower MAIT 
cell frequencies will most likely contribute to the dysregulated immune response against 
diseases (Kwon et al. 2015). MAIT cells play a protective role in TB, but their exact role in TB-
THG or TB-T2D co-morbidity has not been characterized and requires further investigation 
especially in the blood and in BALF, which is a representative sample of the site of TB disease. 
As expected we found higher MAIT cell frequencies in the HCs compared to TB-T2D patients 




groups (HC, TB and TB-T2D). Further characterisation of MAIT cells should be done in our 
patient group, looking at different phenotypes to fully understand their expression in different 
disease states. Seeing that there is limited information on MAIT cells in TB with and without 
T2D, we wanted to measure MAIT cell numbers in TB and TB-T2D patients and include LTBI-
T2D as a control, however, in the end the LTBI-T2D group, as we did not have enough PBMCs 







6.1 Discussion  
Hyperglycaemia during TB is associated with a high T2D risk and poor TB outcome (Moreira 
et al. 2018). Moreira et al. investigated the effect of hyperglycaemia in TB patients and found 
that a larger number of TB patients with hyperglycaemia exhibited adverse outcomes and a 
significantly higher mortality rate compared to euglycaemic patients (Moreira et al. 2018). T2D 
is a risk factor for TB and poor TB treatment outcome including treatment failure and relapse 
(Dooley et al. 2009) and for this reason the WHO, World Diabetes Foundation (WD) and the 
International Union Against TB and Lung Disease (IUATLD) recommend that all newly 
diagnosed TB patients are screened for T2D (Harries et al 2013). The TB-THG group is 
characterised by high HbA1c prior to TB treatment that decreases during the course of TB 
treatment (Tabarsi et al. 2014). It is therefore advised to monitor HbA1c of TB patients during 
TB treatment to confirm T2D status (WHO. 2018). Our study was able to identify a gene 
transcript signature that enables the differentiation between THG and T2D, which could be 
useful in preventing the unnecessary treatment of THG patients who were originally diagnosed 
as having T2D. Since HbA1c testing alone will not be able to distinguish patients with THG 
from T2D a gene signature could complement standard T2D screening of TB patients. 
6.1.1 Gene expression signatures in active TB patients with and without T2D 
Transcriptional analysis of whole blood and Mtb antigen stimulated whole blood has become 
an important tool to study the expression of immune system related genes and shows promise 
for identifying possible biomarkers for TB diagnosis, progression to active TB disease and TB 
treatment responses (Cliff et al. 2013; Zak et al. 2016; Thompson et al. 2017). Despite the 
usefulness of transcriptomic studies in addressing immune related responses, the exploration 
of transcriptional analyses in the context of TB-T2D co-morbidities is scarce (Prada-medina et 
al. 2017). Prada-Medina et al. showed that previously identified TB blood gene transcripts 
specific for diagnosing TB disease may not be affected by the presence of T2D (Prada-Medina 
et al. 2017). More studies in populations where TB-T2D co-morbidity is a burden would be of 
great significance for the identification of new molecular markers specific to T2D in TB patients 
to improve TB care in T2D patients (Donovan et al. 2017).  
Patients with TB-T2D comorbidity are more likely to fail TB treatment and present with more 
severe TB disease compared to TB patients without co-morbidities (Dooley et al. 2009), 
despite higher circulating levels of Th1 and Th17 cytokines in TB-T2D patients (Kumar et al. 
2013). IL-10 is also elevated in TB-T2D patients (Kumar et al. 2013), however stimulation of 
whole blood from TB-T2D patients with PPD, showed higher Th1 associated cytokine profile 
but not Th2 cytokines (Restrepo et al. 2008). The elevated Th1 associated cytokines produced 




Therefore we wanted to determine gene expression in the TB patients with and without T2D 
in South African Coloured population in an attempt to describe the immunological mechanisms 
associated with TB pathology and treatment outcomes. We identified gene transcripts 
including CCL2, CCL4, CCL3, IL-1A, CD163, CXCL2, PLAU, CXCL1, IL-1R1, TNFRSF8, 
CCRL2, NFKB1, PSMD7, PSMB5 and BAX, were downregulated in unstimulated whole blood 
of TB-T2D compared to both TB and TB-THG. MAPKAPK2 was upregulated in unstimulated 
whole blood of TB-T2D and TB-THG compared to TB. The downregulation of the following 
important chemokine gene transcripts; CCL2, CCL4, CCL3, CCRL2, CXCL1, CXCL2 may 
suggest alterations in leukocyte diapedesis and therefore alterations in the recruitment of 
immune cells to the site of inflammation. It has been shown that altered serum chemokine 
protein concentration can alter anti-TB immunity in T2D patients and can fuel TB-T2D 
(Aravindhan et al. 2018). The recruitment of phagocytic cells like neutrophils and 
macrophages are required to control Mtb growth and replication and initiate wound healing 
(Hong et al. 2004). Defects in trafficking of phagocytic cells to the site of inflammation will 
therefore delay innate and adaptive responses.  
CCL2 acts as chemo-attractant for monocytes, as well as some other immune cells such as 
memory T lymphocytes and NK cells (Lu et al. 1998; Deshmane et al. 2009). CCL2 treatment 
of diabetic mice has shown immune cell infiltration into wounds which favours the healing of 
the wounds (Wood et al. 2014). CCL2 mRNA expression was significantly higher in the lungs 
of HN878-infected mice and associated with increased macrophage localization within the 
granuloma, however, in CCR2 knock out mice there was inefficient migration of macrophages 
to the granuloma when less CCL2 mRNA was expressed (Algood et al. 2003; Dunlap et al. 
2018). We found that CCL2 was reduced in unstimulated whole blood of TB-T2D compared 
to TB and TB-THG. Infection of PBMCs with Mtb induced mRNA expression of CCL2 that was 
greater in pulmonary TB patients compared to localized extra pulmonary TB patients (Hasan 
et al. 2009).  
Chemokines such as CCL3 released by neutrophils recruit monocytes to the site of infection 
(Mayadas et al. 2014). CCL3 mRNA was reported to be downregulated in whole blood of TB 
patients when compared to individuals with LTBI (Mistry et al. 2007). In addition, after infecting 
PBMCs with Mtb, there was no observed differences in CCL3 mRNA transcript among 
pulmonary TB, localised extra pulmonary TB and disseminated extra pulmonary groups 
(Hasan et al. 2009). Mtb infected mice were also reported to have low CCL3 mRNA compared 
to normal mice (Schneider et al. 2010). In support of these finding, we showed downregulation 
of CCL3 mRNA in unstimulated whole blood from TB-T2D compared to TB patients. 
CCRL2 is a chemokine receptor also known as lipopolysaccharide (LPS) inducible C-C related 




Otero et al. 2010). CCRL2 binds chemerin which is a chemotactic protein (Zabel et al. 2008). 
A previous study reported an increase in the expression of CCRL2 in the RAW 264.7 
macrophage cell line and in murine macrophages after stimulation with LPS, this study was 
aimed at understanding the role of CCRL2 during microbial infection (Shimada et al. 1998). 
Stimulation of mouse neutrophils with LPS resulted in the increased expression of CCRL2, 
with most of the cells co-expressing CCRL2 and CXCR2 (Del Prete et al. 2017). To determine 
the role of CCRL2, mice deficient in CCRL2 were injected intraperitoneally with LPS and a 
reduction in neutrophil count was reported (Del Prete et al. 2017). In our study, we found 
CCRL2 mRNA to be downregulated in unstimulated whole blood of TB-T2D compared to TB. 
The difference in the study design, the use of cell lines and different antigen stimulants makes 
it difficult to speculate what effect the changes in CCRL2 mRNA will have in our study 
participants. There is however no information available on the expression of CCLR2 during 
TB-T2D. Since CCRL2 binds chemerin and presents it to the leukocytes expressing chemR23 
(Gonzalvo-feo et al. 2014), the reduction in CCRL2 may be associated with reduced migration 
of leukocytes to inflammatory sites.  
CXCL1 has been reported to be important for Th17 differentiation, neutrophil extracellular trap 
formation and reactive oxygen species production (Jin et al. 2014). Together, CXCL1 and 
CXCL2 have been identified as novel paracrine regulators for the production of anti-microbial 
molecules and inflammatory mediators during Mtb infection in humans (Boro et al. 2016). 
CXCL1 and CXCL2 are involved in the activation of inflammasomes and production of IL-1β 
in macrophages. When CXCL1 and CXCL2 were blocked using neutralizing antibodies, there 
was a reduction in IL-1β in supernatants after stimulation of macrophages with Mtb (Boro et 
al. 2017). In bone marrow derived (BMD) DCs from mice infected with BCG, large amounts of 
CXCL1 and CXCL2 were reported and resulted in an increased recruitment of neutrophils in 
the lungs of the mice (Doz et al. 2013). Neutrophils were subsequently responsible for the 
production of IL-10 and reduction in IL-17A production. Furthermore, depletion of the 
neutrophils resulted in a decrease in IL-10 and favoured IL-17A production (Doz et al. 2013).  
CXCL1 and CXCL2 are expressed at low concentrations in the sera and the lung tissue of 
mice infected with Mtb (Schneider et al. 2010). Stimulation of polymorphonuclear granulocytes 
with Mtb and LAM resulted in increased mRNA and protein of CXCL1 by human 
polymorphonuclear granulocytes (Riedel and Kaufmann, 1997). BMD macrophages from mice 
infected with the Erdman Mtb strain had gene expression of CXCL2 (Scott and  Flynn, 2002). 
In addition, infected BMD macrophages with the Erdman Mtb strain as well as the clinical 
isolates CSU22 and CSU46 also resulted in increased CXCL2 gene transcript expression 
(Rhoades et al. 1995). An increase in CXCL2 was also seen in a DM mice (db/db) compared 




found a downregulation of CXCL1 and CXCL2 gene transcript in unstimulated whole blood of 
TB patients. There is however no gene expression data available when comparing TB-T2D 
and TB patients.  
CD163 is a scavenger receptor expressed exclusively on monocytes and macrophages, and 
function as an innate immune sensor for bacteria and induces local inflammation (Kristiansen 
et al. 2001). Increased CD163 expression on the surface of monocyte is associated with 
insulin resistance in patients with T2D, suggesting a novel pathophysiological role for CD163 
(Kawarabayashi et al. 2017). CD163 mRNA was found to be higher in fat depots of obese 
patients compared to non-obese individuals (Kračmerová et al. 2014). Increased soluble 
CD163 was reported to be a strong predictor of risk for developing T2D in obese patients 
(Zanni et al. 2012). A positive correlation between plasma soluble CD163 and mRNA CD163 
was described in the adipose tissue of obese patients (Kračmerová et al. 2014), however, 
CD163 frequency on MNs from adipose tissue was significantly decreased and soluble CD163 
significantly increased in T2D patients with vascular complications compared to patients 
without vascular complications (Min et al. 2016). Suggesting that CD163 protects T2D patients 
from developing T2D associated complications (Min et al. 2016). CD163 protein therefore 
possibly plays a role in the pathophysiology of T2D.  
In this study, we found that CD163 mRNA in TB-T2D was downregulated in unstimulated 
whole blood compared to TB patients. The upregulation of CD163 is a marker of switching 
from pro-inflammatory towards anti-inflammatory profile (Weaver et al. 2013), therefore, the 
downregulation of CD163 mRNA in TB-T2D corresponds to the pro-inflammatory profile in 
these patients. CD163 was also found to be significantly reduced on the surface of MNs from 
T2D patients after stimulation with LPS compared to unstimulated MNs (Khondkaryan et al. 
2018), and was thought to be associated with persistent activation of MNs (Khondkaryan et 
al. 2018). In our study, we showed that stimulation of whole blood with Mtb-antigens, favours 
an Mtb specific upregulation of CD163 mRNA shifting responses to an anti-inflammatory 
profile in TB-T2D upon stimulation when compared to TB patients. The exact role of CD163 
in chronic inflammation remains poorly described (Kawarabayashi et al. 2017) and requires 
further investigation. In our study, the downregulation of CD163 mRNA may be associated 
with immunopathology in TB-T2D patients. 
Mtb promotes its replication by inhibiting apoptosis of infected macrophages (Blomgran et al. 
2012). In our study, gene transcripts from unstimulated blood that plays a role in apoptosis 
(IL-1A, IL-1R1, TNFRSF8, NF-KB, and BAX) were lower in TB-T2D compared to TB. NF-kB 
is the transcription factor in classical macrophages responsible for the development of the Th1 




control Mtb replication (Cooper and Khader, 2008; Liu et al. 2017), as well as IL-1β, TNF-α, 
and IL-6 (Wang et al. 2014).  
S100A8, TAP1, S100A9, GBP1, TLR2, PSMB8 and PSMB9 were reported to be upregulated 
in whole blood of active TB patients compared to individuals with LTBI (Mistry et al. 2007). We 
also found that TAP1, TLR2, S100A9 and S100A8 are upregulated in unstimulated whole 
blood of TB compared to TB-T2D patients. S100A8 and S100A9 are upregulated during 
infection, stress, and many other inflammatory conditions (Wang et al. 2018). The increased 
expression of TLR (a receptor for pathogen associated molecules), in TB patients, shows that 
there is an upregulation of antigen recognition related pathways. The upregulation of TAP1 
and protein subunits of proteasomes, all are related to antigen presentation signalling, which 
shows that during TB-T2D, these pathways may be less represented compared to TB.  
PSMB5 along with C1R and C1QBP form part of the complement cascade and were 
collectively part of a gene signature that could distinguish TB-THG from TB-T2D in 
unstimulated whole blood. The complete cascade, as seen by C1R and C1QBP, as well as 
the antigen presentation pathway are the key pathways that are different in TB-THG and TB-
T2D. The activation of C1R is associated with immune response pathways suggestive of any 
infectious disease (Wu et al. 2017). However, our study did not show differences in C1R 
mRNA between the patients. C1QBP was amongst the gene transcripts significantly 
downregulated in TB patients compared to LTBI in whole blood using microarrays  (Mistry et 
al. 2007). We found, C1QBP to be downregulated in unstimulated whole blood of TB 
compared to TB-THG. In breast cancer the expression of PSMB5 mRNA was observed in M2 
macrophages, and it was hypothesised to be involved in immunosuppressive responses 
(Wang et al. 2017). Knock down of PSMB5 allowed macrophages to differentiate into M1 
phenotype. In our study, both PSMB5 and CD163 were downregulated in unstimulated whole 
blood of TB-T2D compared to TB.  
6.1.2 Gene expression in LTBI with and without T2D 
Blood transcriptional assays that enable early accurate TB diagnosis could have an important 
impact on control of the global TB epidemic (Walter et al. 2016). The immunological factors 
involved in the host immune response network in Mtb infection and LTBI reactivation have not 
yet been clearly elucidated. Identifying the host genes responsible for TB susceptibility and 
resistance may be the key towards better understanding the mechanisms leading to the 
development of the disease and identifying pathways that could be used as potential targets 
for HDT. The immune profile in LTBI-T2D is characterized by diminished production of Th1 
cytokines. Diminished concentration of the Th1 cytokines allows for potential immunological 
mechanisms that could account for the increased risk for TB progression (Kumar and Babu. 




by low Th1 (IFN-y, IL-2 and TNF-α) and Th2 but not Th17 associated cytokines which was 
partially modulated by TGF-β, since blocking TGF-β resulted in increased Th1 and Th2 
cytokines (Kumar et al. 2016). There are however no gene expression data available from 
individuals with LTBI with T2D prior to developing active disease and TB-T2D. We therefore 
wanted to determine the differential gene expression in individuals with LTBI with and without 
T2D to identify host genes and pathways that could be associated with increased susceptibility 
to TB progression in LTBI-T2D. The genes that were differentially expressed in unstimulated 
whole blood of LTBI-T2D compared to LTBI were associated with the following functions or 
pathways: activation of necrosis and cell death of tumour cells, inhibition of immune response 
of leukocytes and maturation of blood cells of which some will impact immune response 
against Mtb. CCL2, CD163, TNFRSF8, CISH, GBP5, PML and TAP1 were differentially 
expressed in LTBI-T2D compared to LTBI and TB-T2D compared to TB patients and could 
potentially be involved in the underlying mechanisms responsible for the increased 
susceptibility to Mtb and the increased chance of developing active TB.  
A three gene signature unique to LTBI-T2D was identified which includes CD59, CD274 and 
TNFSF11. Upon univariate analysis, only CD59 was found to be significantly different between 
the two groups and was higher in LTBI-T2D compared LTBI. The role of CD59 has been 
shown to protect host cells from the membrane attach complex mediated lysis (Koski et al. 
1996). The membrane attack complex can result in tissue injury during dysregulated 
complement activation that occurs during chronic inflammatory conditions (Huang et al. 
2006). This can result in overexpression of CD59, however overexpression of CD59 in tumour 
cells has been associated with tumour development (Fishelson et al. 2003), protecting tumour 
cells from monoclonal antibody treatment (Fishelson et al. 2003). CD59 plays a role in 
promoting tumour cell growth (Fishelson et al. 2003). A study by Cliff et al. investigated 
changes in gene expression before and during TB treatment in whole blood (Cliff et al. 2013). 
Among other gene transcripts, CD59 was upregulated at diagnosis of TB (Cliff et al. 2013). 
There is no information on CD59 in LTBI and T2D. In our LTBI-T2D group, CD59 may help 
Mtb evade immune responses by protecting the Mtb infected cells from complement mediated 
lysis and promote Mtb replication. 
CD274, also referred to as programmed death 1 (PD-1), is a key immune checkpoint receptor 
expressed by activated T cells and mediates immune suppression (Yin et al. 2014). PD-1/PD-
L1 interaction is known to inhibit T cell effector function during TB disease (Shen et al. 2016). 
Wang et al. reported that when PD-L1 and PD-L2 were upregulated, T cell associated gene 
transcripts were down regulated, which indicates that PD-Ls mediated suppression may be 
initiated during TB disease (Wang et al. 2018). PD-1 was shown to induce apoptosis of IFN-γ 




function may impose a Th2 bias on the ensuing effector T cell response leading to inefficient 
clearance of Mtb. Inhibiting PD-1 may therefore affect the T cell response favouring the host 
by rescuing IFN-y producing NKT cells from apoptosis and enhancing Th1 effector T cell 
functions against Mtb (Singh et al. 2014). Phagocytosis and intracellular killing activity of 
macrophages were found to be increased significantly after blocking PD-1/PD-L pathway 
(Shen et al. 2016). Anti-PD-1/PD-L1 therapy holds promise as adjunctive therapy for chronic 
infectious diseases such as TB and should be tested in randomized clinical trials (Rao et al. 
2017). In our study, PD-L1 transcript was upregulated in the LTBI-T2D patients in the 
unstimulated samples compared to LTBI. PD-L1 was also identified as one of the transcripts 
in the signature that could be associated with susceptibility to TB progression in LTBI with T2D 
by suppressing T cell immunity.  
TNFSF11 encodes for receptor activator of the nuclear factor kappa B ligand (RANKL), which 
participates in physiological processes including organ development, bone remodelling and 
calcium homeostasis through osteoblast formation (Griffith et al.2012). There is no existing 
literature on the expression of TNFSF11 in individuals with LTBI. Our study did not show a 
significant difference in TNFSF11 expression between LTBI-T2D and LTBI, but in combination 
with other markers, can help us understand the mechanisms associated with TB susceptibility. 
RANKL has been reported to harbour immunosuppressive functions; blocking RANKL 
however, was not shown to affect immune responses in mice or humans (Guerrin et al. 2015; 
Conte et al. 2015). These findings suggest that RANKL plays a less prominent role in host 
defences against pathogens (Guerrini et al. 2015). In T2D, RANKL protein was upregulated 
compared to healthy patients (Conte et al. 2015). The role of RANKL has been studied in bone 
diseases and was found that a reduction in RANKL is associated with Mtb H37Ra induced 
bone loss. Whether this is enough to implicate TNFSF11 in the pathogenesis of T2D and 
susceptibility to TB progression is not clear. 
6.1.3 Immune and endocrine changes and association with Mtb uptake and killing 
Low-grade inflammation in T2D patients leads to the activation of the HPA-axis which 
subsequently results in increased cortisol secretion by the adrenals. Elevated levels of cortisol 
in serum result in immunosuppression leading to reduced Mtb containment (Pace et al. 2012). 
A few studies have focused on TB-T2D comorbidity (van Crevel and Dockrell, 2014; 
Fernandez et al. 2016). However, to date only a few studies in individuals with LTBI and T2D 
have been carried out (Kumar et al. 2013). We investigated the immune-endocrine profile to 
determine the effect of T2D on immune responses in recently Mtb exposed participants within 
the South African coloured population from the Western Cape. During an infection such as 
Mtb, the human host amounts an acute phase response (Gruys et al. 2005). These include 




glucocorticoid concentrations (Gruys et al. 2005). Comparison of acute phase protein 
responses and sympathetic as well as stress hormones such as catecholamines and cortisol 
in plasma of TB patients and controls was done (Opolot et al. 2015). It was reported that both 
cortisol and dopamine were higher in TB patients, although not significantly for cortisol (Opolot 
et al. 2015). Higher dopamine and lower adrenaline concentration in the TB group was 
reported compared to HCs. Previously, elevated concentrations of adrenaline, noradrenaline, 
dopamine and cortisol were associated with severity of TB disease (Hafeiz et al. 1992). 
Noradrenaline was reported to be higher in TB patients compared to controls (Opolot et al. 
2015). We were unable to analyse the noradrenaline results due to technical errors. Mtb-
induced responses feedback to the brain to orchestrate sympathetic nervous system 
responses which in turn mediate immune responses in the periphery. The same immune cells 
are then also a source of noradrenaline that induces early differentiation of Th1 cells essential 
for protection against mycobacterial infection (Alaniz et al. 1999). Mice genetically deficient of 
the enzyme dopamine-hydroxylase which is required for the synthesis of noradrenaline were 
found to be more susceptible to Mtb (Alaniz et al. 1999), suggesting that it participates in the 
generation of an optimal, protective cell-mediated immune response in vivo.  
Noradrenaline was reported to be produced during early infection with Mtb by adrenergic nerve 
terminals and lymphocytes located in pulmonary inflammatory infiltrates and mediastinal 
lymph nodes, while during late infection noradrenaline production sharply decreases (Barrios-
payán et al. 2016). This suggests that during advanced disease, the sympathetic nervous 
system activity is less important, or perhaps contributes to establishing local pro-inflammatory 
activity due to the absence of the anti-inflammatory effect of noradrenaline on differentiated 
immune cells (Pongratz and Straub, 2014). There was no differences in the catecholamines 
reported between our study groups. No other studies have reported on catecholamines in the 
context of T2D, and makes our study the first to report this. 
Cytokines and hormones influence the cellular immune response, therefore the relationship 
and profile of plasma hormones such as cortisol needs to be investigated to understand how 
they affect immune response. In the plasma of TB patients compared to LTBI and HCs, 
concentration of cortisol was reported to be elevated (Santucci et al. 2011). In addition, cortisol 
levels were reported to be high in plasma of TB and TB-T2D patients compared to HCs 
(Fernandez et al. 2016). No difference have been reported between cortisol levels in TB and 
TB-T2D patients. The concentration of cortisol has also never been investigated in individuals 
with LTBI with and without T2D. We found no difference in cortisol in our study participants. 
Cortisol can inhibit Th1 responses, whereas DHEA induces them (Besedevoski et al. 1998; 
Turnbull et al. 1999). The HPA axis, represent a well-conserved mechanism to control an 




and their redistribution to mount an adequate defensive response (Attilio et al. 2018). During 
an immune response, cortisol can inhibit the proliferation of the effector and differential 
apoptosis of regulatory T cells (Pandolfi et al. 2013). 
The upregulation of IL-6 is associated with inflammatory diseases such as TB (Martinez et al. 
2013) and involved in metabolic disorders such as T2D (Liu et al. 2016). In TB-T2D, IL-6 
plasma levels are high compared to TB (Kumar et al. 2013). In LTBI-T2D we also found IL-6 
serum concentrations to be higher compared to LTBI. High IL-6 concentrations in culture 
supernatants of monocyte-derived macrophages (MDMs) of TB-T2D patients compared to TB 
patients (Lope-Lopez et al. 2018). IL-6 has the ability to impair insulin signalling in insulin-
sensitive tissues (Nikolajczyk et al. 2012). High IL-6 concentrations has been shown to cause 
insulin resistance and T2D (Kumar et al. 2014). In our study, however, we did not calculate 
insulin resistance. Lower IL-6 production by macrophages from DM mice infected with 
Mycobacterial fortuitum was reported to contribute to increased bacterial growth in the infected 
macrophages, which suggest that IL-6 is required for better control of bacteria by 
macrophages (Abdul Alim et al. 2017). Plasma IL-6 concentrations were reported to be 
significantly higher in TB patients and TB-T2D patients compared to HCs (Fernandez et al. 
2016). Despite the fact that IL-6 is pro-inflammatory and plays an important role in bacterial 
control, high expression in the serum from our LTBI-T2D study participants was associated 
with poor Mtb uptake by PBMCs. Contrary to these findings, Zheng et al. found no difference 
in IL-6 concentrations in TB patients with and without T2D and HCs, (Zheng et al. 2013). In 
plasma of individuals with LTBI compared to HCs, IL-6 was elevated (Santucci et al. 2011). 
Our data and data from other human studies, suggest that during T2D, IL-6 is elevated and 
that TB augments the levels of this cytokine. In humans, IL-6 is associated with pathogenesis, 
and reducing IL-6 production may restore insulin resistance and the function of beta-cells, 
reducing heart failure and fatigue in patients with T2D (Conti et al. 2018). 
IL-18 plays a critical role by inducing Th1 responses during Mtb infection (Schneider et al. 
2010; Ponnana et al. 2017). Without IL-18, Th1 responses are decreased and mycobacterial 
replication increases (Schneider et al. 2010). Mice deficient in IL-18 will succumb to Mtb 
infection (Sugawara et al. 1999; Schneider et al. 2010), and have suppressed IFN-ү production 
(Dinarello, 1999). IL-18 was low in TB-T2D patients compared to TB (Restrepo et al. 2008; 
Kumar et al. 2013). IL-18 induces the release of IL-8 from mononuclear cells (Puren et al. 
1998), which is an attractant for neutrophils and also T cells (Puren et al. 1998). Neutrophilic 
inflammation is associated to TB pathogenesis (Berry et al. 2010) and, for this reason, we 
believe that IL-18 is involved in both protective and pathological responses. Liu et al. has 
shown that along with IL-1β and IL-6 elevated levels of IL-18 is associated with T2D (Liu et al. 




to what we found, Kumar et al. found serum IL-18 concentrations to be lower in LTBI-T2D 
(Kumar et al. 2014).This contradicting data suggests that more studies are required to 
evaluate the role of IL-18 in LTBI during T2D in different population groups. 
IL-22 cytokine is produced by cells of the innate and adaptive immune system (Wolk et al. 
2006), its role during host defence against Mtb infection still needs further investigation 
(Ronacher et al. 2018). Decreased plasma concentration of IL-22 was profoundly associated 
with susceptibility to impaired fasting glucose and T2D in Chinese subjects (Shen et al. 2018). 
In T2D foot ulcers, IL-20 subfamily including IL-22 are upregulated during normal wound 
healing (Kolumam et al. 2017). In addition, mice deficient in the receptor for IL-22 was 
associated with delay in the healing of the wounds. IL-22 was also associated with increased 
innate host immune defences and tissue remodelling in the skin (Kolumam et al. 2017). We 
did not find any significant differences in IL-22 serum concentrations between LTBI and LTBI-
T2D, but we found differences between LTBI-T2D and LTB-pT2D, where IL-22 was 
significantly higher in LTBI-pT2D patients. Although the role of IL-22 has been associated with 
protection, excessive IL-22 responses may be detrimental. In fact, Ronacher et al. indicated 
that it is not clear whether IL-22 is increased to counteract immunopathology or if it contributes 
to pathology (Ronacher et al. 2018). Kumar et al. has reported higher IL-22 concentrations in 
LTBI-T2D compared to LTBI (Kumar et al. 2015), whereas we did not observe any significant 
differences between the two groups. The difference between the two studies being that Kumar 
et al. did not categorize the T2D patients into the different subgroups e.g. pre-T2D, T2D and 
pT2D. Comparison of circulating cytokines between individuals with LTBI with high BMI and 
low BMI was done and found higher IL-22 concentrations in high BMI individuals with LTBI 
(Anuradha et al. 2016), suggesting a link between BMI and IL-22 production. In our study, the 
individuals with LTBI with and without T2D did not show any significance difference in BMI, 
and perhaps could be why we did not see any difference in IL-22 concentrations. 
We observed significantly higher IL-22 concentrations in TB-T2D patients compared to TB-
THG at BL and no difference was observed between TB-T2D and TB patients. This is different 
to what Kumar et al. found, where IL-22 was lower in plasma samples of TB-T2D compared 
to TB (Kumar et al. 2013; Kumar et al. 2015). A negative correlation has been observed 
between IL-22 expression in the periphery and the lung, with higher IL-22 measured in BALF 
(Singh et al. 2018). Since serum IL-22 was higher in our TB-T2D patients, it is possible that 
these patients have low IL-22 in the lung where it is needed.  
Vitamin D deficiency is associated with an increased risk of TB disease and poor treatment 
outcome (Kim et al. 2017). When MDMs from T2D patients with low vitamin D receptor 
expression were supplemented with vitamin D, they were able to eliminate Mtb efficiently 




high T2D endemic countries (Lopez-lopez et al. 2014). vitamin D in serum of patients with 
history of TB disease compared to uninfected controls was significantly lower vitamin D 
concentration in individuals with a history of TB compared to uninfected individuals (Kim et al. 
2018). In T2D patients, the same has also been reported where vitamin D is significantly 
reduced in their serum compared to HCs (Chandra et al. 2004). The high vitamin D in HCs, 
may partly be involved in the significantly enhanced phagocytic potential of macrophages 
isolated from these individuals (Chandra et al. 2004).  
Dyslipidaemia in T2D is characterized by high levels of triglycerides, and/or cholesterol as well 
as low HDL (Vrieling et al. 2018). In addition, dyslipidaemia is associated with necrotic 
granulomas and fibroplasia leading to exacerbated lung damage in TB patients and especially 
in TB-T2D patients (Dong et al. 2018). Dong et al. reported low HDL in smear negative patients 
with TB-T2D, which was associated with severe lung lesions in these patients (Dong et al. 
2018). HDL serum levels are reduced during infections and inflammation (Deniz et al. 2006; 
Dong et al .2018). This agrees with what we found where HDL concentrations were lower in 
LTBI-T2D compared to individuals with LTBI. Since low HDL is associated with severe lung 
lesions in TB-T2D patients as reported by Dong et al. and hyperinflammatory response of TB-
T2D (Prada-medina et al. 2017), one can assume that low concentrations in individuals with 
LTBI and T2D may play a role in susceptibility to TB disease. Cholesterol serves as an 
important carbon source utilized by Mtb to growth and persistence in mice (Pandey and 
Sassetti, 2008). High CHL has been identified as a risk factor for TB disease (Martens et al. 
2008; Soh et al. 2016) and statins use, which lowers CHL concentrations, reduces the risk of 
developing TB disease (Lai et al. 2016; Su et al. 2017). A potential therapy targeting CHL 
catabolism can effectively lower intracellular growth of Mtb (Tsai et al. 2017) and more studies 
should focus on investigating the use of cholesterol lowering drugs in conjunction with TB 
treatment to prevent TB disease in groups that are at increased risk such as LTBI-T2D. Lipids, 
such as LDL, may stimulate macrophage phagocytosis and subsequent release of 
inflammatory markers, induce mast cell degranulation and leukocyte recruitment (Medina et 
al. 2015). Our study did not show any relationship between LDL and Mtb killing, but in the 
larger parent study, the ALERT study, we found that LDL was associated with reduced Mtb 
growth in MNs (Manuscript in preparation). This shows that LDL can induce response against 
Mtb possible by facilitating the killing of Mtb in immune cells. 
Macrophages play a central role in the initiation and resolution of inflammatory responses to 
infectious pathogens (Auffray et al. 2009) and are frequently activated in T2D patients 
(Bianciardi, 2015), which means that they could play an important role in T2D development. 
Macrophages are equipped with scavenger receptors that recognize lipids and various 




with T2D (Peleg et al. 2007; Weintrob et al.2009) indicates a dysfunctional innate immune 
response in these patients. In fact, reduced phagocytic and chemotactic activity of MNs and 
neutrophils have been shown (Delamaire et al. 1997; Llorente et al. 2000; Restrepo et al. 
2014). Our results supported previous studies where no difference in Mtb killing by MDMs, 
and PBMCs were observed (Reyes-ruvalcaba et al. 2008; Raposo-Garcia et al. 2017). 
However, it is possible that we do not see differences in the phagocytosis of MNs from T2D 
patients compared to noT2D because of small sample size, as data from the larger ALERT 
study, show differences in Mtb uptake by MNs from T2D compared to noT2D (Manuscript in 
preparation). 
6.1.4 MAIT cells in TB patients with and without T2D  
MAIT cells have innate like functions and have gained much attention as important role players 
in immunity to infectious diseases, such as Mtb, as well as in the pathogenesis of non-
communicable diseases, such as T2D (Shey et al. 2018). Most MAIT cells are identified as 
CD8+ and CD4-, but a small subset of MAIT cells do express CD4 (Kurioka et al. 2015). The 
different MAIT cell subsets suggests that they may also have unique functions. Recently, it 
has been shown that riboflavin tetramers can be used  to identify all MAIT cells (Reantragoon 
et al. 2013). MAIT cells can be activated through TCR dependent and independent pathway 
(Gold et al. 2010; Kurioka et al. 2015), regardless of the disease state. MAIT cells have site 
specific functions. The frequency of IL-17 producing MAIT cells were higher in the adipose 
tissue of T2D patients compared to the periphery (Magalhaes et al. 2015). Higher frequencies 
of MAIT cells producing IL-17 and IL-22 were found in the vaginal tract compared to higher 
frequencies of MAIT cells producing IFN-ү and TNF-α in the periphery (Gibbs et al. 2017).  
At baseline, MAIT cells are significantly reduced in the periphery of TB patients compared to 
uninfected HCs (Gold et al. 2010; Wong et al. 2013) which recover during the course of TB 
treatment (Sharma et al. 2015; Wong et al. 2013). When MAIT cells are reduced in the 
periphery during TB disease they migrate to the lung, as shown by measuring MAIT cell 
frequency in the BALF of TB patients with and without HIV co-infection (Wong et al. 2015). In 
TB-HIV co-infected patients, treatment did not restore MAIT cell frequencies in the periphery 
compared to TB patients (Wong et al. 2013). It has been shown that TB-HIV patients have 
high viral load in the lung (Shankar et al. 2014), because of the presence of the virus the MAIT 
cells remain in the lung. Similarly, in our TB-T2D patients, failure of MAIT cells to increase at 
M6 of TB treatment could mean that MAIT cells are still present in the adipose tissue or the 
lung. Malherbe et al. showed that even at M6 of TB treatment, after TB patients are cured 
based on negative MGIT culture results, there is still lesions in the lung consistent with TB 
disease and Mtb specific mRNA (Malherbe et al. 2016), which means that MAIT cells could 




on MAIT cell frequency in TB-T2D. Our study is the first to and provide information on the 
frequency of CD8+TCR 7.2++CD161++CD26++ MAIT cells and the influence of TB treatment on 
the frequency of these cells in TB and T2D patients. 
6.2 Conclusion 
Our first aim was to identify differentially expressed immune genes in unstimulated and Mtb-
antigen stimulated whole blood of newly exposed LTBI positive participants as well as TB 
patients with and without T2D. To achieve this RNA was isolated from QFT stimulated blood 
and differential expression of 594 genes involved in immune regulation was determined with 
the NanoString technology. 
Our study found fifteen important gene transcripts that need to be further investigated in the 
TB-T2D comorbidity to understand the immunological mechanisms involved in the pathology 
of T2D in TB patients. Proteins associated with these genes have been described, however, 
the true relationship between the protein and their gene transcripts have not been shown and 
this could give us a better understanding of what is happening during Mtb infection. We found 
genes associated with phagocytes trafficking to the site of infection, and those associated with 
apoptosis to be downregulated in the TB-T2D compared to TB and TB-THG. Furthermore, we 
were able to identify a gene signature that differentiates between THG and T2D in TB patients. 
This signature could be useful to identify THG and prevent the unnecessary treatment of these 
patients who would have been diagnosed with T2D. Most importantly, T2D screening of TB 
patients is recommended by the WHO, however HbA1c testing will not be able to distinguish 
patients with THG from T2D. Therefore, our gene signature could complement standard T2D 
screening of TB patients. We also identified a gene signature unique to individuals with LTBI 
with T2D. We show that these gene signatures are associated with complement pathways 
which may be involved in TB progression of individuals with LTBI-T2D.  
Secondly, we aimed to investigate immune and endocrine changes in the serum and plasma 
of individuals with LTBI with and without T2D and determine their association with Mtb uptake 
and killing. Chronic activation of the innate system is associated with T2D, and abnormal 
production of cytokines and chemokines. In our study, Th1 cytokines and IL-22 which is 
produced by Th17 and/ Th22 are more pronounced in LTBI-pT2D, which showed a heighted 
pro-inflammatory cytokine profiles including IL-6, IL-18 and IL-22 compared to individuals with 
LTBI. Lipid production in the plasma was also increased. Our results adds to the small body 
of knowledge that is available on the production of immune products by cells of individuals 
with LTBI with and without T2D. We have shown that there is a need for more studies to define 
the immune profile of these individuals, to help us learn and understand the immune 
mechanisms during Mtb infection and influence of plasma soluble proteins and lipids in Mtb 




Lastly, we wanted to determine the frequency of MAIT cells in TB, TB-THG and TB-T2D at 
BL, M2 and M6 of TB treatment, since the reduction of MAIT cells in metabolic and infectious 
diseases have been widely shown. Despite their frequencies, the functions of MAIT cells in 
human TB-T2D have not be demonstrated. The varying frequencies of MAIT cells both during 
diseases and change during treatment, shows that they have an essential role during TB 
diseases and their roles needs to be delineated especially in patient with TB and T2D. Our 
results showed that the frequency of MAIT cells in TB-T2D was significantly lower compared 
to TB-THG at BL. This could mean that the MAIT cells in TB-T2D have redistributed to the 
tissue, either to the lung or the adipose tissue. The increase in the periphery at M2 and M6 
compared to BL could mean that the number of MAIT cells were restored to the blood due to 
good treatment outcome and reduced Mtb in the lung. MAIT cells could be used as a potential 
subtype for monitoring treatment responses in TB-T2D patients. 
 
Overall, with ALERT data we were able to show the link between the endocrine and the 
immune response. Although we could not show differences in cortisol levels as previously 
thought, the higher insulin production in plasma of LTBI-T2D as well as other cytokines such 
as IL-6, IL-18 and IL-22 from our study may reflect an association and connection between 
the immune and the neuroendocrine system. The reduced association of Mtb with PBMCs 
from individuals with LTBI-T2D as well as reduced Mtb control by MNs from LTBI-T2D may 
be linked to the insulin and cytokine levels in these individuals with LTBI-T2D and may in part 
play a role in the functioning of these immune cells. Insulin resistance has also been 
associated with increased Th1 and Th17 cytokine production. Even though Insulin has been 
shown to drive T cell differentiation towards an anti-inflammatory phenotype, we saw an 
increased insulin along with increased IL-6, IL-18 and IL-22 in our participants. These 
cytokines may also contribute to poor glycemic control and hyperlipidaemia as shown in our 
results where their increase was also accompanied by increased triglycerides in individuals 
with LTBI-T2D. Following this we will be measuring a range of hormones and cytokines directly 
from culture supernatants of the PBMCs and MNs infected with Mtb H37Rv to fully describe 
the interplay between mononuclear cells and hormones during T2D. 
6.3 Strengths and limitations of the study 
The number of study participants with LTBI with and without T2D was small. Recruitment of 
study participants continued beyond the time frame of my PhD, samples that were available 
at the time were used. This work continued to include all the participants enrolled in the study 
to increase the sample size and has now reached the recruitment target and analysis of data 
is ongoing. Serum cytokines and plasma hormone concentrations were correlated to the Mtb 




will continue to measure the cytokine concentrations in the culture supernatants which will 
also be correlated to Mtb killing assays. For the TANDEM study, only a small number of TB-
T2D were recruited, and matching the participants also resulted in even smaller numbers.  We 
were not able to do Mtb killing assays using the PBMCs of TB-T2D patients since the stored 
cells were not enough to do the killing assays. There were a limited number of samples 
available for the TANDEM study which prevented us from running all the ELISA and luminex 
assays on these participants. We were able to perform gene expression assay on both 
TANDEM and ALERT samples. We were not able to perform a direct comparison for our 594 
gene expression between the participant groups of the two different studies as the gene 
expression analysis was batched and run at different times. The first gene expression analysis 
was performed on the TANDEM patients, and a year later we ran the same gene expression 
panel on ALERT patients. Seeing that there is limited information on MAIT cells in TB with and 
without T2D, therefore we wanted to measure MAIT cell frequency in TB and TB-T2D patients 
and include LTBI-T2D as a control, however, we ended up doing this without a LTBI-T2D 
control, since we did not have enough PBMCs for the larger part of these individuals. Another 
limitation to our study for both ALERT and TANDEM populations was the exclusion of HIV 
positive individuals seeing that TB-HIV is quite a concern in South Africa. In general, the use 
of HbA1c and FBG as a diagnostic for T2D without the support of OGTT was another limitation 
since the OGTT is considered the gold standand and has been shown to perform as best 
diagnostic for T2D in our study population (Zemlin et al. 2011).  
6.4 Future work 
The identified genes signature that distinguish between TB-THG and TB-T2D need to be 
validated by screening for these signature in a different cohort so that it can be incorporated 
in a simple test to be used together with HbA1c to describe true T2D patients. The identified 
gene signature in latent TB with T2D will be followed up and further explored using functional 
assays, to understand the role of the transcripts and resulting proteins during Mtb infection. 
Cytokines and hormones are going to be measured from monocytes and PBMC culture 
supernatants and to identify associations between Mtb uptake and killing. This will give us a 
better understanding of what the immune and endocrine profile is during Mtb infection in 
individuals with LTBI with and without T2D and how that influence phagocytosis and Mtb 
killing. We collected and stored whole blood and broncho alveolar lavage from participants 
with LTBI with and without T2D, this will be used to determining the frequency of MAIT cells 
in the periphery and also at the site of TB disease, we would like to do this for TB with and 








Supplementary Figure 1: Differentially expressed gene transcripts between TB, TB-THG and TB-T2D. RNA 
was isolated from whole blood of TB-T2D, TB-THG and TB stimulated with Mtb specific antigen using QFT assay 
(Ag/nil, stimulated only represented in the figure). Gene expression of 594 genes as part of the nCounter GX 
Human Immunology kit V2 was done on the extracted RNA. Down and upregulated transcripts from unstimulated 
blood of TB compared to TB-THG (A), TB vs. TB-T2D (B) and TB-THG vs TB-T2D. JMP SAS was used to generate 
heatmaps and used Student T test to determine statistical difference between the groups. Genes with a p value 
was < 0.01 and FDR < 0.05 was statistically significant. Figure A Red TB, Blue TB-THG, Figure B red TB, blue TB-
T2D and Figure C red TB-THG and blue TB-T2D.  
 
Supplementary Figure 2: Differentially expressed gene transcripts between TB, TB-THG and TB-T2D at 
month 6. RNA was isolated from whole blood of TB-T2D, TB-THG and TB stimulated with Mtb specific antigen 
using QFT assay (Ag/nil, stimulated only represented in the figure). Gene expression of 594 genes as part of the 
nCounter GX Human Immunology kit V2 was done on the extracted RNA. Down and upregulated transcripts from 
unstimulated blood of TB compared to TB-THG (A), TB vs. TB-T2D (B) and TB-THG vs TB-T2D. JMP SAS was 
used to generate heatmaps and used Student T test to determine statistical difference between the groups. Genes 
with a p value was < 0.01 and FDR < 0.05 was statistically significant. Figure A Red TB, Blue TB-THG, Figure B 
















ABCB1 NM_000927.3 BST1 NM_004334.2 CCL11 NM_002986.2 CD163 NM_004244.4 CD58 NM_001779.2 
ABL1 NM_005157.3 BST2 NM_004335.2 CCL13 NM_005408.2 CD164 NM_006016.4 CD59 NM_000611.4 
ADA NM_000022.2 BTK NM_000061.1 CCL15 NM_032965.3 CD19 NM_001770.4 CD6 NM_006725.3 
AHR NM_001621.3 BTLA NM_181780.2 CCL16 NM_004590.2 CD1A NM_001763.2 CD7 NM_006137.6 
AICDA NM_020661.1 C14orf166 NM_016039.2 CCL18 NM_002988.2 CD1D NM_001766.3 CD70 NM_001252.2 
AIRE NM_000383.2 C1QA NM_015991.2 CCL19 NM_006274.2 CD2 NM_001767.3 CD74 NM_001025159.1 
APP NM_000484.3 C1QB NM_000491.3 CCL2 NM_002982.3 CD209 NM_021155.2 CD79A NM_001783.3 
ARG1 NM_000045.2 C1QBP NM_001212.3 CCL20 NM_004591.1 CD22 NM_001771.2 CD79B NM_021602.2 
ARG2 NM_001172.3 C1R NM_001733.4 CCL22 NM_002990.3 CD24 NM_013230.2 CD80 NM_005191.3 
ARHGDIB NM_001175.4 C1S NM_001734.2 CCL23 NM_145898.1 CD244 NM_016382.2 CD81 NM_004356.3 
ATG10 NM_001131028.1 C2 NM_000063.3 CCL24 NM_002991.2 CD247 NM_198053.1 CD82 NM_002231.3 
ATG12 NM_004707.2 C3 NM_000064.2 CCL26 NM_006072.4 CD27 NM_001242.4 CD83 NM_004233.3 
ATG16L1 NM_198890.2 C4A/B NM_007293.2 CCL3 NM_002983.2 CD274 NM_014143.3 CD86 NM_175862.3 
ATG5 NM_004849.2 C4BPA NM_000715.3 CCL4 NM_002984.2 CD276 NM_001024736.1 CD8A NM_001768.5 
ATG7 NM_001136031.2 C5 NM_001735.2 CCL5 NM_002985.2 CD28 NM_001243078.1 CD8B NM_004931.3 
ATM NM_000051.3 C6 NM_000065.2 CCL7 NM_006273.2 CD34 NM_001025109.1 CD9 NM_001769.2 
B2M NM_004048.2 C7 NM_000587.2 CCL8 NM_005623.2 CD36 NM_001001548.2 CD96 NM_005816.4 
B3GAT1 NM_018644.3 C8A NM_000562.2 CCND3 NM_001760.2 CD3D NM_000732.4 CD97 NM_078481.2 
BATF NM_006399.3 C8B NM_000066.2 CCR1 NM_001295.2 CD3E NM_000733.2 CD99 NM_002414.3 
BATF3 NM_018664.2 C8G NM_000606.2 CCR10 NM_016602.2 CD3EAP NM_012099.1 CDH5 NM_001795.3 
BAX NM_138761.3 C9 NM_001737.3 CCR2 NM_001123041.2 CD4 NM_000616.4 CDKN1A NM_000389.2 
BCAP31 NM_005745.7 CAMP NM_004345.3 CCR5 NM_000579.1 CD40 NM_001250.4 CEACAM1 NM_001712.3 
BCL10 NM_003921.2 CARD9 NM_052813.4 CCR6 NM_031409.2 CD40LG NM_000074.2 CEACAM6 NM_002483.4 
BCL2 NM_000657.2 CASP1 NM_001223.3 CCR7 NM_001838.2 CD44 NM_001001392.1 CEACAM8 NM_001816.3 
BCL2L11 NM_138621.4 CASP10 NM_032977.3 CCR8 NM_005201.2 CD46 NM_172350.1 CEBPB NM_005194.2 
BCL3 NM_005178.2 CASP2 NM_032982.2 CCRL1 NM_016557.2 CD48 NM_001778.2 CFB NM_001710.5 
BCL6 NM_001706.2 CASP3 NM_032991.2 CCRL2 NM_003965.4 CD5 NM_014207.2 CFD NM_001928.2 
BID NM_001196.2 CASP8 NM_001228.4 CD14 NM_000591.2 CD53 NM_001040033.1 CFH NM_001014975.2 
BLNK NM_013314.2 CCBP2 NM_001296.3 CD160 NM_007053.2 CD55 NM_000574.3 CFI NM_000204.3 
CFP NM_002621.2 CXCL1 NM_001511.1 FCER1A NM_002001.2 HLA-DMA NM_006120.3 IFNG NM_000619.2 





CIITA NM_000246.3 CXCL11 NM_005409.4 FCGR1A/B NM_000566.3 HLA-DOB NM_002120.3 IGF2R NM_000876.1 
CISH NM_145071.2 CXCL12 NM_000609.5 FCGR2A NM_021642.3 HLA-DPA1 NM_033554.2 IKBKAP NM_003640.3 
CLEC4A NM_194448.2 CXCL13 NM_006419.2 FCGR2A/C NM_201563.4 HLA-DPB1 NM_002121.4 IKBKB NM_001556.1 
CLEC4E NM_014358.2 CXCL2 NM_002089.3 FCGR2B NM_001002273.1 HLA-DQA1 NM_002122.3 IKBKE NM_014002.2 
CLEC5A NM_013252.2 CXCL9 NM_002416.1 FCGR3A/B NM_000570.4 HLA-DQB1 NM_002123.3 IKBKG NM_003639.2 
CLEC6A NM_001007033.1 CXCR1 NM_000634.2 FCGRT NM_004107.4 HLA-DRA NM_019111.3 IKZF1 NM_006060.3 
CLEC7A NM_197954.2 CXCR2 NM_001557.2 FKBP5 NM_001145775.1 HLA-DRB1 NM_002124.2 IKZF2 NM_016260.2 
CLU NM_001831.2 CXCR3 NM_001504.1 FN1 NM_212482.1 HLA-DRB3 NM_022555.3 IKZF3 NM_183232.2 
CMKLR1 NM_004072.1 CXCR4 NM_003467.2 FOXP3 NM_014009.3 HRAS NM_005343.2 IL10 NM_000572.2 
CR1 NM_000651.4 CXCR6 NM_006564.1 FYN NM_002037.3 ICAM1 NM_000201.2 IL10RA NM_001558.2 
CR2 NM_001006658.1 CYBB NM_000397.3 GATA3 NM_001002295.1 ICAM2 NM_000873.3 IL11RA NM_147162.1 
CRADD NM_003805.3 DEFB1 NM_005218.3 GBP1 NM_002053.1 ICAM3 NM_002162.3 IL12A NM_000882.2 
CSF1 NM_000757.4 DEFB103A NM_001081551.2 GBP5 NM_052942.3 ICAM4 NM_001039132.1 IL12B NM_002187.2 
CSF1R NM_005211.2 DEFB103B NM_018661.3 GFI1 NM_005263.2 ICAM5 NM_003259.3 IL12RB1 NM_005535.1 
CSF2 NM_000758.2 DEFB4A NM_004942.2 GNLY NM_006433.2 ICOS NM_012092.2 IL13 NM_002188.2 
CSF2RB NM_000395.2 DPP4 NM_001935.3 GP1BB NM_000407.4 ICOSLG NM_015259.4 IL13RA1 NM_001560.2 













NM_001037631.1 EGR1 NM_001964.2 GZMB NM_004131.3 IFIH1 NM_022168.2 IL17B NM_014443.2 
CTNNB1 NM_001098210.1 EGR2 NM_000399.3 GZMK NM_002104.2 IFIT2 NM_001547.4 IL17F NM_052872.3 
CTSC NM_001814.4 ENTPD1 NM_001098175.1 HAMP NM_021175.2 IFITM1 NM_003641.3 IL18 NM_001562.2 
CTSG NM_001911.2 EOMES NM_005442.2 HAVCR2 NM_032782.3 IFNA1/13 NM_024013.1 IL18R1 NM_003855.2 
CTSS NM_004079.3 ETS1 NM_005238.3 HFE NM_139011.2 IFNA2 NM_000605.3 IL18RAP NM_003853.2 
CUL9 NM_015089.2 FADD NM_003824.2 HLA-A NM_002116.5 IFNAR1 NM_000629.2 IL19 NM_013371.3 





CX3CR1 NM_001337.3 FCAR NM_133280.1 HLA-C NM_002117.4 IFNB1 NM_002176.2 IL1B NM_000576.2 
          
IL1R1 NM_000877.2 IL6ST NM_002184.2 JAK1 NM_002227.1 LEF1 NM_016269.3 MAPKAPK2 NM_004759.3 
IL1R2 NM_173343.1 IL7 NM_000880.2 JAK2 NM_004972.2 LGALS3 NM_001177388.1 MARCO NM_006770.3 
IL1RAP NM_002182.2 IL7R NM_002185.2 JAK3 NM_000215.2 LIF NM_002309.3 MASP1 NM_139125.3 
IL1RL1 NM_016232.4 IL8 NM_000584.2 KCNJ2 NM_000891.2 LILRA1 NM_006863.1 MASP2 NM_139208.1 
IL1RL2 NM_003854.2 IL9 NM_000590.1 KIR_Activating_Subgroup_1 NM_001083539.1 LILRA2 NM_006866.2 MBL2 NM_000242.2 
IL1RN NM_000577.3 ILF3 NM_001137673.1 KIR_Activating_Subgroup_2 NM_014512.1 LILRA3 NM_006865.3 MBP NM_002385.2 
IL2 NM_000586.2 IRAK1 NM_001569.3 KIR_Inhibiting_Subgroup_1 NM_014218.2 LILRA4 NM_012276.3 MCL1 NM_021960.3 
IL20 NM_018724.3 IRAK2 NM_001570.3 KIR_Inhibiting_Subgroup_2 NM_014511.3 LILRA5 NM_181879.2 MIF NM_002415.1 
IL21 NM_021803.2 IRAK3 NM_007199.1 KIR3DL1 NM_013289.2 LILRA6 NM_024318.2 MME NM_000902.2 
IL21R NM_021798.2 IRAK4 NM_016123.1 KIR3DL2 NM_006737.2 LILRB1 NM_001081637.1 MR1 NM_001531.2 
IL22 NM_020525.4 IRF1 NM_002198.1 KIR3DL3 NM_153443.3 LILRB2 NM_005874.1 MRC1 NM_002438.2 
IL22RA2 NM_181310.1 IRF3 NM_001571.5 KIT NM_000222.2 LILRB3 NM_006864.2 MS4A1 NM_152866.2 
IL23A NM_016584.2 IRF4 NM_002460.1 KLRAP1 NR_028045.1 LILRB4 NM_001081438.1 MSR1 NM_002445.3 
IL23R NM_144701.2 IRF5 NM_002200.3 KLRB1 NM_002258.2 LILRB5 NM_001081442.1 MUC1 NM_001018017.1 
IL26 NM_018402.1 IRF7 NM_001572.3 KLRC1 NM_002259.3 LITAF NM_004862.3 MX1 NM_002462.2 
IL27 NM_145659.3 IRF8 NM_002163.2 KLRC2 NM_002260.3 LTA NM_000595.2 MYD88 NM_002468.3 
IL28A NM_172138.1 IRGM NM_001145805.1 KLRC3 NM_007333.2 LTB4R NM_181657.3 NCAM1 NM_000615.5 
IL28A/B NM_172139.2 ITGA2B NM_000419.3 KLRC4 NM_013431.2 LTB4R2 NM_019839.4 NCF4 NM_000631.4 
IL29 NM_172140.1 ITGA4 NM_000885.4 KLRD1 NM_002262.3 LTBR NM_002342.1 NCR1 NM_004829.5 
IL2RA NM_000417.1 ITGA5 NM_002205.2 KLRF1 NM_016523.1 LTF NM_002343.2 NFATC1 NM_172389.1 
IL2RB NM_000878.2 ITGA6 NM_000210.1 KLRF2 NM_001190765.1 LY96 NM_015364.2 NFATC2 NM_012340.3 
IL2RG NM_000206.1 ITGAE NM_002208.4 KLRG1 NM_005810.3 MAF NM_005360.4 NFATC3 NM_004555.2 
IL3 NM_000588.3 ITGAL NM_002209.2 KLRG2 NM_198508.2 MALT1 NM_006785.2 NFIL3 NM_005384.2 
IL32 NM_001012633.1 ITGAM NM_000632.3 KLRK1 NM_007360.1 MAP4K1 NM_007181.3 NFKB1 NM_003998.2 
IL4 NM_000589.2 ITGAX NM_000887.3 LAG3 NM_002286.5 MAP4K2 NM_004579.2 NFKB2 NM_002502.2 
IL4R NM_000418.2 ITGB1 NM_033666.2 LAIR1 NM_002287.3 MAP4K4 NM_004834.3 NFKBIA NM_020529.1 
IL5 NM_000879.2 ITGB2 NM_000211.2 LAMP3 NM_014398.3 MAPK1 NM_138957.2 NFKBIZ NM_001005474.1 
IL6 NM_000600.1 ITLN1 NM_017625.2 LCK NM_005356.2 MAPK11 NM_002751.5 NLRP3 NM_001079821.2 
IL6R NM_000565.2 ITLN2 NM_080878.2 LCP2 NM_005565.3 MAPK14 NM_001315.1 NOD1 NM_006092.1 







NOD2 NM_022162.1 PSMC2 NM_002803.3 SH2D1A NM_001114937.2 TCF7 NM_003202.2 TNFRSF4 NM_003327.2 
NOS2 NM_000625.4 PSMD7 NM_002811.3 SIGIRR NM_021805.2 TFRC NM_003234.1 TNFRSF8 NM_152942.2 
NOTCH1 NM_017617.3 PTAFR NM_000952.3 SKI NM_003036.2 TGFB1 NM_000660.3 TNFRSF9 NM_001561.4 
NOTCH2 NM_024408.3 PTGER4 NM_000958.2 SLAMF1 NM_003037.2 TGFBI NM_000358.2 TNFSF10 NM_003810.2 
NT5E NM_002526.2 PTGS2 NM_000963.1 SLAMF6 NM_001184714.1 TGFBR1 NM_004612.2 TNFSF11 NM_003701.2 
PAX5 NM_016734.1 PTK2 NM_005607.3 SLAMF7 NM_021181.3 TGFBR2 NM_001024847.1 TNFSF12 NM_003809.2 
PDCD1 NM_005018.1 PTPN2 NM_002828.2 SLC2A1 NM_006516.2 THY1 NM_006288.2 TNFSF13B NM_006573.4 
PDCD1LG2 NM_025239.3 PTPN22 NM_015967.4 SMAD3 NM_005902.3 TICAM1 NM_014261.1 TNFSF15 NM_001204344.1 
PDCD2 NM_144781.2 PTPN6 NM_002831.5 SMAD5 NM_005903.5 TIGIT NM_173799.2 TNFSF4 NM_003326.2 
PDGFB NM_033016.2 PTPRC_all 
(common 
probe) 
NM_080921.2 SOCS1 NM_003745.1 TIRAP NM_148910.2 TNFSF8 NM_001244.3 
PDGFRB NM_002609.3 CD45R0 NM_080921.3 SOCS3 NM_003955.3 TLR1 NM_003263.3 TOLLIP NM_019009.2 
PECAM1 NM_000442.3 CD45RA NM_002838.4 SPP1 NM_000582.2 TLR2 NM_003264.3 TP53 NM_000546.2 
PIGR NM_002644.2 CD45RB ENST00000367367.1 SRC NM_005417.3 TLR3 NM_003265.2 TRAF1 NM_005658.3 
PLA2G2A NM_000300.2 PYCARD NM_013258.3 STAT1 NM_007315.2 TLR4 NM_138554.2 TRAF2 NM_021138.3 
PLA2G2E NM_014589.1 RAF1 NM_002880.2 STAT2 NM_005419.2 TLR5 NM_003268.3 TRAF3 NM_145725.1 
PLAU NM_002658.2 RAG1 NM_000448.2 STAT3 NM_139276.2 TLR7 NM_016562.3 TRAF4 NM_004295.2 
PLAUR NM_001005376.1 RAG2 NM_000536.3 STAT4 NM_003151.2 TLR8 NM_016610.2 TRAF5 NM_004619.3 
PML NM_002675.3 RARRES3 NM_004585.3 STAT5A NM_003152.2 TLR9 NM_017442.2 TRAF6 NM_145803.1 
POU2F2 NM_002698.2 RELA NM_021975.2 STAT5B NM_012448.3 TMEM173 NM_198282.1 TYK2 NM_003331.3 
PPARG NM_015869.3 RELB NM_006509.2 STAT6 NM_003153.3 TNF NM_000594.2 UBE2L3 NM_198157.1 
PPBP NM_002704.2 RORC NM_001001523.1 SYK NM_003177.3 TNFAIP3 NM_006290.2 VCAM1 NM_001078.3 
PRDM1 NM_001198.3 RUNX1 NM_001754.4 TAGAP NM_054114.3 TNFAIP6 NM_007115.2 VTN NM_000638.3 
PRF1 NM_005041.3 S100A8 NM_002964.3 TAL1 NM_003189.2 TNFRSF10C NM_003841.3 XBP1 NM_005080.2 
PRKCD NM_006254.3 S100A9 NM_002965.2 TAP1 NM_000593.5 TNFRSF11A NM_003839.2 XCL1 NM_002995.1 
PSMB10 NM_002801.2 S1PR1 NM_001400.3 TAP2 NM_000544.3 TNFRSF13B NM_012452.2 XCR1 NM_005283.2 
PSMB5 NM_001130725.1 SELE NM_000450.2 TAPBP NM_003190.4 TNFRSF13C NM_052945.3 ZAP70 NM_001079.3 
PSMB7 NM_002799.2 SELL NR_029467.1 TBK1 NM_013254.2 TNFRSF14 NM_003820.2 ZBTB16 NM_006006.4 
PSMB8 NM_004159.4 SELPLG NM_003006.3 TBX21 NM_013351.1 TNFRSF17 NM_001192.2 ZEB1 NM_001128128.1 
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